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General Introduction
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 10    Chapter 1
It has been shown convincingly by many studies that the immune system plays a crucial role in the induction 
and progression of allergy. In addition, evidence is accumulating showing the immunomodulatory 
capacity of food components. Both atopic allergy and immunomodulation by food involve the mucosal 
immune system of the gastro-intestinal tract, respiratory tracts and oral cavities.
In this introduction the mucosal immune system (I), allergy (II) and the research aim and thesis outline 
(III) are discussed.
I MUCOSAL IMMUNE SYSTEM
General features of mucosal immunity
The respiratory tract and the gastro-intestinal 
tract harbour large mucosal immune systems. The 
intestinal mucosal immune system constitutes the 
largest ‘immune organ’ in the body. The respiratory 
and especially gastro-intestinal tract encounters 
high loads of foreign materials, both innocuous and 
pathogenic. The majority of antigens the intestine 
is exposed to are food components and bacteria, 
commensal as well as potentially pathogenic. 
To prevent massive intestinal inflammation, it is 
crucial that food components and commensal 
bacteria are tolerated as they are in principle non-
pathogenic and harmless. Apart from tolerance, 
induction of an inflammatory immune response 
is required when food components and bacteria 
cause pathology. Under homeostatic conditions; 
the mucosal immune system is geared towards 
inducing tolerance [1-4]. Key players in the 
induction of oral tolerance are tolerogenic 
dendritic cells, regulatory T cells (Treg) and IgA-
producing B cells.
In addition, the mucosal immune system 
influences the composition of the intestinal 
microbiota, both pathogenic and commensal, thus 
preventing translocation over the epithelium and 
the induction of inflammatory responses towards 
pathogens [5, 6]. In addition to pathogens, 
commensal or mutualistic bacteria also need to be 
controlled as these bacteria that are harmless and 
often useful in the lumen may cause pathology 
once they have entered the internal milieu of the 
host.
In mucosal body defence an innate and an adaptive 
compartment can be distinguished. The innate 
mucosal immune system consists of a mucus layer 
exposed to the intestinal lumen, an epithelial cell 
layer with tight junctions, and neutrophils and 
antigen presenting cells underlying the epithelium 
(Figure 1). The cellular compartment of the 
adaptive immune system is limited to the inner 
milieu, and consists of T cells and B cells. 
The innate immune system depends on features like 
extracellular and intracellular pattern recognition 
receptors (PRR) that recognize general molecular 
patterns. Different types of PRR have been 
described, identifying microbe-, pathogen- and 
danger-associated molecular patterns (abbreviated 
as MAMP, PAMP and DAMP respectively). PRR 
enhance ligation and phagocytosis of microbes 
or have signalling ability allowing activation of 
the cell. Ligation of the latter pattern recognition 
receptors can result in production of oxygen 
radicals with microbial killer activity and 
production of cytokines. Production of cytokines 
can affect epithelial integrity and chemo-attraction 
of other immune cells of both the innate and 
adaptive immune system [7-11]. Ligation of 
extracellular toll like receptors (TLR) by bacterial 
ligands like lipo-poly saccharide (LPS) (binds to 
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TLR4), peptidoglycan (PGN) (TLR2) and flagellin 
(TLR5) results in MyD88-dependent production 
of inflammatory cytokines like interleukin (IL)-1ß, 
IL-6, IL-8, and partly TNF-α. In important part of 
the innate intestinal immune system is formed by 
Paneth cells that produce antimicrobial peptides 
that are secreted into the lumen. 
Next to soluble antimicrobial activity by the 
production of antimicrobial peptides, the innate 
immune system has a cellular compartment that 
takes up antigens from the local environment. 
Antigen-uptake can be enhanced by extracellular 
type I and II C-type lectin PRRs [12]. Phagocytosis 
of bacteria is enhanced when these bacteria are 
opsonized by IgG that can be bound by Fc IgG 
receptors on APC. Similarly, soluble antigens 
can be bound by IgG, processed and presented. 
In the mucosa, luminal secretory (sIgA) binds 
to antigens. IgA-antigen complexes can be retro-
transported from the lumen to the internal milieu, 
where the IgA-antigen complex can be bound by 
APC that in turn process and present the antigen. 
Under inflammatory conditions neutrophils are 
attracted under the influence of interleukin (IL)-
8, which can be produced by epithelial cells and 
APCs. Neutrophils can infiltrate the tissue in 
minutes upon infection and will remove bacteria 
present from the tissue. Bacteria taken up are 
killed intra-cellular by neutrophils; whereas 
antigen presenting cells (APC) also have the ability 
to present short linear peptides on MHC II after 
digestion. Antigenic peptides presented in the 
context of MHC II molecules can be recognised 
by peptide-specific CD4+ helper T cells (Th) of 
the adaptive immune system. This is accompanied 
by production of different cytokine profiles and 
expression of co-stimulatory surface molecules 
(for instance CD80, CD86) that are required 
to induce and regulate downstream immune 
responses of T cells and B cells [13-16].
The CD4+ T helper cell population expresses a 
wide repertoire of T-cell receptors (TCR) that can 
specifically recognize peptides presented in the 
context of MHC II class molecules. Activation 
of T helper cells further depends on expression 
of co-stimulatory molecules on the membrane 
of APCs and production of specific cytokines. 
Depending on the combination of different 
stimuli a naïve T cell receives, different Th cell 
subpopulations are being induced with different 
cytokine expression profiles. Initially the Th1 and 
Th2 cells were identified, of which Th1 enhanced 
Figure 1. Major innate and adaptive 
cells types of the mucosal immune 
system. IEC is intestinal epithelial 
cell, DC is dendritic cell, MΦ is mac-
rophage
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macrophage activation via interferon (IFN)-γ 
and Th2 was found to enhance B cell antibody 
production via IL-4 and IL-10. Since then several 
other Th types like Th17, Th9 and Th22 have been 
identified, characterized by production of IL-17, 
IL-9 and IL-22 respectively. It is still debated to 
what extent differentiated Th cells are stable and to 
what extent Th types harbour intrinsic plasticity. 
Activation and differentiation of Th cells is crucial 
for both inflammatory and regulatory (Treg 
mediated) immune responses. Tregs produce anti-
inflammatory cytokines IL-10 and transforming 
growth factor (TGF)-ß. The Th cell phenotype 
specific cytokine profiles in turn affect APCs, B 
cells and antibody production, and other cells of 
the immune system (both innate and adaptive) 
[17]. Also the specific location of activation of 
immune cells determines the fate and functional 
effect of the cell. 
Like T cells, B cells produce specific receptors in the 
form of immunoglobulins (Ig). Immunoglobulins 
can be expressed on the membrane of B cells or 
secreted. Secreted Ig can bind to soluble antigens 
and particulate antigens like bacteria. The advantage 
of soluble receptors in the form of Ig is that soluble 
proteins can easily be disseminated through the 
tissue and whole body (local versus systemic 
activation). By this, immune receptors reach 
places like the intestinal lumen that are relatively 
inaccessible for cells. In addition, Ig can be bound 
by receptors on the membrane of other immune 
cells resulting in downstream activation of cellular 
programs in other cell types like neutrophils and 
DCs. These downstream responses can be both 
inflammatory and tolerogenic, depending on the 
specific Ig-receptors involved and for instance the 
presence of antigen-specific T cells. B cells are able 
to produce a highly variable repertoire of Igs that 
recognize all kinds of antigens. In addition to the 
antigen-specificity of an Ig molecule, the different 
constant parts of the Ig isotypes (e.g. IgG and 
IgA and their subclasses IgG1-4 and IgA1 and 2) 
result in different downstream effector functions 
(discussed elsewhere). 
Mucosal immune skewing
Different subsets of dendritic cells and 
macrophages are present in the mucosal tissues, 
with differential capabilities in directing Th cell 
differentiation. It has become apparent that next 
to classical immune cells, endothelial, epithelial 
and stromal cells affect the immune response [4, 
18-20].
Epithelial cells are polarized, which enables them 
to discriminate the external lumen from the inner 
environment [21, 22]. TLR expression is polarized 
on intestinal epithelial cells and therefore the cells 
can discriminate basolateral from apical TLR 
activation [22]. Under homeostatic conditions 
intestinal epithelial cells are potent initiators of 
tolerogenic downstream immune responses [4]. 
To our current understanding of the intestinal 
immune system, the intestinal tolerogenic milieu 
depends on retinoic acid (RA), TGF-ß, and 
prostaglandin (PG)E2 produced by epithelial and 
stromal cells (Figure 2). Also Treg derived IL-10 
is a crucial regulatory cytokine by suppressing 
inflammatory immune responses.
Under the influence of specific stimuli naïve 
Th cells can differentiate and produce different 
cytokine profiles, which have different downstream 
consequences. Activation and maturation status of 
APC’s is usually determined by flow cytometric 
analysis of expression levels of CD80 and CD86 
respectively CD83. CD80 (B7-1) and CD86 (B70-
2) are costimulatory molecules expressed on APCs 
(often referred to as signal 2 commencing after 
initial recognition of the antigen-derived peptide 
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as signal 1) and ligate to CD28 expressed on Th 
cells. A third signal of APC dependent activation 
of Th cells is mediated by the production of 
inflammatory cytokines like IL-1ß, IL-6, IL-12 
and TNF-α, and the regulatory cytokines IL-10 
and TGF-ß. Expression of these co-stimulatory 
molecules and cytokines can be inhibited by IL-
10, resulting in reduced activation of Th cells [23].
Allergic disease is widely considered to be Th2 
mediated. Differentiation of Th2 is inhibited by 
Th1 cells mainly by IFN-γ and Th1 cells can inhibit 
Th2 differentiation mainly by IL-4. Production of 
the Th1 skewing cytokine IL-12 by APC is also 
inhibited by IL-10. Next to absolute production 
levels, the ratio between IL-10 and IL-12 is 
used to identify if a stimulus is skewing towards 
Th1 or Th2. Precise evaluation of the cytokine 
production requires both absolute production 
levels and cytokine ratios. However in case of 
tissue damage, inflammation or translocation of 
intestinal microbiota, intestinal DCs can initiate 
differentiation of Th1 and Th17 cells, which are 
characterized by a more inflammatory phenotype. 
Apart from its harmful function in allergy and 
autoimmunity, Th2 cells are generally tolerogenic 
by inducing antibody secretion. There is evidence 
that colonic induction of Th2 cells is crucial in 
the prevention of development of inflammatory 
diseases like Crohn’s disease [24]. Colonic DCs 
preferable induce Th2 rather than Th1 responses. 
CD11c+ DCs isolated from blood are potent 
inducers of Th2 cells when cultured in the 
presence of thymic stromal lymphopoietin (TSLP) 
compared to DCs cultured in the presence of 
CD40L [20]. Epithelial cells produce TSLP, which 
seems to be lost in patients suffering from Crohn’s 
disease. On the other hand, TSLP can be involved 
in the induction of allergy by its DC mediated Th2 
promoting capabilities [25].
In a mouse model, co-stimulation with ovalbumin 
(OVA) and Staphylococcus enterotoxin B was shown 
to increase Th2 induction. This was dependent 
on expression of T-cell immunoglobulin-domain 
and mucin-domain (TIM)-4 by intestinal CD11c+ 
DCs [26]. Together with expression of TIM-4, 
CD80 and CD86 expression on the cell surface 
increased and increased levels of IL-4 and IL-13 
were produced. When cells or mice were only 
stimulated with OVA or SEB, no increase in Th2 
induction was observed. This study did not report 
Figure 2. Mucosal factors in-
volved in induction of Tregs and 
IgA by B cells. IEC is intestinal 
epithelial cell, DC is dendritic 
cell, Th is T helper cell, B is B 
cell, pIgR is polymeric Ig recep-
tor, RA is retinoic acid
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the specific subset of DC’s involved in breaking 
tolerance and inducing Th2 cells. 
Increased permeability of the intestinal epithelium 
may cause increased induction of allergy and 
anaphylaxis [27]. The relation between increased 
permeability of the gut and induction of allergy 
has recently been reviewed by Perrier et. al. [28].
The intestinal immune system is mainly located 
in the small intestine and colon with differences 
in the anatomical patterning and physiological 
functions [29]. It is important to be aware of the 
compartmentalization of the intestine even if the 
intestinal immune system associated with the 
small intestine has been subject to more studies 
and is the most widely described [30]. According 
to the compartment, differences in immune 
responses in response to local antigens can be easily 
understood: food antigens are more numerous in 
the small intestine while in the ileum and colon 
they have essentially been digested and absorbed. 
In contrast, commensal microbes are scarce in the 
duodenum but more numerous in the ileum and 
above all in the colon. The gut microbiota forms 
multiple complex interactions with each other and 
the host immune system [31]. The composition 
of the gut microbiota or presence of specific 
species has been associated with diseases. Several 
bacterial species and strains have been identified 
that reduce or increase inflammatory and allergic 
phenotypes. In the KOALA birth cohort study 
presence of E. coli was associated with increased 
eczema and Clostridium difficile with multiple 
atopic manifestations [32]. Though still topic of 
debate and subject to experimental variation, 
several probiotic strains have been identified that 
reduce allergic symptoms in either humans or 
mouse models [33-35]. However, recent reviews 
conclude that protection against asthma or allergy 
is strongly dependent on the specific probiotic 
used [36, 37].  The increased Th1 skewing as 
identified by IFN-y production could explain at 
least part of the protective effect by microbes on 
allergy development. 
Mucosal B cell IgA production and secretion 
into the lumen is a crucial mechanism in both 
protection against infections and protection 
against inflammatory responses to antigen. 
Absence of IgA in the lumen is associated with 
increased mucosal leakiness and consequently 
increased numbers of bacteria can translocate 
over the epithelium into the sub-epithelial area [5, 
38]. Production of IgA is induced by bacteria, as 
shown by introducing bacteria in germ free mice. 
In mice, a dual origin for IgA plasma cells in the 
small intestine has been shown. IgA plasma cells 
originate from two lineages of B cells designated 
B-1 and B-2, which differ according to their origins, 
anatomical distribution, cell surface markers, 
Ab repertoire and self-replenishing potential. 
B-1 cells are maintained by self-renewal of cells 
resident in the peritoneal cavity, and they utilize 
a limited repertoire that is mostly directed against 
ubiquitous bacterial Ags. B-2 cells, originated from 
bone-marrow precursors, are present in organized 
follicular lymphoid tissues, within Peyer’s patches 
(PP), as precursors of plasma cells, and use a large 
repertoire of Abs and are believed to be more 
abundant in the distal ileum compared to colon 
[30]. Thus the sIgA response to specific protein-
antigens requires a classical co-stimulation by Ag-
specific T cells, an entero-enteric cycle as described 
previously, and are secreted by IgA plasma cells 
derived from B2 lineage precursors in the PP. By 
contrast, sIgA Abs against Ags from commensal 
bacteria can be induced independent from T cell 
help. Those IgA antibodies are polyspecific, and 
are secreted by IgA plasma cells derived from the 
peritoneal cavity B-1 cells. They protect the host 
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from the penetration of commensal bacteria. In 
mice, B-1 lineage could represent 40% of total 
IgA plasma cells. The contribution of peritoneal 
B cells to the intestinal lamina propria plasma cell 
population in humans is still a matter of debate 
[39]. IgA production is induced by Th cells and 
independent of T cell help as shown by CD40 and 
APRIL (role of APRIL is discussed below) knock 
out mouse models.
B cell immunity
An important reason why humoral immunity 
is effective in protecting against infections is the 
ability to produce different immunoglobulin 
isotypes. This provides the humoral immune system 
to fine tune downstream response by adapting 
the produced immunoglobulin (sub) class. 
Immunoglobulin class is partly associated with 
location, as IgG is dominantly present in systemic 
fluids, whereas IgA is dominantly produced in 
mucosal tissues, with a production between 3 and 
5 g of IgA per day in the gastrointestinal system. 
B cell immune maturation
Before an efficient B cell response is mounted, 
B cells need to mature either from naïve B cells 
or pre-activated B cells. The purpose of B cell 
activation is to produce the proper isotype and 
antigen recognition repertoire. Like with T cell 
repertoires, B cell repertoires are analysed based 
on the complementarity determining region 3 
(CDR3) [40, 41]. The humoral immune system 
needs to mature after birth or hatch (in case of 
birds). 
Naïve B cells produce IgM and a non-maturated 
antigen repertoire. Upon activation B cells can 
undergo class switch recombination (CSR) to 
other immunoglobulin isotypes (discussed 
below). The antigen specificity repertoire is for 
a large part determined by the CDR3. Upon co-
stimulation with Th cells the expression of the 
enzyme activation induced deaminase (AID) can 
be initiated resulting in subsequent mutations 
to increase the affinity of the immunoglobulin 
produced by that B cell [42]. Intestinal body 
defence partly depends on affinity maturated 
B cells, but also on B cells expressing a more 
naïve repertoire that is determined by proximal 
V gene sequences on the germline. Antibodies 
produced by those B cells are referred to as natural 
antibodies (nAb), which recognize more general 
patterns with relatively low affinity. Systemic nAb 
are generally of the IgM isotype whereas mucosally 
a proportion of the IgA antibodies also might 
have nAb characteristics. nAb represent a more 
primitive defence layer and are useful for instance 
for the detection of molecular patterns of bacteria 
present in the intestinal lumen [43, 44].
Antibodies specific for an antigen, generally 
do not recognize the whole antigen but a part 
called an epitope. Epitopes can recognize linear 
or conformational sequences. Numerous studies 
have been performed identifying IgE-epitopes of 
allergens. IgE-epitope length varies from 3 to 30 
amino acids in length [45]. Antibodies bind to 
antigens with varying affinity. Affinity of antibody-
binding to epitopes is enhanced by activation of 
the B cell by specific Th cells, which induce somatic 
hypermutation by B cells. 
Next to the antigen specificity of a B cell and the 
immunoglobulin isotype, differentiation into 
memory or plasma cells is an important feature of 
B cells. Memory cell formation is crucial for long 
term source of affinity maturated antibodies [46]. 
Typically, vaccination strategies aim at inducing 
affinity maturated B cells. Antigen experienced B 
cells that have undergone affinity maturation and 
isotype switching express CD27 [47]. Memory B 
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cells can secrete antibodies upon activation by for 
instance antigen encounter.
Antibody secreting plasma cells can be 
discriminated by detection of CD38 and CD138 
on their membrane [48, 49]. Plasma cells are 
the major source of immunoglobulins present 
in systemic fluids as well as at mucosal surfaces. 
Plasma cells can reside in systemic immune organs 
like spleen and bone marrow, as well is in local 
mucosal tissues of both the intestinal tract and the 
respiratory tract.
To exert their effector function, B cells can be 
conditioned to migrate to specific sites in the body. 
This is regulated by the expression of for instance 
the integrins ß1 and ß7 and chemokine receptors 
(CCR)10 and CCR9 to migrate to peripheral organs 
(including the respiratory tract) respectively the 
intestines [50, 51]. CCR7 expression is crucial for 
homing from the periphery to the  lymph nodes 
[52].
Antibody production and class switching
CD4+ Th cells are potent activators of B cells by 
expressing CD40 ligand [13, 53]. Subsequent 
immunization or antigenic challenges result in 
Th dependent affinity maturation. Next to this, 
Th cells can direct CSR, which affects the effector 
function of the antibodies produced. Naïve B cells 
produce IgM but can switch to other isotypes 
under the influence of Th cells. Isotype switching 
requires activation of AID and can be directed 
by specific cytokines. B cells can switch directly 
or sequentially from IgM to any isotype [54, 55]. 
Most manifestations of allergy depend on the 
presence of allergen specific IgE. To our current 
knowledge, class switching to IgE depend on Th2 
cell help and is mediated by production of IL-4 
and IL-13 [55, 56]. Th2 cells are responsible for 
induction of both IgG4 and IgE. In the presence 
of IL-10 IgE production is inhibited and IgG4 
production initiated [57]. Tregs can serve as an 
important source for IL-10.
Switching by definition is only possible 
downstream as intervening DNA is looped out 
during switch recombination [58]. The order of 
heavy chain isotypes on the human chromosome 
14 is subsequently IgM, IgD, IgG3, IgG1, IgA1, 
IgG2, IgG4, IgE and IgA2 (human genome, 
genbank build 37.3). Sequential switching has been 
reported for IgG to IgE and from IgG and IgM to 
IgA2 via IgA1 [18, 53]. The possibility of sequential 
class switching provides opportunities to change 
effector functions of B cells while retaining their 
epitope specificity. For instance, IgE-producing B 
cells might be able to switch downstream to IgA2. 
The humoral immune system is a crucial part 
of the first line of defence at mucosal sites. The 
majority of secretory IgA is produced mucosally at 
high levels, even exceeding levels of IgG produced 
systemically [59]. IgA is produced in dimeric 
form and linked by a J-chain, which is bound by 
secretory component to be transported over the 
mucosal epithelia by the polymeric Ig receptor 
(pIgR) [60, 61]. Lack of expression of pIgR results 
in strongly reduced IgA levels in the intestinal 
lumen and in an increase in exposure of the sub-
epithelial immune system to intestinal microbiota 
[5, 60, 62].
Recent evidence is accumulating showing that B 
cell activation and isotype switching is not solely 
induced under the influence of Th cells. Especially 
in the mucosa extra-follicular B cell activity is 
observed. Th cell independent class switching 
has been described several times for IgA [63-65]. 
As epithelial-DC axis mediated cytokines like 
APRIL and BAFF upregulate AID expression, B 
cells might be able to undergo any type of isotype 
switching under the influence of these cytokines, 
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independent of the presence of Th cells. Class 
switching to IgE has been reported to also occur in 
the mucosa [54, 66]. However it has not yet been 
revealed of this occurs solely dependent on Th2 
cells or also might occur on the influence of innate 
cytokines like APRIL and BAFF.
Immunoglobulin effector functions
Isotypes have different capabilities to either bind 
to Fc receptors or activate the complement system. 
IgM and IgG cooperate with the complement 
system, but not IgE and IgA [67]. Like IgG, IgE 
can be bound be both high and low affinity isotype 
specific receptors [56, 68]. Otherwise, IgG4 is a 
non-cytophilic IgG subclass that is not bound by 
Fc receptors, hence can be involved in maintenance 
or induction of tolerance.
Several Fc domain binding receptors have been 
identified, with different affinities and isotype 
specificities. IgA is bound by the FcαRI (CD89) 
or transferrin receptor (CD70). IgE is bound 
by the high affinity FcεRI or low affinity FcεR 
(CD23). Binding of IgG occurs by high affinity 
FcγRI (CD64) and low affinity FcγRII (CD32) and 
FcγRIII (CD16). Expression of those receptors 
varies per cell type. Monocyte derived DCs may 
preferentially express the low affinity receptor 
CD32, whereas monocytes also express CD89, 
some of the high affinity receptor CD64 and 
minor levels of CD16 [69-71]. Ligation of CD89 
by IgA-antigen complexes results in production 
of IL-10. Expression of CD16 is more prominent 
on neutrophils, which can become activated 
upon binding of immune complexes. Similarly, 
to initiate an intracellular signaling cascade via 
CD32, complexes may be required [69, 72]. It is 
important to note that not all IgG subclasses are 
bound by the Fc gamma receptors. Mainly IgG1 
and IgG3 are bound, which are therefore called 
cytophilic IgGs. IgG2 and especially IgG4 are well-
known for their relatively tolerogenic features 
in allergy, which could be explained by the lack 
binding of those subclasses by Fc receptors.
To be functionally active on mucosal surfaces 
that are exposed to the external milieu, transport 
over the epithelium is required. This transport is 
restricted to J-chain linked IgA or IgM that can 
be transported by the pIgR. Therefore pentameric 
IgM and dimeric IgA specifically are able to exert 
a protective role at mucosal surfaces. Next to pIgR, 
the neonatal Fc receptor (FcRn) can be expressed 
at the mucosa. The most well-known role of FcRn 
is to transfer maternal IgG present in breast milk 
over the intestinal epithelium [73].
Systemic and local immune responses
An important feature of the adaptive immune 
system is that a local antigenic challenge can result 
in a systemic memory Th cell pool [74, 75]. For 
primary activation of naïve Th cells professional 
APC’s like DCs are required. Intestinal DCs 
migrate through the lymph to the MLN upon 
activation [76]. Maturation of naïve Th cells into 
a systemic matured Th cell population requires 
homing of activated peripheral cells to lymphoid 
organs and subsequent recirculation. 
Activated APC’s from the intestine travel to 
the mesenteric lymph node to present digested 
peptides to Th cells [52]. From the MLN cells 
recirculate through the bloodstream and 
contribute to systemic immunity. Typically, allergy 
is characterized by a systemic Th2 and an IgE 
producing B cell population. Peripheral B cells 
recognizing antigen are easily activated when 
matured Th cell with similar antigen specificity are 
encountered [77].
IgA is the dominantly produced immunoglobulin 
class at mucosal surfaces. Production of IgA 
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Figure 3. Different stages 
of B cell differentiation, 
under the influence of Th 
cells or DCs. Th cell are 
more potent inducers of 
SHM and may more often 
induce CSR to IgE and 
IgG compared to DCs, 
which preferably induce 
IgA under homeostatic 
condition in the mucosa. 
These different routes of B 
cell differentiation may dif-
fer in frequency between 
systemic and mucosal 
tissues. Terminal differentiation to plasma cell is enhanced by mucosal factors and plasma cells are also main-
tained in the bone marrow.B is B cell, Th is T helper cell, CSR is class switch recombination, SHM is somatic 
hypermutation, DC is dendritic cell, IEC, intestinal epithelial cell, BM is bone marrow.
does not solely depend on Th cells, but can also 
be induced by local DCs. It even is hypothesized 
that large amounts of locally produced IgA is 
independent of T cell help [65, 78] and probably 
remain at the mucosa and is not disseminated 
through the body. This could relate to the nature of 
the effector function of mucosal IgA, to form a first 
line of defence by binding to general molecular 
patterns on bacteria. To exert this function, poly-
specific IgA molecules are produced which do 
not depend on affinity maturation, in contrast 
to IgA responses to specific pathogenic or toxic 
structures. Induction of IgA can occur via the 
epithelial-DC axis. Epithelial cells express toll like 
receptors an can produce the cytokine APRIL [18]. 
II ALLERGIES
Type I allergy is an IgE mediated hypersensitivity 
to in principle harmless food proteins and inhalant 
allergens like pollen en dust. Production of allergen 
specific IgE depends on Th2 cells that produce the 
cytokines IL-4 and IL-13. Those cytokines induce 
production of IgE. IgE is secreted and recirculates 
through the body and is bound by high affinity IgE 
receptors expressed on among others basophils 
and mast cells. Allergen bound by IgE immobilized 
on those cells can cause degranulation resulting 
in allergic symptoms within half an hour or even 
minutes after encountering the allergen.
Allergy is associated with reduced numbers 
of Tregs, which inhibit production of IgE by 
producing IL-10. Tregs also have the ability to 
enhance production of allergen specific IgG4, 
which can compete with IgE epitopes present 
on allergens and thereby prevent activation 
of mast cells and basophils. Below different 
diagnostic approaches and the role of the different 
immunoglobulin isotopes in relation to allergy are 
discussed in more detail.
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Inhalant and food allergy
The gastro-intestinal and respiratory tracts have a 
number of features in common, but also differences 
exist with implications for allergy. The gasto-
intestinal tract harbours high loads of microbial 
antigens and more than 100 grams of food proteins 
are encountered on a daily basis. Compared to 
this, the antigenic load and composition is very 
different in the respiratory tract. The intestines are 
also characterized by more abundant lymphoid 
follicles and Peyers patches (several hundreds in a 
human gut) compared to the respiratory tract.  It 
may be partly due to these differences in antigenic 
content that explain a better correlation between 
allergen specific IgE and clinical status of patients 
for inhalant allergens compared to food allergens. 
Types of immune cells found in the respiratory 
tract seem to resemble those found in the intestine. 
Both have epithelial cells producing TSLP that 
is involved in induction of Th2 cells, mucus 
producing goblet cells and B cells producing 
IgA. However, inhalant allergy may result in 
development of chronic asthma, mediated by 
infiltrated inflammatory cells like eosinophils. 
A number of inhalant allergens, like house dust 
mite, fungi and pollen can have protease activity 
and coackroach and house dust mite allergens 
are accompanied with endotoxin from faeces. 
Though the mechanisms haven’t been elucidated, 
the protease activity of allergens and presence of 
endotoxin may enhance the allergenicity of airway 
allergens. In addition, doses of exposure may vary 
between inhalant and food allergen. Finally, in 
contrast to inhalant allergens, food allergens are 
exposed to food digestions processes, including 
pH changes and enzymatic modifications.
In conclusion, though the gastro-intestinal tract 
and respiratory tract harbour similar immune 
cells and structures, food and inhalant allergy have 
important different features.
Diagnosis of allergy
Primary diagnosis of allergy is performed by 
anamneses by a trained physician, aiming at 
identifying if the patient is truly suffering from 
allergy, and subsequently what type of allergy. 
History of exposure to allergens and clinical 
manifestations are used to indicate what type 
of allergen or allergens may cause the allergic 
reactions. In many cases several diagnostic tools 
are employed to obtain a more precise diagnosis. 
Diagnosis of allergy aims at discriminating allergic 
sensitization from clinically relevant allergy. The 
diagnostic tests described below mainly discuss 
the assays commonly applied in research settings, 
which assess allergic sensitization, but do not 
link to clinical status or at best remotely relate to 
clinical features of allergy [79]. 
One of the most common used analysis is 
serological detection of allergen specific IgE. In 
general, the presence of specific IgE is a prerequisite 
to diagnose allergy, except for very young children. 
Though the presence of allergen specific IgE 
is generally considered to be a prerequisite for 
allergy, it often doesn’t correlate with severity of 
the symptoms encountered. More laborious or 
invasive diagnostic tools, like skin prick testing, 
double blind provocations or a mediator release 
assay are used to enhance the clinical relevance of 
the diagnosis. As skin prick testing is performed 
on the subject, presence of specific IgE is not the 
only determinant of the response measured. One 
of the essential differences is that for skin prick 
testing degranulation of for instance mast cells is 
required to from a wheal. Mast cell degranulation 
does not only depend on the presence of specific 
IgE on its membrane, but also on the epitopes 
detected and the location of those epitopes on an 
allergen [80]. Several IgE molecules are required 
to bind an allergen at the same time to result in 
degranulation. Detection of allergen specific 
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IgE does not provide information of the likeness 
of mast cell degranulation. To circumvent this, 
mediator release assays are used [81]. A commonly 
used assay is the basophil activation test (BAT), 
which requires allergen crosslinking of IgE loaded 
on the cell membrane in vivo to result in activation 
of the cell.
In specific cases, IgE does not explain the allergic 
symptoms observed. Recent research indicates the 
role of IgG in activating for instance basophils [82]. 
But also neutrophils could be activated by allergen 
specific IgG that binds to FcγRII [83]. The IgG 
subclass 4 is linked to protection against allergy, 
by blocking formation of allergen-IgE complexes 
on either basophils and mast cells or B cells [84].
To study cross-reactivity between allergens, 
inhibition ELISA’s or western blots are used [85]. 
In both assays binding of allergens by antibodies 
are detected. Binding by antibodies reflects 
immunogenicity of the allergens, while the above 
mentioned ability of allergens to crosslink mast 
cell bound IgE and cause mediator release is called 
allergenicity of the allergen. Serum samples can 
be pre-incubated by another allergen resulting in 
decreased levels of unbound allergen specific IgE. 
In case pre-incubation with the other allergens 
results in reduced detection of antibodies binding 
to the immobilized allergen, it is concluded that 
the same antibody is involved in binding both the 
immobilized and the pre-incubated allergen.
The most physiological and reliable (when 
performed properly) diagnostic tool is nasal 
(inhalant allergen) or oral (food allergen) 
provocation, preferably performed doubled 
blinded and randomized [86]. Disadvantage of 
this method is the risk and discomfort for the 
patient and the costs. Even though double blind 
placebo controlled provocation is considered the 
best available diagnostic tool, interpretation of 
outcomes still can be dubious. As described later 
in this introduction, nasal and oral provocation 
also involves potential protective effect of locally 
present IgA antibodies, which are less abundantly 
present in serum.
A problematic group of patients to diagnose are 
for instance young (one year of age) children 
allergic to cow’s milk as often no specific IgE can 
be detected [87, 88].
Allergy and immunoglobulins 
Immunglobulin isotypes in relation to allergy
Most allergies depend on the presence of allergen 
specific IgE. This IgE bound by the high affinity IgE 
receptor was still present after six weeks in a mouse 
model [89]. Specific IgE was injected in B cell 
deficient mice. IgE was undetectable after six days, 
but animals could still develop allergic symptoms 
after challenge. The receptors for IgE on mast 
cells and basophils are of high affinity that rapidly 
binds IgE in solution. This kinetics likely affects 
the relation between serologically detectable IgE 
and cell-bound IgE resulting in absence of soluble 
IgE whilst IgE is still present on the membranes of 
the mast cells and basophils. Probably, the finding 
that IgE still can cause clinical symptoms allergies 
while soluble IgE is undetectable can explain the 
absence of detectable IgE in for instance young 
cow’s milk allergic children. 
Allergen specific IgE levels do not correlate very 
well with clinical symptoms, especially for food 
allergy [79, 90]. IgE levels regulate the amount 
of IgE receptors on basophils and mast cells [91]. 
Therefore it is unlikely that expression levels of the 
high affinity IgE receptor could explain the poor 
correlation between specific IgE levels and severity 
of the clinical symptoms. Still, the threshold for 
activation of mast cells and basophils could differ 
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between individuals. For activation of mast cells 
and basophils, accessibility of the IgE epitopes 
is crucial. This accessibility can be affected by 
other immunoglobulin classes that have similar 
specificity compared to IgE and thereby can 
block or compete with IgE for binding allergens. 
Blocking antibodies can be of IgG4 class and 
probably of IgA as discussed below.
Recently IgD was shown to bind to basophils 
and cause production of a number of cytokines 
in including IL-4, antimicrobial factors and 
B cell-activating factors [92]. Induction of 
IgD production was reported to occur in the 
respiratory mucosa [92]. Thus far, the specificity 
of IgD immunoglobulins has mainly been linked 
to microbes, and also to inhalant allergens [93]. 
IgD levels have been linked to atopic allergy [94]. 
Smoking has been associated with increased IgD 
levels, though data is conflicting [95, 96]. Taken 
together, IgD is induced in the respiratory tract 
and associated with atopy. The precise mechanism 
is unknown, but data suggests a role for IgD in 
airway allergy.
Immunoglobulin production and immunotherapy 
IgG4 is often used as parameter to assess 
effectiveness of immunotherapy. IgG4 has been 
proven to inhibit interaction between IgE and 
allergens. IgE and IgG4 could recognise the same 
or different epitopes. To functionally protect, IgG4 
needs to prevent crosslinking on cell-bound IgE. 
This can be achieved by blocking several epitopes, 
or by steric hindrance. Not necessarily all epitopes 
have to be blocked, as a single interaction between 
IgE and allergen strongly reduces mast cell and 
basophil activation compared to cross-linking 
IgE-allergen complexes. Studies have shown that 
epitopes for IgE and IgG4 are partly overlapping 
[97-99]. An elegant assay to identify the induction 
of blocking IgG-antibodies by immunotherapy is 
the facilitated allergen presentation assay (FAP-
assay) that identifyies the presence of blocking 
antibodies by reduced binding of allergen-IgE 
complexes to CD23 on B cells [100-102].
IgG levels are high in systemic fluids, but low at 
external mucosal surfaces under homeostatic 
conditions [103]. Therefore, protection against 
allergy by IgG4 is mainly expected to be relevant 
in the internal milieu. At the mucosal surface, 
antibody-mediated protection against allergy may 
depend on IgA binding allergens. The majority 
of IgA is being produced locally in the mucosa. 
Therefore assessing a relationship between 
allergen specific IgA is likely more relevant on 
mucosal fluids and not systemic fluids like serum. 
In addition, the ratio between IgA subclasses is not 
the same in different body compartments [104]. 
Recent efforts have shown an association between 
increased mucosal IgA levels and protection 
against allergy [105, 106].
Shellfish allergy
Allergies to shrimp, lobster, crab, mussel, oyster 
and others are referred to by the common name 
shellfish allergy. Prevalences of self-reported 
mollusc allergy ranges from about 0.15% (4/2716) 
in school children in France [107] to about 0.4% 
(or 20% of all seafood allergic cases) in a household 
survey of 14,948 individuals in the USA [108]. In a 
meta-analysis, shellfish allergy prevalence ranged 
from 0 till 1.4% or was on average 2.5%, depending 
on whether numbers were based on self-reported 
or skin prick testing or IgE sensitization [109]. 
This allergy is persistent, severe and presents itself 
with eczema, urticaria (hives), allergic asthma, 
gastro-intestinal problems, and anaphylaxis. In 
westernized countries shrimp allergy occurs 
most frequently [110]. Most occurring route 
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of exposure to shellfish is the gastro-intestinal 
tract. However, there are also some reports about 
inhalant exposure by shellfish workers [111, 112].
The group of shellfish allergens is composed of 
crustacean and molluscan species, which are 
biological distinct groups. This is also reflected 
when tropomyosin sequences are aligned, 
which result in separate clusters for crustacean 
and molluscan [113]. The fact that crustacean 
and molluscan are different is also reflected in 
much more sensitizations to for instance shrimp 
compared to mussel or oyster [113, 114]. Of 
course, also consumption patterns vary, and levels 
of allergens in those species. 
Tropomyosin
The major shell fish allergen is identified as 
tropomyosin [115]. The protein tropomyosin has 
an uncomplicated tertiary structure; two chains 
are intertwined in parallel direction. Tropomyosin 
is involved in muscle action and is able to resist 
heat treatment relatively well. Tropomyosin levels 
differ between different seafood species and the 
specific amino acid composition of tropomyosin 
is species specific. Tropomyosin is referred to as a 
highly cross-reactive pan-allergen of shellfish and 
logically, its amino acid composition is conserved 
[116, 117]. As a result, initial sensitization to 
tropomyosin of one species could result in allergy 
to a whole group of foods. 
Next to sea food, tropomyosin is present in 
terrestrial species like cockroaches and probably 
more important, house dust mite [118]. Although 
house dust mite doesn’t belong to crustacean (eg 
shrimp, lobster, crab), its tropomyosin sequence 
is highly similar (approximately 80%). It has been 
reported that shrimp allergic patients also had 
specific IgE against tropomyosin of house dust 
mite [119].
House dust mite allergy
House dust mites are widely present in the 
environment in-house of Westernize societies. 
Major exposure to allergens from house dust 
mite originates from faeces present in for instant 
pillows and mattresses. Related to house dust mite 
are storage mites. House dust mite is an important 
cause for asthmatic symptoms in children and 
exposure was associated with wheeze and asthma 
[120, 121]. Several allergens have been identified, 
including tropomyosin. Though tropomyosin is 
not a major house dust mite allergen, it still could 
be a potential sensitizer and cause cross-reactivity 
with shellfish species.
As tropomyosin of house dust mite is very similar 
to tropomyosin of crustacean species, there is a 
potential risk for house dust mite to be a primary 
sensitizer resulting in subsequent sensitization 
to other crustaceans. This has been reported for 
lobster, but was not caused by tropomyosin [122]. 
Cross reactivity between shrimp and house dust 
mite has been reported, but the primary sensitizer 
is not always identified [119]. 
House dust mite allergy is an inhalant allergy, 
therefore primarily affecting nasal and oral 
surfaces. Cross-reactivity to food allergens like 
shrimp and lobster will result in exposure of the 
intestinal mucosa with subsequent intestinal 
related allergic symptoms. It should be noted 
that inhaled allergens can be swallowed and 
subsequently reach the gastro-intestinal mucosa.
Mucosa and allergy
The majority of known allergens are primarily 
encountered at the respiratory or intestinal 
mucosa. Inhaled allergens that reach the nasal 
mucosa and trachea can be transferred to the 
gastro-intestinal tract by cilia that can clear 
allergens from the respiratory tract. Consequently, 
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inhaled allergens can also be encountered at 
the mucosa of the gastro-intestinal tracts. The 
allergenicity of an allergen may depend partly on 
the IgA present at the site of exposure. Allergen 
specific IgA might prevent binding of the allergen 
by IgE and therefore reduce the allergic reaction in 
number and/or severity.
Assays to monitor immunotherapy or perform 
diagnosis of allergy rely on systemically present 
antibodies, mainly IgE and IgG4. IgG4 can be 
induced by immunotherapy resulting in reduced 
sensitivity to the allergen [123]. However, IgG4 
is not actively transported in large amounts to 
the mucosal surfaces or locally produced in the 
mucosa, like IgA. Therefore the protective role 
of IgG4 against allergy might be mainly at the 
systemic levels, whereas IgA might prevent allergy 
at mucosal surfaces.
Data describing systemic processes in allergy and 
tolerance induction by specific immune therapy is 
becoming widely available [124, 125]. Tregs have 
been identified as mediators for re-introducing 
tolerance to allergens, involving both IL-10 and 
TGF-ß [126]. Those Tregs can be allergen specific 
and produce IL-10 that inhibits production of IgE 
and enhances production of IgG4 and IgA. Next 
to an active site for Treg induction by tolerogenic 
DCs, the mucosa are sites of local antibody class 
switch recombination. Local features of class 
switching to IgE and IgA have recently been 
identified [18, 54, 65, 127]. Class switching to IgE 
was observed after allergen exposure in the nasal 
mucosa.
Though still debated, reports are increasingly 
showing an association between IgA levels and 
protection against allergy [106, 128]. IgA is 
mainly present at the mucosa and to a large extent 
produced locally. Therefore clinical relevance 
of Ig detection may be enhanced by combining 
serological detection of allergen specific IgE with 
detection of (allergen) specific IgA in mucosal 
secretions. Also IgA levels in breast milk have been 
related to allergy in the offspring [129, 130]. Many 
attempts to relate IgA levels to allergy have been 
unsuccessful or could only partly be related [131, 
132]. This may be explained by the notion that IgA 
in serum doesn’t resemble mucosally produced 
IgA. This is confirmed by reports showing that 
salivary IgA does correlate with protection against 
allergy [106, 133]. In addition to the fluid used 
for IgA detection, discriminating IgA1 and IgA2 
may enhance specificity of the assay. This is in line 
with a report showing allergen specific IgA2 in 
nasal tissue after allergen specific immunotherapy 
[105]. Another indication is the organization of 
the human immunoglobulin operon, where IgA2 
is located downstream of IgE, which therefore is 
the only class switch possibility for IgE producing 
B cells (human genome, genbank build 37.3). 
III RESEARCH AIM AND THESIS OUTLINE 
Research aim
Type I allergy is an IgE mediated disease that is 
dependent on activation of allergen specific Th2 
cells. IgE needs to be specific for an allergen, and 
in addition different IgE-molecules have to bind 
to the allergen at multiple locations to efficiently 
cross-link and activate mast cells and basophils. 
The first part of the work described in this thesis 
aimed at identifying IgE-reactivity to allergens, 
either in relation to primary sensitization or in 
relation to potential cross-reactivity to related 
allergens. 
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As allergens are mainly encountered at mucosal 
sites, we also studied if the presence of mucosal 
IgA can protect against symptoms of allergy. To 
this aim, allergen-specific IgE and IgA levels to 
house dust mite allergens were related to clinical 
status. As humans produce two subclasses 
of IgA, IgA1 and IgA2, we studied if allergen 
specific levels were different for IgA1 and IgA2 
and whether IgA1 and IgA2 levels were different 
between serum (systemic) and saliva (mucosal). 
Differences in IgA1 and IgA2 levels to allergens 
in relation to clinical status of patients might 
have implications for diagnostics in the clinic, 
and for strategies for immunotherapy. Especially 
IgA2 production may be initiated by DCs that 
are conditioned by epithelial cell-derived TGF-ß 
and RA. Therefore we aimed at identifying the 
effect of TGF-ß and RA on DC phenotype and 
functionality and at identifying mucosal factors 
derived from epithelial cells and DCs that could 
selectively induce production of IgA2 in a T-cell 
independent manner. Allergies can develop early 
in life and have been associated with microbiota 
composition in the intestines. Knowledge on 
the development IgA production and antigen 
specificity repertoire is limited. Therefore, also 
the ontogeny of intestinal IgA repertoire and 
production in relation to microbiota composition 
may contribute to our understanding of the 
role of the mucosal IgA production in allergy. 
Dairy products form an important part of the 
western diet. Bovine milk contains cytokines and 
antibodies. We wanted to know whether these 
cytokines and antibodies could interact with the 
human immune system and thereby modulate the 
mucosal immune responses.
Thesis outline
Activation of mast cells requires cross-linking of 
several IgE molecules bound by the high affinity 
IgE receptor (FcεR1) on the membrane by binding 
to allergens (Chapter 1). This cross-linking 
requires the presence of at least two IgE binding 
epitopes on the allergen. Cross-reactivity of IgE 
molecules with allergens from related species also 
requires multiple IgE epitopes on the allergen to 
induce cross-linking and to become clinically 
relevant. If the allergen to which IgE binds in a 
cross-reactive manner only has a single epitope to 
which igE can bind, the allergenicity of the cross-
reactive allergen is significantly reduced. Location 
of IgE epitopes and likeliness of cross-reactivity 
was studied using tropomyosin from shellfish 
(Chapter 2).
For diagnostics of cross-reactive allergies 
elucidation of the primary sensitizing allergen may 
be required. To this extent inhibition assays are 
applied, which point to the primary sensitizer as 
the allergen that inhibits most of the IgE reactivity. 
We used ImmunoCap allergens as inhibitory 
source for fig and ficus cross-reactive allergy as 
described in chapter 3.
Serological detection of allergen-specific IgE is 
a widely used method to identify the allergens a 
patient is sensitized to. Though for most allergies 
presence of specific IgE is required, it poorly relates 
to clinical status of patients. As the vast majority of 
allergens is encountered on mucosa surfaces, we 
studied if allergen-specific levels of the mucosal 
immunoglobulin class IgA is related to clinical 
status of patients. In chapter 4 we correlate 
allergens specific IgA levels to clinical status of 
house dust mite allergic patients. In addition, the 
difference between the IgA subclasses IgA1 and 2 
was studied.
As the majority of IgA is produced at the mucosa 
and several mechanisms of IgA induction have 
been described, we wondered if IgA1 and IgA2 
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production is differentially regulated. Recent 
data has shown a role for DCs in IgA induction. 
Tolerogenic CD103+ DCs are able to produce 
TGF-ß and RA that induce Tregs but also may 
enhance IgA production. As data on the role of 
DCs in regulation of IgA subclass production is 
not available in the literature, we aimed at the role 
of DCs in production of IgA subclasses rather 
than total IgA. To this extent, we characterized the 
effect of mucosal factors RA and TGF-ß1 on DC 
phenotype and functionality (chapter 5) and the 
role of DCs and factors produced by DCs on IgA 
production (Chapter 6).
Environmental factors in early life influence the 
development of allergies, both early and later 
in life. As production of IgA has to be initiated 
during ontogeny by environmental factors, those 
environmental factors may affect IgA antigen 
specificity development. Those environmental 
factors consist for al large part of bacterial ligands. 
The interplay between initiation of the IgA immune 
response and microbiota in early life is poorly 
studied. In chapter 7 we present data about the 
interplay between microbiota and IgA production 
and repertoire after hatch in layer hens.
The intestinal immune system is exposed to 
about 100 grams of dietary proteins daily. Dietary 
proteins can modulate the immune system. Dairy 
products form an important part of the diet, 
especially for infants. Like breast milk, cow’s 
milk contains proteins of the immune system 
including cytokines and antibodies. In chapter 8 
the immune regulating effect of bovine IL-10 on 
the human immune system is studied. Likewise, in 
chapter 9 we studied the interaction of bovine IgG 
with the human immune system.
The findings discussed in chapters 2 till 9 are 
discussed and related to the literature. Implications 
of the results obtained and directions for future 
research are discussed in chapter 10.
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ABSTRACT
Seafood-allergic patients react more frequently, and with more severe allergic symptoms, to con-
sumption of crustacean than to consumption of mollusc. Our objective was to explain this difference 
between allergy to crustaceans and molluscs. 
IgE reactivity to the major seafood allergen tropomyosin was studied by comparing the occurrence 
and composition of IgE-epitopes, and sequence similarity between different crustacean (shrimp, 
lobster, crab) and mollusc (mussel, squid, oyster) seafood species. Data on IgE-epitopes were col-
lected from the literature and related to tropomyosin-specific IgE levels of seafood allergic patients. 
By 3D modelling tropomyosin, the location of IgE-binding epitopes relevant to patients clinically 
allergic to seafood was analysed.
Phylogenetic analysis showed that tropomyosin full-length sequences, as well as the IgE-binding 
epitopes, are divergent between crustacean and mollusc species. Likewise, IgE from seafood-allergic 
patients could discriminate mollusc from crustacean tropomyosin. IgE levels to allergens of differ-
ent seafood species were associated with similarity of IgE-binding epitopes of tropomyosin of those 
species. Analysis of IgE-epitopes and amino acid residues essential for IgE binding totropomyosin 
of the most studied crustacean species shrimp revealed that the epitope located in the C-terminus 
(position 249 – 281) most likely is the most important cross-reactive IgE epitope in seafood tropo-
myosin.
We conclude that tropomyosin IgE-binding epitopes and IgE reactivity patterns are different be-
tween crustacean and mollusc allergens. Consequently, crustacean and mollusc allergy may have to 
be diagnosed differentially.
INTRODUCTION
Consumption of seafood, whether species of crus-
taceans or molluscs, can cause severe hypersensi-
tivity reactions including IgE mediated anaphylac-
tic reactions. The major seafood allergen identified 
is the muscle protein tropomyosin, which is highly 
conserved throughout the animal kingdom. IgE-
cross-reactivity between tropomyosin of different 
species has been reported frequently, mainly for 
crustaceans 1-8. Though different seafood allergies 
share the major seafood-allergen tropomyosin, 
shrimp allergy has been studied and described 
most often and seems to occur most frequently as 
evidenced by epidemiological studies 9-11.
Cell culture experiments in our laboratory with 
cells from healthy donors could not explain dif-
ferences in sensitization to shrimp (crustacean) 
and mussel (mollusc) (data not shown). Dendritic 
cells were cultured in the absence or presence of T 
cells and stimulated with different concentrations 
of shrimp or mussel extracts. No increased DC ac-
tivation or DC or T cell cytokine production was 
observed upon stimulation with shrimp extract 
compared to mussel extract.
In addition to sensitization frequency, severity of 
symptoms vary between patients allergic to crusta-
ceans or molluscs10. The observation that frequency 
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and severity of mollusc and crustacean allergy var-
ies might suggest that cross-reactivity of IgE bind-
ing to allergens of those animal (sub)phyla  plays 
a limited role in the clinical picture. This would 
be in accordance with the fact that mollusc and 
crustacean species are clearly distinct groups in 
the animal kingdom. However, until now the role 
of tropomyosin in cross-reactivity between crus-
tacean and mollusc allergy is still controversial. In 
addition, some clinics distinguish crustacean and 
mollusc allergy, while others refer to seafood only. 
To resolve this controversy, a detailed comparison 
of IgE-reactivity and epitopes between tropomyo-
sin of both animal classes is needed.
Because clinical relevance of exposure to mollusc 
allergens and cross-reactivity of IgE-binding to 
crustacean allergens is unclear in Western coun-
tries, we aimed at identifying differences in IgE 
reactivity to mollusc and crustacean allergens in 
seafood-allergic patients. The molecular basis for 
tropomyosin cross-reactivity between crustaceans 
and molluscs was linked to IgE levels and sensiti-
zation prevalence data. Tropomyosin sequences of 
different species were analysed and related to IgE-
reactivity and IgE-epitope specificity. Finally, IgE-
binding epitopes were visualised using a 3D model 
of tropomyosin. Together, our data may help to 
explain the clinically observed heterogeneity be-
tween crustacean and mollusc allergies.
 
MATERIALS AND METHODS
Patients
Databases of two large allergy centres were 
screened for case records containing positive 
(≥0,35 kU/L) results of serum specific IgE tests 
to any of the following seafood allergen sources: 
mussel, oyster, squid, octopus, snail, shrimp, lob-
ster, crab and the allergen tropomyosin. From a 
total of approximate 7500 records over the past 5 
years, there were specific IgE measurements noted 
in 141 cases. 
Independent of the retro perspective screening 
of databases, serum was collected from seven pa-
tients with seafood allergy. Their allergies were all 
based on a convincing medical history of anaphy-
lactic reactions to these foods, reports and clear 
descriptions of these reactions from emergency 
department records and on positive IgE sensitiza-
tion to seafood as documented by skin tests and/
or specific IgE levels. Anaphylactic reactions were 
mainly documented upon ingestion of crackers 
and shrimp. Because of the anaphylactic charac-
ter of their allergic reactions no food challenges 
with seafood were done in these patients. Serum 
was collected during a follow up visit for further 
diagnosis in serum collection tubes (Greiner), cen-
trifuged and stored at -20ºC.
Detection of specific IgE
The seven patient sera were analysed for the pres-
ence of allergen-specific IgE with ImmunoCAP 
100 or 250 (Phadia/Thermo Scientific, Sweden) 
using default procedures and allergen-CAPs. The 
test panel (codes behind allergens indicate Phadia 
ImmunoCAPs used) consisted of: house dust mite 
(d1), recombinant tropomyosin from house dust 
mite (d205), shrimp (f24), recombinant tropomy-
osin of shrimp (pen a1, f351), oyster (f290), lob-
ster (f80), crab (f231) blue mussel (f37) and pacific 
squid (f58) and scallop (f338).
Western blot
Frozen shrimp or life mussels were obtained by a 
local fishmonger, Wageningen, The Netherlands. 
Abdomen of shrimp (most common species: Eu-
ropean shrimp Crangon crangon) or abductor 
muscle of mussel (blue mussel, Mytilus edulis) 
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was minced, sonicated and centrifuged (20 min 20 
000g, 4oC) and stored in aliquots at -20oC until use. 
Gel electrophoresis was performed using 12.5% 
SDS-PAGE gels in a mini-protean II gel system 
(Bio-Rad, USA). 20 µg of non-reduced protein ex-
tract was added per lane and 7µl marker (Precision 
Plus Protein Dual Color Standard, #161-0374EDU, 
Bio-Rad, USA). Samples were prepared by adding 
loading buffer. Gels were run for 30 minutes at 80V 
and subsequently for 60 minutes at 130V. 
For western blotting the samples were transferred 
to a nitrocellulose membrane using a semi-dry 
transfer system (Bio-Rad) at 15V and 0.25mA per 
membrane for 40 minutes. The membrane was 
blocked with 2.75% biotin-free casein (SDT-rea-
gents, Germany) and subsequently five times di-
luted patient serum was added, and incubated for 1 
hour at room temperature on a shaker. For inhibi-
tion assays, 500 µl extract (1 mg/ml) was added to 
500 µl undiluted serum and incubated for 30 min. 
before addition to the blot.
The membrane was washed three times with 
TBS-tween (10mM Tris-Cl, 150mM NaCl, 0.05% 
tween-20, pH 7.5) and incubated with 250 times 
diluted biotinylated monoclonal mouse anti hu-
man IgE (1 mg/ml, BD Biosciences) for 1 hour 
on a shaker at room temperature. Subsequently, 
the membrane was washed (three times) and in-
cubated with 5000 times diluted streptavidin poly 
HRP80 (SDT-reagents, Germany) for one hour 
while shaking at room temperature. The develop-
ing reaction was carried out using ECL western 
blotting reagent (GE Healthcare, UK) and subse-
quently a film (Lumi-Film Chemiluminescent De-
tection Film, 11666657001, Roche USA) was ex-
posed for 5 minutes or one hour in the dark. After 
exposure films were developed and fixed (Sigma).
To confirm identity of the proteins at 37 kDa, 
coomassie stained bands were excised and ana-
lysed by nanoLC`-ESI-Iontrap-MS/MS followed 
by a Mascot database search (Panatecs, Tübingen, 
Germany).
Tropomyosin sequence analysis
The literature databases Scopus, ISI Web of Science 
and NCBI PubMed were used to search for papers 
reporting seafood allergy. Of each paper the meth-
od of allergen determination, country, IgE-binding 
epitopes and epitope determination method (if 
reported), cross-reactivity, clinical symptoms and 
age and nationality of the patients was recorded.
Tropomyosin sequences used are indicated in Ta-
ble S1, including genbank accession numbers. The 
relation shown in the trees were inferred using 
the p-distance model Neighbor-Joining method. 
The bootstrap consensus tree inferred from 1000 
replicates and the percentage of replicate trees in 
which the associated taxa clustered together in a 
bootstrap test is shown next to the branches. Phy-
logenetic analyses were conducted in MEGA4 12.
3D modelling of tropomyosin
To predict the 3D structure of mussel and shrimp 
tropomyosin, homology modeling using the pro-
gram Modeller was performed13. To obtain a suit-
able template structure, blast searches were per-
formed against the PDB; based on E-value and 
resolution of the structure, entry 1c1g was selected 
14. Default parameters were applied in Modeller us-
ing the automodel class. Out of 1,000 tropomyosin 
structures the best one based on objective score was 
selected for further analysis. For analysis of tropo-
myosin – IgE Fab fragment interactions, multiple 
copies of the IgE Fab fragment in PDB entry 2r56 
were assembled onto the modelled tropomyosin 
structure. This was performed by overlaying the 
bovine Beta-Lactoglobulin allergen bound to IgE 
in PDB entry 2r56 with the various tropomyosin 
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epitopes. Figures were generated using MolScript 
15 and Raster3D 16.
Statistical analysis
IgE levels to allergens obtained from retro-per-
spective database searches were entered in IBM 
SPSS Statistics version 19. IgE level to crustacean 
and mollusc allergens were compared using non-
parametric independent samples median test 
(Figure 1).
Differences in specific IgE levels to allergens of the 
seven patients were tested using non-parametric 
mean comparison, or correlations untransformed 
or log transformed when needed to obtain nor-
mally distributed data.
Correlation between specific IgE levels and epitope 
or critical amino acid similarity was tested with the 
non-parametric Wilcoxon rank test.
 
RESULTS
Differences in diagnosis frequency and IgE reac-
tivity between crustacean and mollusc allergens
Databases of two allergy centres were screened in 
retrospect for reports about seafood allergic pa-
tients. 141 patient reports were found with docu-
mented specific IgE levels to any seafood of at least 
0.35 kU/L . Of 27 (19%) of those patients mollusc 
specific IgE levels of more than 0.35kU/L were 
reported. 135 (96%) of the 141 patients had IgE 
levels to crustacean of 0.35 kU/L or more. For 25 
patients both mollusc and crustacean-specific IgE 
levels were determined, and only 19 patients were 
reported to be sensitized to both crustaceans and 
molluscs, of which the majority (17 out of 19, 89%) 
had higher levels of specific IgE to crustaceans in 
comparison with molluscs.
The majority of patient sera were tested for levels 
Figure 1. Specific IgE levels of shellfish allergic patient show that molluscan and crustacean allergens are 
differentially recognized. Results are shown from serological analysis of 25 patients (A). Each line repre-
sents data from one individual. The thick black line with large black bar indicates average specific IgE levels. 
SDS-PAGE (B) and western blot showing IgE-specific bands (C) of mussel and shrimp extract using serum 
of shellfish-allergic patients, indicating tropomyosin as the major allergen and very limited cross-reactivity be-
tween mussel and shrimp. Mussel (mu), shrimp (shr) and marker (M) were separated on size and transferred 
to nitrocellulose for western blot analysis. Serum was incubated directly (no inh.) or inhibited with mussel (inh. 
mu) or shrimp (inh. Shr) extract prior to addition to the nitrocellulose membrane. Western blot analysis was 
performed for seven patients, yielding similar results.
A B C
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of specific IgE against shrimp (120 patients, 85%). 
25 of the 27 records containing data on IgE to mol-
lusc also contained data on specific IgE levels to 
crustacean allergen extracts.  Of the 25 patient 
records containing specific IgE level data against 
both crustacean and mollusc allergen extracts, the 
IgE levels between those extracts were compared. 
Comparison of specific IgE levels against crus-
tacean and mollusc allergens indicated that pa-
tient IgE differentially recognized crustacean and 
mollusc allergens (Figure 1A). Specific IgE levels 
(range 0.4- 94.9 kU/L) to crustacean allergens were 
significantly higher compared to IgE levels against 
mollusc allergens (p=0.001). 
To determine the dominant seafood allergens for 
clinically diagnosed seafood-allergic patients, 
mussel and shrimp extracts were separated on size 
(SDS-PAGE) and analysed for IgE-reactivity by 
western blot. The dominant allergen is around 37 
kDa. The protein band at 37 kDa of both shrimp 
and mussel extract was excised and confirmed to 
be tropomyosin. We compared several batches 
of shrimp and mussel extract, and tropomyosin 
concentrations are consistently higher in shrimp 
extracts compared to mussel extracts (example 
shown in Figure 1B). IgE-binding was much high-
er to shrimp than to mussel extracts. The dominant 
shrimp allergen bound by patients’ IgE was tropo-
myosin, whereas binding of IgE to tropomyosin 
of mussel was observed some but not all patients. 
IgE-binding could be almost completely inhibited 
when serum was incubated with shrimp extracts, 
whereas incubation of serum with an excess of 
mussel extract did not inhibit binding of IgE (Fig-
ure 1C), indicating that patients were primarily 
and mainly sensitized to shrimp and not to mussel 
allergens, and that IgE from sensitized individuals 
discriminate between shrimp and mussel allergens. 
Literature review of IgE-binding to tropomyosin
As specific IgE levels were observed to discriminate 
between crustacean and mollusc tropomyosin, a 
literature search to IgE-binding activity and cross-
reactivity to the major seafood allergen tropomyo-
sin was performed. If specified in the publications, 
we also indicated the primary sensitizing allergen, 
which is indicated at the top of Figure S1A in red. 
Cross-reactivities are published between IgE re-
acting to the class Arachnida, class Malacostraca 
(subphylum Crustaceans) and class Insecta, and 
also the phylum Mollusca (mainly classes Bivalvia, 
Cephalopoda, Gastropoda), which are detailed be-
low.
IgE cross-reactivity is caused by similarity of IgE 
epitopes present on tropmyosin and is frequently 
observed between tropomyosin of crustacean spe-
cies 4, 17. Cross-reactivity of IgE directed against 
tropomyosin has been reported across animal 
classes; between house dust mite and snail 18, 19 
and between shrimp, house dust mite and cock-
roach 20. Also cross-reactivity between IgE bind-
ing to crustacean (shrimp) tropomyosin and dif-
ferent mollusc species has been reported 2. Those 
reports also describe cross-reactivity of IgE against 
tropomyosin between squid (mollusc) and lobster 
(crustacean) 21. Most reports about cross-reactivity 
between crustacean and mollusc originate from 
Asian countries, whereas reports from American 
and European countries are less frequent (Table 
S2).
Sequence analysis and IgE epitopes of tropomyo-
sin
The tropomyosin amino acid sequence is avail-
able for many species. Therefore we compared 
these tropomyosin sequences and studied the IgE-
binding epitopes reported in literature. As cross-
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reactivity is not defined by the overall sequence 
identity but by the structural similarities in IgE-
binding epitopes, we also compared IgE-binding 
regions (epitopes) and the reported single amino 
acids that are essential for IgE reactivity. Epitopes 
substitution studies showed that the amino acids 
in the middle of the IgE-epitope is most important 
for IgE binding and that one or two substitutions 
could already inhibit most of the IgE reactivity 20, 22.
Tropomyosin sequences were aligned with 
ClustalW and a neighbor joining tree was con-
structed (Figure 2A). Crustacean and mollusc 
tropomyosin sequences form non-overlapping 
clusters, indicating that sequence similarity within 
crustacean species and within mollusc species is 
higher than homology between crustacean and 
mollusc species. All known tropomyosin allergens 
in our analysis have a sequence identity with hu-
man tropomyosin of less than 60%. Cockroach 
and mite tropomyosin clustered together with 
crustacean tropomyosin sequences but not with 
molluscs. A number of shrimp species (Litope-
naeus vannamei, Penaeus monodon, Farfantepe-
naeus aztecus (pen a1)) have identical amino acid 
sequences of tropomyosin, whereas others differ 
(Metapenaeus ensis, Crangon crangon).
When only IgE epitopes (Figure 2B, green shaded) 
were included for construction of the neigbor join-
ing tree, the division between crustacean and mol-
luscs was maintained, as was the general distribu-
tion of species (Figure 2B). When this analysis was 
performed for amino acid residues critical for IgE-
reactivity to tropomyosin of shrimp, crustacean 
and molluscs sequences still clustered separately, 
but bootstrap values indicated decreased reliability 
of the dendogram (Figure 2C).
Figure 2. Neigbor joining tree of (A) the full tropomyosin amino acids sequences (284 positions), (B) the 
IgE-binding epitopes, including critical amino acids (95 positions) and (C) amino acids critical for IgE reactivity 
only (20 positions). Especially the topology of A and B is very similar, and the topology of C still distinguishes 
molluscan (blue shaded) and crustacean (green shaded) sequences. Reliability of the trees is indicated by the 
bootstrep values (%) shown for each branch.
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Tropomyosin 3D model
At least two IgE molecules have to bind to the dis-
tinct sites of cross-reactive allergen to cause mast 
cell and basophil degranulation resulting in clini-
cally relevant symptoms of allergy. The IgE epitope 
differences and amino acids reported to be essen-
tial for IgE-reactivity were modelled (Figure 3) to 
identify distribution of the IgE epitopes and assess 
likeliness of cross-reactivity by modelling amino 
acids substitutions between species. 
Tropomyosin consists of two parallel oriented al-
pha helices, resulting in a relatively simple tertiary 
structure (Figure 3). Reported shrimp IgE-binding 
epitopes and amino acids essential for binding of 
IgE are indicated in Figure 3A and 3B (coloured 
residues), including non-homologous substitu-
tions (blue) between shrimp and mussel. Evalua-
tion of the epitope differences indicated high per-
centage (79%) of identical or homologous amino 
acids across species for epitope V, low similarity for 
epitope III (sequence identity 41%) and intermedi-
ate similarity for epitopes I, II and IV (sequence 
identity 46%, 58% and 55% respectively). The low-
est observed similarity for epitope III is even more 
interesting in light of the observation that there is 
an Asparagine that could putatively be glycosylated 
(based on the occurrence of an Nx[ST] motif) im-
mediately preceding epitope III in shrimp tropo-
myosin, which is not present in mussel tropomyo-
sin. Glycosylation could result in increased affinity 
of binding to IgE 23, 24. Such putative glycosylation 
motif is also present at similar positions in various 
other tropomyosin sequences (octopus (O. vul-
garis), oyster (C. gigas) and sea snail (T. cornutus)). 
The size of the IgE-bound antigen surface in the 
available structure of an IgE Fab fragment in com-
plex with the major birch pollen allergen (Bet v1) 
25 is roughly 20 by 10Å (PDB entry 2r56; data not 
shown). The IgE-binding epitopes on tropomyo-
sin depicted in figure 3, have similar sizes as de-
termined by measuring the surface that could be 
approached from one side of the epitope by the 
IgE Fab. The size of the putative interaction sur-
face ranges from 18 by 10Å for the smallest epitope 
(epitope IV) to 40 by 10 Å for the largest one 
(epitope V). In addition, the modelled structures 
revealed that the different epitopes occur at a quite 
regular distance from each other, at approximately 
70Å (Figure 3C). The roughly ~50Å diameter of 
the above mentioned IgE Fab structure, impli-
age gender allergen causing anaphylaxis Muller time
other known sensitizations 
and allergies
15 f shrimp, lobster III - fruits, grass pollen, tree pollen, animal dander
50 m shrimp and/or mussel I - III 45 min HDM, cat
25 f mixed (Asian) sea food, but SPT only positive for shrimp I < 1 hour cat, dog
71 m shrimp IV 1 hour HDM
45 f shrimp II - III - -
42 f shrimp, crab II 45 min tree pollen, grass pollen, apple
shrimp cracker
(exercise induced)
Table 1.  Summary of clinical symptoms of allergic patients.
Time indicates lag between consumption and occurrence of clinical symptoms. – indicates data unavailable; SPT, 
skin prick test; HDM, house dust mite.
53 m I <15 min HDM, grass pollen, tree pollen, animal dander
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Figure 3. Structural context of tropomyosin epitopes. (A) Mussel tropomyosin structure model, with epitopes 
indicated (I-V). Epitope residues in mussel are conserved (red) or non-conserved (blue) when compared with 
shrimp. Parts of sequence alignment of mussel and shrimps are shown. (B). Critical amino acids for mussel 
tropomyosin, using similar color scheme as in panel B. (C) Mussel tropomyosin structure model showing two 
parallel helices (green and yellow) and illustrating potential binding modes of IgE Fab fragments.
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cates that shrimp tropomyosin can simultaneously 
be bound by multiple IgE molecules and thereby 
cause cross-linking of IgE immobilized on mast 
cells and basophils.
Specific IgE levels correlate with tropomyosin 
epitope similarity
Sera from seven patients with a clinically relevant 
seafood allergy were obtained, independently from 
the sensitization data used for Figure 1. Seafood al-
lergic patients with anaphylactic symptoms mainly 
respinded to crustacean allergens, and often were 
also sensitized or allegic to other allergens (Table 
1). The sera were analysed for specific IgE lev-
els to house dust mite (HDM, Dermatophagoides 
pteronyssinus), house dust mite tropomyosin (der 
p 10), shrimp tropomyosin (pen a 1), crab, lob-
ster, oyster, blue mussel and pacific squid. Con-
sistent with data obtained in retrospect from al-
lergist databases (shown in Figure 1), all patients 
showed only minor specific IgE levels to mollusc 
extracts compared to levels to crustacean extracts 
(p=0.027; data not shown). A non-parametric cor-
relation analysis was performed to test correlations 
between specific IgE levels to different mollusc and 
crustacean extracts. Total house dust mite-specific 
IgE levels did not correlate with any of the other 
specific IgE levels. IgE levels to tropomyosin of 
shrimp and house dust mite correlated significant-
ly with the other crustacean-specific (crab, lobster) 
IgE levels, but not with the mollusc-specific IgE 
levels (Table 2). Crab- lobster-, pacific squid- and 
oyster-specific IgE levels correlated significantly 
with each other, but not with blue mussel. Specific 
IgE levels to the mollusc pacific squid correlated 
significantly with IgE levels to the mollusc oyster, 
but not blue mussel.
Correlations between tropomyosin-specific IgE 
levels were compared with overall sequence iden-
tity of tropomyosin. When specific IgE levels to 
different species showed a significant correlation, 
the tropomyosin sequences showed relatively 
high sequence identity (Table 1). In addition to 
sequence identity, we correlated IgE-epitope iden-
tity with specific IgE levels (Figure 4). A significant 
correlation was observed between IgE levels and 
Figure 4. Allergen specific IgE levels from patients were plotted against similarity compared to shrimp tropo-
myosin epitopes (A) and amino acids identified to be essential for IgE reactivity of shrimp allergic patients (B). 
Abbreviations in legend denote pacific squid (Pac_sq), house dust mite and shrimp tropomyosin (TM_HDM 
respectively (TM_shr). Log_relIgE on y-axes indicates log transformed specific IgE levels.
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IgE epitope similarity (p<0.001). This was also ob-
served when IgE levels were correlated with amino 
acids critical for IgE reactivity to tropomyosin 
(Pen a 1) of shrimp (p<0.001).
DISCUSSION
Allergy to crustacean is more prevalent than al-
lergy to mollusc and generally causes more severe 
clinical reactions. The current report aimed at 
studying the role of the major allergen tropomyo-
sin in the distinct IgE reactivity to crustacean and 
mollusc allergens. In order to study this, a detailed 
analysis of IgE binding patterns and sequence ho-
mology of the major allergen tropomyosin was 
performed, in combination with studying in vitro 
IgE reactivity of crustaceans and mollusc species.
Among seafood-sensitized patients the prevalence 
of crustacean sensitized (mainly shrimp) patients 
was highest in databases of the allergy centres and 
reports of epidemiological surveys in the United 
States and Australia9, 10. Moreover it is reported 
that shrimp allergic patients have far more often 
anaphylactic reactions than patients with mollusc 
allergy 10. 
An extensive literature study was performed to 
review reported incidences of seafood allergy and 
the frequency of cross-reactivity between different 
species. IgE binding to crustacean was more often 
reported to be cross-reactive with tropomyosin al-
lergens from other species. Furthermore, different 
mollusc species are studied in Asia (mostly Cepha-
lopda) compared to Europe (mostly Gastropoda) 
(Table S2). The fact that different allergen sources 
are studied in different countries could be caused 
by different sensitization patterns. IgE-cross-reac-
tivity between mollusc and crustacean has mainly 
been reported by Asian laboratories. Dietary and 
genetic differences, in line with indications that 
link ethnicity with IgE levels and atopy may help 
explain different allergen-sensitizations reported 
between Asian and Western countries 26, 27. Ethnic 
background of patients may be associated with dif-
ferent sensitization patterns and clinical allergic 
manifestations. Recently, the literature of Asian-
Pacific seafood allergies have been reviewed by 
Lee  et. al. 28. The authors indicate that unneces-
sary avoidance is advised by clinicians that are not 
aware of the biological and allergenic differences 
between seafood phyla. Consequently, in many 
cases patients allergic for crustacean may safely 
consume mollusc animals, and vice versa.
Mollusc and crustacean tropomyosin sequences 
and IgE epitopes clustered separately in a den-
dograms. This suggests that IgE cross-reactivity be-
tween those (sub)phyla might be limited too. Tro-
pomyosin identity between human and seafood is 
below 60%. But also tropomyosin identity between 
mussel and shrimp is below 60%, which indicated 
that cross-reactivity might be quite limited due 
to the large differences between tropomyosin of 
crustaceans and molluscs. Consistent with other 
studies, the differences observed in IgE reactivity 
to mollusc and crustacean allergen extracts signifi-
cantly associated with the overall sequence simi-
larity of tropomyosin, as well as the similarity in 
amino acid-sequences of the IgE-binding epitopes 
(Table 1 and Figure 6)29. The 3D protein model of 
tropomyosin presented here visualizes the loca-
tion of amino acid substitutions in IgE epitopes. 
Tropomyosin has a relatively simple structure and 
because of the high similarity between the shrimp 
and mussel tropomyosin sequences with the tem-
plate sequence, the position of amino acids in the 
model is expected to relatively accurately predict 
surface exposure of epitopes to IgE. Modelling IgE 
epitopes has an additional added value because of 
the prediction of spatial distribution of epitopes 
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30. Crosslinking of multiple IgE molecules on 
mast cell or basophils may be more or less likely 
depending on the spatial distribution of distinct 
IgE epitopes. In this context, given the possibili-
ties for binding multiple IgE molecules that we 
observed based on the structure model, it is in-
teresting to note that the middle epitope (residues 
133 – 154) is most different between shrimp and 
mussel. If substitution between shrimp and mussel 
observed in this middle epitope results in reduced 
binding of cross-reactive IgE, also the risk of clini-
cally relevant cross-linking is reduced. In addition, 
we propose that a putative glycosylation site which 
is present in shrimp but not in mussel might result 
in differential sensitization to shrimp and mus-
sel tropomyosin 31. Although the occurrence of a 
glycosylation motif does not necessarily mean that 
glycosylation occurs, it is relevant to note that a 
similar site occurs in various other tropomyosin 
sequences, and that evidence exists for both gly-
cosylation in crustaceans 32 and glycosylation of 
myofibrillar proteins, in particular myosin and 
tropomyosin 33. 
Interestingly, specific IgE to tropomyosin from 
house dust mite correlated strongly with shrimp 
tropomyosin, crab and lobster IgE levels. This 
could mean that the widely abundant house dust 
mite tropomyosin is a potential sensitizer for crus-
tacean seafood allergy. But also, shrimp tropomy-
osin-allergic patients may be sensitized to house 
dust mite tropomyosin 20. 
Most tropomyosin IgE-epitope studies are per-
formed on shrimp tropomyosin. However, we did 
find a few studies reporting IgE epitopes for mol-
lusc species. The IgE-binding epitopes reported 
for the mollusc species Crassostrea gigas, Turbo 
cornutus and Octopus vulgaris overlapped with 
the positions of the epitopes reported for shrimp 
tropomyosin 34-36. Those studies originate from 
Asian laboratories and suggest that in those coun-
tries mollusc allergy might be more frequent com-
pared to Western countries. The epitope of the T. 
cornutus and O. vulgaris (aa 92- 105, equivalent to 
epitope II) is a partly conserved part of tropomyo-
sin that based on our 3D model may cause cross-
reactivity. The other IgE-binding epitopes identi-
fied for O. vulgaris also overlap with the epitopes 
identified for shrimp tropomyosin, but those 
epitopes contain more non-homologous substi-
tutions that could interfere with IgE binding. For 
clinically relevant IgE cross-reactivity, more than 
one cross-reactive epitope needs to be recognized. 
Therefore, the finding that other epitopes contain 
numerous substitutions at the surface of the pro-
tein is a likely explanation for limited IgE cross-
reactivity between crustaceans and molluscs. As a 
consequence, shrimp-allergic patients should not 
be advised to avoid eating mollusc seafood out of 
for fear for food allergy.  
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Table S1 Tropomyosin allergens
Allergen Species Genbank no
abalone hal a Haliotis asinina Q7YZR0
abalone hal d Haliotis diversicolor Q9GZ71
abalone hal r Haliotis rufescens Q25145
barnacle bal r Balanus rostratus BAF46896
cockroach bla g7 Blattella germanica Q9NG56
cockroach per a7 Periplaneta americana Q9UB83
cockroach per f Periplaneta fuliginosa Q8T6L5
crab eri i Erimacrus isenbeckii BAF47269
crab eri s Eriocheir sinensis ABS12234
crab por s Portunus sanguinolentus ABL89183
crab por t Portunus trituberculatus
 
cuttlefish oct v Octopus vulgaris Q2V0V0
cuttlefish sep e Sepia esculenta Q2V0V4
hdm der f10 Dermatophagoides farinae Q23939
hdm der p10 Dermatophagoides pteronyssinus B6E457
krill eup p Euphausia pacifica A7VKE1
krill eup s Euphausia superba A7VKE0
lobster hom a Homarus americanus O44119
midge chi k Chironomus kiiensis CAA09938 
mite ale o10 Aleuroglyphus ovatus AAX37287
mussel myt e Mytilus edulis Q25457
mussel myt g Mytilus galloprovincialis P91958
mussel per v Perna viridis Q9GZ70
oyster Crassostrea gigas BAH10152.1
shrimp ora o Oratosquilla oratoria A9CSJ9
shrimp pan e Metapenaeus ensis Q25456
shrimp pen a 1 Farfantepenaeus aztecus AAZ76743.1
shrimp pen j1 Penaeus japonicus A2V731
shrimp pen m1 Penaeus monodon A1KYZ2
shrimp pen v1 Litopenaeus vannamei B4YAH6
silverfish lep s Lepisma saccharina Q8T380
snail hel a Helix aspersa O97192
squid sep l Sepioteuthis lessoniana Q2V0V3
squid tod p Todarodes pacificus Q2V0V2
human hom s Homo sapiens P09493
bovine bos t Bos taurus Q5KR49
pig sus s Sus scrofa P42639
chicken gal g Gallus gallus P04268
mouse mus m Mus musculus P58771
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Table S2 Overview country of origin of research papers about tropomyosin allergy
continent
Papers
no      % Phylum # %
Sub-
Phylum # % Class # %
Europe 10 15.4 Mollusca 4 40.0    Gastropoda 3 75.0
 Bivalvia 1 25.0
 Cephalopda 0 0.0
 Arthropoda 4 40.0 Crustacea 0 0.0 Maxillipoda   
 Malacostraca  
 Chelicerata 1 25 Arachnida 1 100.0
    Insecta 3 75.0
 Nematoda 2 20.0       
Asia 41 63.1 Mollusca 18 43.9    Gastropoda 2 11.1
 Bivalvia 7 38.9
 Cephalopda 9 50.0
 Arthropoda 23 56.1 Crustacea 17 73.9 Maxillipoda 2 11.8
 Malacostraca 15 88.2
 Chelicerata 3 13.0 Arachnida 3 100.0
    Insecta 3 13.0
 Nematoda 0 0.0       
Africa 2 3.1 Mollusca 2 100.0    Gastropoda 2 100.0
 Bivalvia 0 0.0
 Cephalopda 0 0.0
 Arthropoda 0 0.0 Crustacea 0  Maxillipoda   
 Malacostraca  
 Chelicerata 0  Arachnida 0  
    Insecta 0 0.0
 Nematoda 0 0.0       
N-America 7 10.8 Mollusca 1 14.3    Gastropoda 0 0.0
 Bivalvia 0 0.0
 Cephalopda 1 100.0
 Arthropoda 6 85.7 Crustacea 5 83.3 Maxillipoda 0 0.0
 Malacostraca 5 100.0
 Chelicerata 1 16.7 Arachnida 1 100.0
    Insecta 0 0.0
 Nematoda 0 0.0       
S-America 5 7.7 Mollusca 0 0.0    Gastropoda   
 Bivalvia  
 Cephalopda  
 Arthropoda 2 40.0 Crustacea 0 0.0 Maxillipoda   
 Malacostraca  
 Chelicerata 0 0 Arachnida   
    Insecta 2 100.0
 Nematoda 3 60.0       
Total (World) 65 100 Mollusca 25 38.5    Gastropoda 7 28.0
 Bivalvia 8 32.0
 Cephalopda 10 40.0
 Arthropoda 35 53.8 Crustacea 22 62.9 Maxillipoda 2 9.1
 Malacostraca 20 90.9
 Chelicerata 5 14.3 Arachnida 5  
    Insecta 8 22.9
   Nematoda 5 7.7       
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Table S3. Sequence identity of tropom
yosin sequences 
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0.92 0.58 0.57 0.58 0.58
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0.56
0.59
0.58
0.52
0.58
0.58
0.58
0.57
0.58
0.58
0.55
0.54
0.55
0.56
0.55
0.55
0.53 0.56 0.52 0.52 0.52 
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us m
 
0.90 0.90 0.90 0.92   
0.58 0.57 0.57 0.57
0.57 0.58 0.58 0.56 0.48 0.55 0.54
0.55
0.59
0.58
0.51
0.58
0.58
0.58
0.56
0.57
0.57
0.54
0.54
0.55
0.55
0.55
0.54
0.53 0.56 0.52 0.52 0.52 
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D
M
 D
er f10 
0.58 0.58 0.58 0.58 0.58 
0.98 0.82 0.82
0.82 0.82 0.83 0.78 0.65 0.81 0.81
0.81
0.98
0.83
0.61
0.83
0.83
0.83
0.77
0.78
0.83
0.64
0.65
0.65
0.65
0.64
0.64
0.63 0.65 0.56 0.57 0.57 
7 H
D
M
 D
er p10 
0.57 0.57 0.57 0.57 0.57 0.98 
0.80 0.80
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0.60
0.82
0.82
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0.81
0.63
0.63
0.64
0.63
0.63
0.62
0.61 0.64 0.55 0.55 0.56 
8 S
H
R
IM
P
 P
en m
1 
0.56 0.56 0.56 0.58 0.57 0.82 0.80   
1.00
1.00 0.97 0.93 0.79 0.68 0.82 0.82
0.83
0.81
0.93
0.58
0.92
0.93
0.92
0.90
0.92
0.98
0.63
0.63
0.63
0.64
0.63
0.63
0.61 0.64 0.56 0.57 0.57 
9 S
H
R
IM
P
 P
en v1 
0.56 0.56 0.56 0.58 0.57 0.82 0.80 1.00 
1.00 0.97 0.93 0.79 0.68 0.82 0.82
0.83
0.81
0.93
0.58
0.92
0.93
0.92
0.90
0.92
0.98
0.63
0.63
0.63
0.64
0.63
0.63
0.61 0.64 0.56 0.57 0.57 
10 S
H
R
IM
P
 P
en j1 
0.56 0.56 0.56 0.58 0.57 0.82 0.80 1.00 1.00
0.97 0.93 0.79 0.68 0.82 0.82
0.83
0.81
0.93
0.58
0.92
0.93
0.92
0.90
0.92
0.98
0.63
0.63
0.63
0.64
0.63
0.63
0.61 0.64 0.56 0.57 0.57 
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H
R
IM
P
 P
an e 
0.57 0.57 0.57 0.59 0.58 0.82 0.81 0.97 0.97
0.97   
0.93 0.79 0.69 0.82 0.82
0.83
0.81
0.92
0.59
0.92
0.93
0.92
0.88
0.90
0.96
0.64
0.63
0.64
0.65
0.64
0.63
0.62 0.64 0.57 0.58 0.58 
12 LO
B
S
TE
R
 H
om
 a 
0.57 0.57 0.57 0.58 0.58 0.83 0.82 0.93 0.93
0.93 0.93 
0.80 0.68 0.83 0.82
0.83
0.83
0.97
0.60
0.96
0.97
0.97
0.86
0.87
0.94
0.63
0.63
0.64
0.64
0.63
0.62
0.61 0.63 0.57 0.57 0.58 
13 M
ID
G
E
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hi k 
0.55 0.55 0.55 0.56 0.56 0.78 0.76 0.79 0.79
0.79 0.79 0.80 
0.64 0.87 0.86
0.87
0.78
0.80
0.58
0.80
0.80
0.80
0.75
0.77
0.80
0.61
0.62
0.62
0.62
0.60
0.60
0.59 0.62 0.55 0.56 0.56 
14 S
ILV
E
R
FIS
H
 Lep s 
0.48 0.48 0.48 0.49 0.48 0.65 0.64 0.68 0.68
0.68 0.69 0.68 0.64 
0.64 0.65
0.65
0.65
0.68
0.48
0.67
0.68
0.68
0.66
0.66
0.68
0.58
0.57
0.57
0.59
0.55
0.55
0.54 0.56 0.48 0.49 0.49 
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H
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la g7 0.55 0.55 0.55 0.56 0.55 0.81 0.80 0.82 0.82
0.82 0.82 0.83 0.87 0.64 
0.97
0.98
0.81
0.83
0.57
0.83
0.83
0.83
0.77
0.79
0.83
0.60
0.61
0.61
0.62
0.62
0.61
0.60 0.62 0.56 0.57 0.57 
16 C
O
C
K
R
O
A
C
H
 P
er a7 0.54 0.54 0.54 0.56 0.54 0.81 0.80 0.82 0.82
0.82 0.82 0.82 0.86 0.65 0.97 
0.98
0.81
0.83
0.58
0.83
0.83
0.83
0.77
0.79
0.83
0.61
0.61
0.62
0.62
0.62
0.61
0.60 0.63 0.56 0.57 0.57 
17 C
O
C
K
R
O
A
C
H
 P
er f 
0.55 0.55 0.55 0.56 0.55 0.81 0.80 0.83 0.83
0.83 0.83 0.83 0.87 0.65 0.98 0.98
0.81
0.84
0.58
0.84
0.83
0.84
0.78
0.80
0.83
0.61
0.61
0.61
0.62
0.62
0.61
0.60 0.63 0.56 0.57 0.57 
18 M
ITE
 Ale o10 
0.59 0.59 0.58 0.59 0.59 0.98 0.96 0.81 0.81
0.81 0.81 0.83 0.78 0.65 0.81 0.81
0.81
0.83
0.61
0.83
0.82
0.83
0.76
0.78
0.82
0.65
0.65
0.66
0.65
0.65
0.64
0.63 0.65 0.56 0.57 0.57 
19 C
R
A
B
 P
or s 
0.57 0.57 0.57 0.58 0.58 0.83 0.82 0.93 0.93
0.93 0.92 0.97 0.80 0.68 0.83 0.83
0.84
0.83
0.59
0.99
1.00
1.00
0.85
0.87
0.93
0.63
0.63
0.64
0.64
0.63
0.62
0.61 0.63 0.57 0.57 0.58 
20 B
A
R
N
A
C
LE
 B
al r 
0.51 0.51 0.51 0.52 0.51 0.61 0.60 0.58 0.58
0.58 0.59 0.60 0.58 0.48 0.57 0.58
0.58
0.61
0.59
0.59
0.59
0.59
0.57
0.58
0.60
0.73
0.74
0.74
0.73
0.77
0.76
0.75 0.74 0.67 0.67 0.67 
21 C
R
A
B
 E
ri i 
0.57 0.57 0.57 0.58 0.58 0.83 0.82 0.92 0.92
0.92 0.92 0.96 0.80 0.67 0.83 0.83
0.84
0.83
0.99
0.59
0.99
0.99
0.85
0.86
0.93
0.63
0.63
0.64
0.64
0.63
0.62
0.61 0.63 0.57 0.57 0.58 
22 C
R
A
B
 E
ri s 
0.57 0.57 0.57 0.58 0.58 0.83 0.82 0.93 0.93
0.93 0.93 0.97 0.80 0.68 0.83 0.83
0.83
0.82
1.00
0.59
0.99
0.99
0.85
0.87
0.94
0.63
0.63
0.64
0.64
0.63
0.62
0.61 0.63 0.57 0.57 0.58 
23 C
R
A
B
 P
or t 
0.57 0.57 0.57 0.58 0.58 0.83 0.82 0.92 0.92
0.92 0.92 0.97 0.80 0.68 0.83 0.83
0.84
0.83
1.00
0.59
0.99
0.99
0.85
0.87
0.93
0.63
0.63
0.64
0.64
0.63
0.62
0.61 0.63 0.57 0.57 0.58 
24 KR
ILL Eup s 
0.56 0.56 0.56 0.57 0.56 0.77 0.75 0.90 0.90
0.90 0.88 0.86 0.75 0.66 0.77 0.77
0.78
0.76
0.85
0.57
0.85
0.85
0.85
0.98
0.90
0.63
0.63
0.63
0.64
0.62
0.62
0.60 0.63 0.56 0.56 0.56 
25 KR
ILL Eup p 
0.57 0.57 0.56 0.58 0.57 0.78 0.77 0.92 0.92
0.92 0.90 0.87 0.77 0.66 0.79 0.79
0.80
0.78
0.87
0.58
0.86
0.87
0.87
0.98
0.92
0.63
0.63
0.63
0.64
0.63
0.62
0.61 0.63 0.56 0.56 0.57 
26 S
H
R
IM
P
 O
ra o 
0.56 0.56 0.56 0.58 0.57 0.83 0.81 0.98 0.98
0.98 0.96 0.94 0.80 0.68 0.83 0.83
0.83
0.82
0.93
0.60
0.93
0.94
0.93
0.90
0.92
0.64
0.64
0.64
0.64
0.64
0.63
0.62 0.65 0.57 0.58 0.58 
27 SQ
U
ID
 Tod p 
0.54 0.54 0.54 0.55 0.54 0.64 0.63 0.63 0.63
0.63 0.64 0.63 0.61 0.58 0.60 0.61
0.61
0.65
0.63
0.73
0.63
0.63
0.63
0.63
0.63
0.64
0.96
0.98
0.91
0.81
0.80
0.78 0.82 0.69 0.70 0.71 
28 S
Q
U
ID
 S
ep l 
0.54 0.54 0.54 0.54 0.54 0.65 0.63 0.63 0.63
0.63 0.63 0.63 0.62 0.57 0.61 0.61
0.61
0.65
0.63
0.74
0.63
0.63
0.63
0.63
0.63
0.64
0.96
0.98
0.92
0.82
0.81
0.79 0.84 0.70 0.71 0.71 
29 C
U
TTLE
FIS
H
 S
ep e 
0.54 0.54 0.54 0.55 0.55 0.65 0.64 0.63 0.63
0.63 0.64 0.64 0.62 0.57 0.61 0.62
0.61
0.66
0.64
0.74
0.64
0.64
0.64
0.63
0.63
0.64
0.98
0.98
0.92
0.82
0.81
0.78 0.84 0.70 0.71 0.71 
30 C
U
TTLE
FIS
H
 O
ct v 
0.55 0.55 0.55 0.56 0.55 0.65 0.63 0.64 0.64
0.64 0.65 0.64 0.62 0.59 0.62 0.62
0.62
0.65
0.64
0.73
0.64
0.64
0.64
0.64
0.64
0.64
0.91
0.92
0.92
0.83
0.82
0.79 0.83 0.70 0.71 0.71 
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B
A
LO
N
E
 H
al a 
0.55 0.55 0.54 0.55 0.55 0.64 0.63 0.63 0.63
0.63 0.64 0.63 0.60 0.55 0.62 0.62
0.62
0.65
0.63
0.77
0.63
0.63
0.63
0.62
0.63
0.64
0.81
0.82
0.82
0.83
0.99
0.96 0.87 0.74 0.75 0.75 
32 A
B
A
LO
N
E
 H
al d 
0.55 0.55 0.54 0.55 0.54 0.64 0.62 0.63 0.63
0.63 0.63 0.62 0.60 0.55 0.61 0.61
0.61
0.64
0.62
0.76
0.62
0.62
0.62
0.62
0.62
0.63
0.80
0.81
0.81
0.82
0.99
0.97 0.86 0.74 0.74 0.74 
33 A
B
A
LO
N
E
 H
al r 
0.53 0.53 0.53 0.53 0.53 0.63 0.61 0.61 0.61
0.61 0.62 0.61 0.59 0.54 0.60 0.60
0.60
0.63
0.61
0.75
0.61
0.61
0.61
0.60
0.61
0.62
0.78
0.79
0.78
0.79
0.96
0.97
0.85 0.71 0.72 0.72 
34 S
N
A
IL H
el a 
0.56 0.56 0.55 0.56 0.56 0.65 0.64 0.64 0.64
0.64 0.64 0.63 0.62 0.56 0.62 0.63
0.63
0.65
0.63
0.74
0.63
0.63
0.63
0.63
0.63
0.65
0.82
0.84
0.84
0.83
0.87
0.86
0.85 
0.70 0.70 0.71 
35 M
U
S
S
E
L P
er v 
0.51 0.51 0.51 0.52 0.52 0.56 0.55 0.56 0.56
0.56 0.57 0.57 0.55 0.48 0.56 0.56
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Table S3. Sequence identity of tropomyosin sequences
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Figure S1. Overview of tropomyosin cross-reactivities (A) and IgE epitopes (B) as reported in literature. (A) 
The allergens that are primarily binding IgE antibodies are listed vertically. These same IgE antibodies also re-
act in a secondary manner to the allergens listed in the top row (indicated by a filled box). The most prominent 
allergens that IgE antibodies show secondary reactions to, are indicated with red letters (Der p 10, Met e 1, 
Pen a 1, and Per a 7). (B) Several epitope regions have been identified, which are indicated with roman letter 
and grey shading of the shrimp (pen a 1) sequence.
next page: Figure S2. ClustalW Alignment of amino acid sequences of tropomyosin. Shrimp (pen a1) is used 
as template; amino acids identical to shrimp are indicated with a dot. 
A
A
 50    Chapter 2 
chapter 3
An alternative inhibition method for diagnosis 
of allergy: Two patients with a ficus (Ficus benja-
mina) and fig (Ficus carica) sensitization
Gerco den Hartog, Ad P. H. Jansen, Yvonne Schmidt,
Annelies Verlaet, Nicolette W. de Jong, Lisette Berendsen,
Huub F. J. Savelkoul, Janneke Ruinemans-Koerts
 52    Chapter 3 
ABSTRACT
Inhibition assays are a useful tool to identify the allergen of primary sensitization of cross-reactive 
allergens. Inhibition assays often depend on extracts made at the laboratory that may be subject 
to significant batch differences and are laborious to obtain. We developed an ImmunoCap based 
inhibition method that uses commercially available Caps as allergen source. This ImmunoCap 
inhibition method was used to study cross-reactivity between fig (Ficus carica) and ficus (Ficus 
benjamina). The newly developed method was validated against a classically applied inhibition 
method.
The ImmunoCap inhibition method showed reproducible results, and were consistent with the 
classical inhibition method. We conclude that ImmunoCaps are a useful allergen source for 
inhibition assays.
INTRODUCTION
Cross-reactivity between allergens from different 
species is a common phenomenon in IgE-
mediated allergy. When the primary sensitizing 
agent is in question, inhibition assays are applied 
to determine the primary sensitizing allergen. 
Classically, information about cross-reactive 
allergens is obtained by adding allergen extract to 
the patients’ serum and detecting the remaining 
unbound IgE (1, 2). This method requires the 
availability of the cross-reactive allergen extracts. 
As availability of commercial allergen extracts is 
limited and making allergen extracts that generate 
reproducible results is laborious, a simple and 
reliable alternative inhibition method is desirable.
Specific IgE measurement against more than 400 
allergens can be performed on the ImmunoCap 
system (Phadia, Thermofischer Scientific) with 
allergen-coated cellulose sponges (Caps). We 
developed a procedure to use these Caps as an 
alternative allergen source in inhibition assays 
and tested this method for two patients with both 
a ficus (Ficus benjamina, also called weeping 
or Benjamin’s fig) and fig (common fig having 
consumable fruits, Ficus carica) sensitization. 
Exposure to ficus is likely mainly through 
inhalation, whereas exposure to the fruits of 
common fig is mainly through ingestion (3, 4). In 
addition, ficus and fig have been reported as cross-
reactive allergens before (5,6).
Results of the alternative inhibition method were 
compared to a classical inhibition method (IgE 
inhibition with allergen extracts). Differences in 
the results of the inhibition experiments between 
the patients were correlated to clinical symptoms 
and results of the in vitro functional Basophil 
Activation Test (BAT).
MATERIALS AND METHODS
Allergen Extracts
For SPT, fig fruit (Ficus carica) extract was prepared 
from ripe figs with peel. Ficus (Ficus Benjamina) 
extract was prepared from parts of leaves and stem. 
The parts were cut into small pieces, minced in 25 
% (w/v) extract in phosphate-buffered saline, pH 
7.4, containing 0.03 % human serum albumin and 
0.5 % phenol (PBS) and centrifuged. Supernatants 
were passed through a 0.22 μm filter (Millipore). The 
same procedure was followed extract For inhibition 
assays, except that 10% w/v extracts were prepared in 
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phosphate buffered saline, pH 7.4, with 0.2% NaN3, 
0.2% tween, 0.3% BSA (PBS-AT).
IgE-based inhibition with allergen coated CAP-
sponges
Eight ficus (k81) and four fig (f328) coated 
celullose sponges (Phadia, Uppsala, Sweden, now 
part of Thermofisher Scientific) were carefully 
removed from the capsule. The preserving liquid 
was first removed by drying the sponge between 
filtering paper twice. Subsequently, the sponge 
was washed 3 times with 0.5 ml wash solution and 
the remaining liquid in the sponge was squeezed 
out with a stire wire, followed by drying between 
filtering paper. Then the sponge was placed back in 
a clean and dry capsule and the capsule was placed 
in an eppendorf cup.
Patient serum (40 µl) was pipetted to 4 ficus 
sponges and incubated at 37 ºC for 30 min (Figure 
1). The sponges were centrifuged at 12.000g for 3 
min. The 4 eluates were pooled and 40 µl was added 
to 3 ficus sponges, incubated and centrifuged. The 
3 eluates were pooled and 40 µl was added to two 
fig sponges and 1 ficus sponge. The two eluates of 
the fig sponges were pooled and 40µl was added 
to a new fig sponge. The eluate of the ficus sponge 
was not further analysed. All the incubated 
sponges were placed back in a new clean capsule 
and placed in the ImmunCap250. IgE binding was 
measured according to the standard procedure of 
the ImmunoCap250 and buffer was used as sample 
instead of serum (see also Figure 1A).
This procedure was repeated to study inhibition by 
fig allergens as visualized in figure 1B.
IgE-based inhibition with allergen extracts
A dose-dependent inhibition study was performed 
by incubating ficus or fig extract with patient serum 
at room temperature for 2h. Final concentration 
of extract protein in the patient serum was 400 
μg/ml protein for fig and 711 μg/ml protein for 
ficus. After incubation with the allergens, the 
remaining unbound IgE was measured by the 
ImmunoCap method. The percentage of inhibition 
at concentration inhibitor x was calculated as % 
inhibitionx =(IgE0%-IgEx)/(IgE0%)*100. Incubation 
of serum with PBS was taken as 0% inhibition 
(IgE0%).
Basophil Activation Test (BAT)
The BAT was performed with the Flow2-CAST 
(Bühlmann, Basel, Switzerland) according to the 
instructions of the manufacturer. CD63 expression 
on basophils > 6% was regarded as a positive test 
result. Concentration of ficus and fig allergen in 
the stimulation was up to 100 and 5000 ng/ml 
respectively.
RESULTS
Clinical description of patients
Patient A is a 61 year old woman with intermittent 
moderate to severe allergic rhinitis due to a three 
pollen allergy. She frequently ate dried figs until 
she experienced an acute anaphylactic shock while 
eating it. She recuperated swiftly after treatment 
with adrenaline in a local emergency department. 
She has no history of asthma or food allergy. She 
never had known contact with F. benjamina.
Patient B is a 53 year old woman with persistent 
mild allergic rhinitis and IgE sensitisation to house 
dust mite, but not to grass or tree pollen. In her 
living room, she has several F. benjamina plants, 
but she has no complaints while tending to these 
plants. She has often eaten dried figs without any 
adverse reaction. While on holiday in Turkey, she 
ate a fresh fig for the first time. Within minutes, 
she experienced an acute hypersensitivity reaction 
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with generalized urticaria, vomiting, diarrhea, 
facial angio-edema and asthma. This reaction 
was treated with adrenaline in a local emergency 
department.
IgE-based inhibition with allergen coated 
sponges
Inhibition of serum of patient A with one ficus 
sponge resulted in complete inhibition of ficus 
specific IgE. However, for patient B after two 
inhibition rounds with ficus sponges about 3.5% of 
the initial IgE level of ficus IgE was still detected 
(also observed after repeating the analysis) (Figure 
1A). Pre-incubation of serum with ficus sponges 
completely or 88% inhibited detection of fig 
specific IgE in serum of patient A respectively B.
Inhibition with one fig sponge resulted in complete 
inhibition of fig IgE, and 50% inhibition of ficus 
IgE for patient A. For patient B, inhibition with 
one fig sponge was not complete and with a second 
and third sponge 8.5% of the initially detected 
fig specific IgE was still detected (Figure 1B). 
Inhibition with three fig sponges resulted in about 
55% inhibition of ficus specific IgE.
IgE-based inhibition with allergen extracts
Inhibition with fig extract resulted in 100% 
inhibition of fig specific IgE, but partly (around 
30%) inhibition of ficus specific IgE (Figure 2A). 
The shape of the inhibition curves is similar for 
both patients.
Inhibition with ficus extract resulted in 80-
Figure 1. Inhibition of IgE-binding to fig and ficus allergens by ficus (A) and fig (B). Allergens on CAPS are 
used as allergen source for inhibition. IgE levels bound by the inhibitor-CAP are analysed and remaining 
allergen-specific Ig is detected on new CAPS using the default ImmunoCAP procedure.
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100% inhibition of both ficus and fig specific 
IgE. However, the shape of the inhibition curves 
of patient A and B differ clearly. Inhibition of 
ficus and fig specific IgE was observed at a lower 
concentration for patient A than for patient B.
Basophil Activation Test (BAT)
Ficus extract resulted in 90% and 80% of activated 
basophils for patient A and B respectively (Figure 
2C). The allergen concentration at which 50% 
activation was detected was 10  ng/ml for patient A 
and 20 ng/ml for patient B respectively.
Addition of fig extract in the BAT resulted in 
60% of activated basophils for both patients, 
However, the allergen concentration at which 50% 
stimulation was reached was significantly different 
between the two patients; 4000 ng/ml for patient A 
and 1200 ng/ml for patient B.
Figure 2. ELISA inhibition assay with fig (A) and ficus (B) extract, and BAT (C). Values on x-axes show con-
centration of inhibitor allergen (A and B), and concentration of allergen added to basophils (C). Y-axes indicate 
percentage of inhibition (A and B) or percentage of activated basophils (C). 
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DISCUSSION
In this study we aimed at applying an ImmunoCap-
based inhibition method to identify the allergen of 
primary sensitization. Both the classically applied 
inhibition method and the ImmunoCap based 
inhibition method showed that pre-incubation 
with ficus resulted in almost complete inhibition of 
detectable fig specific IgE in serum. When fig was 
used during pre-incubation, only partial inhibition 
of detectable IgE specific for ficus was achieved. 
Based on this we conclude that ficus was the 
allergen of primary sensitization. This is consistent 
with the different levels of specific IgE; specific IgE 
to ficus was higher compared to fig.
Although both patients were primarily sensitized 
to ficus, IgE inhibition results showed that for 
patient B, higher amounts of ficus and fig allergen 
were required to inhibit binding of remaining IgA 
to ficus or fig allergen. In addition, binding of IgE 
of patient B could not be completely inhibited 
in both inhibition assays. This indicates that 
IgE of patient A and B may recognize different 
epitopes of the allergens and that the affinity of 
IgE may be different for the fig and ficus allergens. 
This difference in IgE profile might explain the 
difference in results of the BAT and clinical 
symptoms for patient A and B; patient A is allergic 
to dried fig, patient B only to fresh fig (dryed fig 
was tolerated) and lower concentrations of fresh fig 
extract in the BAT resulted in a higher response 
of activated basophils for patient B compared to 
patient A.
In conclusion, we developed a reproducible 
alternative inhibition method using ImmunoCaps. 
This novel method makes use of commercially 
available allergens of a validated diagnostic 
instrument and provides result consistent with 
a classical inhibition assay, which can give 
information of the primary sensitizing allergen 
and differences in IgE profiles.
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Allergen-specific IgA2, but not IgA1, is 
associated with protection against eczema in 
house dust mite allergic patients
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ABSTRACT
Upon inhalation, house dust mite (HDM) allergens are deposited at the nasal and oral mucosa, 
where IgA is produced abundantly.
It is currently not known if and how the human IgA subclasses IgA1 and IgA2 contribute to the 
clinical status of house dust mite-allergic patients.
HDM-allergic patients were subjected to a standardized nasal provocation tests (SNPT) with multiple 
concentrations of HDM. Peak nasal inspiratory flow (PNIF) measurements were performed and the 
allergen threshold was determined by a nasal composite symptom score (NCSS). Saliva and serum 
samples were collected, and HDM-specific IgG4, IgE, IgA1 and IgA2 levels were determined.
As expected, HDM-specific serum IgE levels correlated positively with serum IgG4 levels. HDM-
specific levels of IgA1 in serum were similar to levels measured in non-allergic controls, but HDM-
specific levels of IgA2 in serum were decreased in allergic subjects. Division of the HDM-allergic 
patients into groups of patients that suffered from eczema and patients that did not have eczema 
showed that this decrease in IgA2-levels was most prominent in HDM-allergic patients that also 
suffered from eczema alone, or in combination with asthma. In addition, HDM-specific IgA2 levels 
in saliva were decreased significantly in HDM-allergic patients compared to non-allergic controls. 
The ratio of HDM-specific serum IgE over HDM-specific IgA2 levels in saliva correlated significantly 
with the combination of the HDM provocation threshold and PNIF. 
Taken together, our findings indicate that HDM-specific IgA2, but not IgA1, levels in serum and 
saliva are reduced in HDM-allergic patients suffering from eczema.
INTRODUCTION
Detection of allergen-specific IgE in serum is a 
widely used method to evaluate sensitization to 
allergens. However, levels of allergen-specific 
IgE in serum often correlate poorly with the 
intensity of clinical manifestations of allergy [1, 2]. 
Increasing evidence is showing that production of 
allergen-specific IgG4 antibodies correlate with 
protection against allergy [3]. Moreover, IgG4 is 
able to block crosslinking of IgE on mast cells and 
basophils [4]. IgG4 production is increased after 
allergen-specific immunotherapy, and increased 
production of allergen-specific IgG4 correlates 
with clinical efficacy [5]. Allergen-specific IgG4 
can also decrease allergen-IgE complex binding 
to CD23 and subsequent activation of T cells [6, 
7]. This has been shown to correlate better to the 
clinical status of allergy patients than allergen-
specific IgE levels per se. 
In addition to IgG4, IgA has been postulated in the 
past to protect against allergy, and recently salivary 
IgA was shown to be associated with protection 
against allergy [8-12]. IgA is the dominant isotype 
present at mucosal surfaces, and therefore is the 
first antibody isotype to come into contact with 
allergens that are deposited in the airways or the 
gastro-intestinal tract. The presence of allergen-
specific IgA at mucosal surfaces may therefore 
prevent allergens from entering the body by 
inducing aggregates, or by blocking IgE-binding 
epitopes. In line with this, allergen-binding IgA2- 
but not IgA1-producing B cells in nasal tissue 
have been observed after successful birch-pollen 
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immunotherapy [13].
Despite this hypothetical mechanism of IgA-
mediated protection, attempts to correlate allergen-
specific serum-IgA levels with the presence or 
absence of allergy or with severity of allergic 
symptoms have generally been unsuccessful [14-
16]. The majority of mucosal IgA is produced 
locally in the mucosal tissue, and does not 
originate from systemic sources [17-23]. This may 
explain why studies relating allergen-specific IgA 
in saliva to inhalant allergies were more successful 
than studies measuring IgA in serum [8, 9].
Humans produce two subclasses of IgA, namely 
IgA1 and IgA2 [24]. The distribution of IgA 
subclasses is throughout the body differs between 
IgA1 and IgA2; IgA1 levels are higher compared to 
IgA2 in serum and most mucosal sites including 
saliva, whereas jejunum and colon are dominated 
by IgA2 [25-27]. IgA2 is more resistant to bacterial 
proteolysis due to the shorter hinge region of the 
antibody [28]. The structural difference between 
IgA1 and IgA2 as well as the different distribution 
throughout the body suggest a different role in 
mucosal immunity for the two IgA subclasses.
The vast majority of studies on the role of IgA in 
allergy only report allergen-specific levels of total 
IgA without differentiating between IgA1 and 
IgA2. This may contribute to the lack of correlation 
between serum-IgA levels and allergy. Therefore 
the aim of this study was to relate allergen-specific 
levels of IgA1 and IgA2 in serum and saliva to 
clinical symptoms in house dust mite allergic 
patients.
MATERIALS AND METHODS
Patients and controls
HDM-allergic patients, male and female and aged 
14 years or older, with a positive medical history 
of allergic rhinitis with or without concomitant 
clinically stable asthma (FEV1 > 80% predicted), 
and with or without mild to moderate atopic 
dermatitis (SCORAD < 2) were skin tested with 
common inhalant allergens (HAL Allergy BV, 
Leiden, the Netherlands). The mean HDM-specific 
IgE levels of patients was 14.5 kU/L (standard 
deviation +/- 22). Patients with a positive HDM skin 
test underwent a standardized nasal provocation 
test (SNPT) to multiple increasing allergen doses 
as defined in table 1. Patients were screened for 
contraindications such as severe asthma or use 
of interfering medication. If applicable, patients 
had to stop the use anti-histamines three days and 
steroid nasal sprays one week before the SNPT. 
Immediately after reaching the provocative nasal 
threshold, saliva (using salivettes, 51.1534.500, 
Sarstedt, Nümbrecht, Germany) and serum 
samples (serum vacutainers, BD, Franklin Lakes, 
NJ USA) were collected and stored at -20°C until 
use. All SNPTs were done outside the pollen 
seasons to correct for active hay fever symptoms.
Nasal
Combined
Score
HDM
concentration
(AU/mL)
PNIF
1 10 >80
2 10 40-80
3 10 <40
4 1 >80
5 1 40-80
6 1 <40
7 100 >80
8 100 40-80
9 100 <40
Table 1.  Nasal combined score (NCS)
The NCS is derived from peak nasal inspiratory 
flow (PNIF) and maximum tolerated house dust 
mite (HDM) dose. Increasing clinical symptoms is 
reflected by higher NCS.
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All procedures were performed as specified in the 
EAACI position article and guidelines [29].The 
investigations were approved by the local Medical 
Ethical Committee.
Control subjects did not suffer from asthma or 
eczema. In the inclusion of control subjects (seven 
males, seven females), no clinical symptoms of 
allergy or sensitization to house dust mite was 
allowed. Four of the fourteen controls suffered 
from seasonal rhinitis due to pollen allergy. 
Samples from patients and control subjects were 
collected outside the pollen season.
Standardized titrated nasal provocation test 
(SNPT)
The SNPT on the HDM-patients was performed 
according to a protocol described elsewhere [30]. 
In short, after an hour acclimatization period the 
baseline NCSS (according to Lebel) and baseline 
nasal inspiratory flow (PNIF) (highest value of 
three measured by nasal inspiratory flow meter 
(Clemens Clarke, Harlow, UK) were noted. 
Symptoms were recorded using the following 
scoring system: sneezes ≤ 2 = 0 points, sneezes 
3-4 = 1 point, sneezes ≥ 5 = 3 points, anterior 
rhinorrhoea = 1 point, posterior rhinorrhoea = 1 
point, difficult breathing = 1 point, one blocked 
nostril = 2 points, two blocked nostrils = 3 points, 
nasal itch = 1 point, pruritus in palate or ear = 1 
point, conjunctivitis = 1 point (total score range: 
0-11 points). The pre-diluent NCSS was not 
allowed to be  ≥ 3 points. The NCSS was considered 
positive once a total score ≥ 6 was reached.
The SNPT started with the allergen’s diluent 
followed by spraying of 1 puff into each nostril 
of a standardized HDM extract (HAL Allergy, 
Leiden, the Netherlands) in stepwise incremental 
concentrations of 100, 1,000 and 10,000 AU/
ml. The upper airway response was quantified by 
NCSS and PNIF 15 minutes after each challenge.
Nasal combined score
To relate HDM-specific IgA levels to NCSS, PNIF 
and the maximum tolerated HDM dose and the 
measurements of SNPT were combined into a 
nasal combined score (NCS), as described in Table 
1. Patients able to tolerate a higher dose and less 
nasal obstruction received a low score, whereas 
patient tolerating a low dose of allergen and having 
a reduced PNIF received a high score, reflecting 
more severe clinical symptoms.
Detection of HDM-specific IgE and IgG4
HDM (Dermatophagoides pteronyssinus, CAP d1) 
specific IgG4 and IgE levels in serum and saliva 
were determined with ImmunoCap 250 (Thermo 
scientific, Uppsala, Sweden), using the standard 
procedure. 
Detection of HDM-specific IgA1 and IgA2
HDM extract (0.2 µg/ml, HAL allergy, Leiden, 
The Netherlands) was coated overnight at 4°C. 
Plates (medium binding, Greiner Bio-one) were 
blocked with biotin free Universal Casein Diluent/
Blocker (SDT reagents, Germany) for one hour 
at room temperature. Plates were washed three 
times with PBS containing 0.05% tween-20. All 
samples were tested in duplicate and diluted 5 
and 20 times. Plates were washed (3 times) and 
2000 times diluted biotinylated mouse anti human 
IgA1 or IgA2 (Southern Biotech, Birmingham, 
AL, USA) was added and incubated for 1 hour at 
room temperature. Plates were washed (5 times) 
and streptavidin poly HRP 80 (SDT reagents) 
was added and incubated. Plates were washed six 
times and stable soluble 1-component TMB was 
added (SDT reagents). 1% HCl was used as stop 
solution. Plates were read at 450 nm with 650 nm 
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as reference. HDM-specific IgA2 levels did not 
correlate with IgA total levels or HDM-specific 
IgA1 levels, indicating that the assay show HDM-
specific levels of IgA subclasses.
Statistics
ELISA data were entered in PASW Statistics version 
19. The independent samples T-test was used to 
test concentration differences between groups and 
the procedure Generalized linear models was used 
to evaluate the nasal combined score in relations to 
detected allergen specific Ig levels.
RESULTS
Patient description
 In total 19 HDM-allergic subjects, six males and 
13 females, were included in the study and were 
subjected to the SNPT. All 19 patients suffered 
from rhinitis. 10 patients also had eczema, and four 
of these also suffered from asthma. One patient 
had symptoms of asthma but not eczema (Table 2).
All 19 clinically diagnosed HDM-allergic 
patients had significantly increased serum levels 
of HDM-specific IgE compared to non HDM-
allergic subjects, who did not have detectable 
levels of HDM-specific IgE (Table 2). Serum of 
HDM-allergic patients and non-allergic subjects 
contained HDM-specific IgG4, however levels 
were significantly higher in serum of HDM-
allergic patients (Table 2). 
Nasal provocation of HDM-allergic patients 
with HDM-allergens mainly caused rhinorrhoea 
in patients with HDM allergy and concomitant 
pollen-related hay fever, and symptoms of blocked 
sinus in patients suffering from HDM-allergy only. 
HDM-allergic patients that also had pollen-related 
hay fever had increased levels of HDM-specific IgE 
(p=0.068) and IgG4 (p=0.053) in serum (data not 
shown).
HDM-specific IgA1 and IgA2 levels in serum 
and saliva
As detection of combined allergen-specific IgA 
levels is inconclusive in relation to the clinical 
status of patients, we analysed subclass-specific 
levels of HDM-specific IgA in serum. HDM-
allergic as well as non HDM-allergic control 
subjects had detectable levels of HDM-specific 
IgA1 and IgA2 levels in their serum. HDM-specific 
levels of serum IgA1 were similar between HDM-
allergic patients and non HDM-allergic control 
subjects (Figure 1). HDM-specific levels of IgA2 
in serum were decreased in HDM-allergic patients 
(p=0.082). This difference between HDM-specific 
IgA1 and IgA2 levels in serum suggests that the two 
IgA subclasses may play different roles in allergy. 
As locally produced IgA may be associated with 
protection against allergy, HDM-specific IgA2 
levels were measured in saliva as readily accessible 
mucosal secretion. Levels of HDM-specific IgA2 
in saliva were lower in HDM-allergic patients 
IgE IgG4
kU/l mg/l
14.5 0.27 Female 5 0 4 4 13
SD 22 SD 0.16 Male 1 1 0 4 6
<0.35 0.13 Female 0 0 0 5 5
SD 0.0 SD 0.11 Male 0 0 0 5 5
6 1 4 22 33
HDM-
allergic
Control
Total
Eczema
and
asthma
No eczema 
or asthma
Table 2.   Clinical symptoms of HDM-allergic patients and controls
Specific Ig levels
eczema asthma Total
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compared to non HDM-allergic control subjects 
p=0.084). HDM-allergic patients showed an 
insignificant trend of having decreased levels of 
HDM-specific IgA1 (Figure1). Taken together, 
decreased levels of HDM-specific IgA2 is 
associated with having HDM allergy. 
Clinical symptoms eczema and asthma are 
associated with decreased IgA2 levels
Eczema has previously been reported to be 
inversely associated with IgA levels [12, 31, 32]. 
Therefore we compared HDM-specific levels of 
IgA1 and IgA2 in serum and saliva in the absence 
or presence of eczema in HDM-allergic patients. 
Levels of HDM-specific serum-IgA1, saliva-IgA1 
and saliva-IgA2 were not different between HDM-
allergic patients with or without eczema (Figure 2). 
However, HDM-specific levels of IgA2 in serum 
were significantly lower when HDM-patients also 
suffered from eczema. Levels of HDM-specific 
Figure 1. HDM-specific levels 
of IgA1 (left) and IgA2 (right) in 
serum (top) and saliva (bot-
tom) of HDM-allergic and non 
HDM-allergic individuals. Error 
bars indicate standard error, and 
p-values of significant differences 
are indicated.
Figure 2. HDM-specific levels of 
IgA2 in serum, but not IgA1 or IgA 
levels in saliva are decreased in 
HDM-allergic patients that also 
have eczema (grey bars). Error 
bars indicate standard error, and 
p-values of significant differences 
are shown.
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IgA2 were similar between non-HDM-allergic 
subjects and HDM-allergic patients not suffering 
from eczema. Therefore the different serum-IgA2 
levels between HDM-allergic patients and control 
subjects seem to be caused by the sub-group of 
patients also suffering from eczema. Four of the ten 
HDM-allergic patients that suffered from eczema 
also suffered from asthma. Therefore we also 
analysed the relation between HDM-specific IgA2 
and the combination of eczema and asthma. Levels 
of HDM-specific IgA2 were further decreased 
in patients suffering from eczema and asthma 
compared to patients suffering from eczema alone 
(p=0.063) and HDM-allergic patients not suffering 
from eczema or asthma (p=0.001) (Figure 3). 
Based on these observations we conclude that 
serum IgA2 is associated with the severity of 
allergic symptoms noted in HDM-allergic patients.
The ratio of HDM-specific serum IgE over HDM-
specific IgA2 in saliva is linked to clinical status
To link the clinical parameters PNIF and maximally 
tolerated HDM dose (in SNPT) to levels of HDM-
specific immunoglobulins, the two parameters 
were combined into the ‘nasal combined score’ 
(NCS, Table 1). The NCS did, however, not correlate 
significantly with HDM-specific levels of serum 
IgE, IgG4, IgA1 and IgA2 or salivary IgA1 and IgA2 
alone (data not shown). As we hypothesized that 
the presence of IgA subclasses, especially IgA2 in 
the mucosa, is related to clinical status in addition 
to IgE, the ratio of HDM-specific IgE over IgA2 in 
saliva was calculated. The ratio of HDM-specific 
IgE over IgA2 correlated significantly (p=0.033) 
with clinical status as reflected by the ‘nasal 
combined score’. This correlation was significant 
for the ratio serum-IgE over saliva IgA2 levels, but 
not for serum-IgE over serum-IgA2 or serum-IgE 
over serum-IgG4 levels (Figure 4). 
DISCUSSION
he aim of this study was to identify if and how IgA 
subclasses relate to the clinical status of house dust 
mite-allergic patients. HDM-allergic patients had 
significantly lower levels of IgA2 in serum, which 
was most prominent in the subgroup of HDM-
patients that also suffered from eczema. Levels of 
HDM-specific IgE and IgA (IgA1 or IgA2) alone 
did not correlate to clinical status, but the ratio of 
allergen-specific serum-IgE over saliva-IgA2 was 
associated with the clinical status (nasal combined 
score) of the patients.  The data reported here 
demonstrate that the location of IgA (serum or 
saliva) and HDM-specific IgA2, but not IgA1, 
levels are highly relevant parameters to measure in 
Figure 3. Increased symptoms of HDM-allergic 
patients in associated with decreased levels of 
HDM-specific IgA2 in serum, as determined by 
absence or presence of eczema and asthma. Box 
plots indicate median (horizontal bar), 50% data 
range (box) and 1st and 4th quartile range (error 
bars), including all data points, except for a single 
outlier (*, allergic only).
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relation to HDM allergy. 
Both the PNIF and maximally tolerated dose of 
HDM-allergens were not directly associated with 
any of the concentrations of HDM-specific antibody 
classes. However, when PNIF and the maximally 
tolerated dose of HDM-allergens were combined 
as a measure of nasal hyperresponsiveness, a 
significant correlation was observed with the 
ratio of HDM-specific serum-IgE over saliva-
IgA2. The fact that not IgA2 levels alone but the 
ratio of serum-IgE over salivary-IgA2 correlated 
significantly with clinical symptoms in the nose 
suggests that IgA2 did not neutralize all allergens. 
In line with our hypothesis, local levels of allergen-
specific IgA2, but not systemic serum levels of IgA2 
correlated with nasal symptoms upon allergen 
challenge. This is in line with literature showing 
reduced development of wheezing in children later 
in life when higher secretary IgA levels in saliva 
were observed [33]. 
After immunotherapy allergen-specific IgG4 
levels in serum are increased and protect against 
allergy whilst IgE is still present [6, 34]. Increased 
levels of allergen-specific IgG4 induced after 
immunotherapy can block binding of allergen-IgE 
complexes to CD23 (IgE receptor) on B cells and 
prevent histamine release by basophils [35-37]. The 
ability of allergen-specific IgG4 to block IgE-CD23 
interaction depends on IgE repertoire complexity, 
as well as on the ratio of IgE over IgG [38]. 
Consequently, IgG4 that inhibits CD23-dependent 
IgE-allergen binding correlates better with clinical 
outcome than the ratio between allergen-specific 
IgE and IgG4 [39]. Allergen-specific serum-IgA is 
not able to block IgE-allergen-complex formation 
[13, 36]. Specific IgA2 levels, but not IgA1levels 
seem to be correlated with presence or absence 
of eczema, whereas the majority of serum IgA 
is of the IgA1 subclass, which may explain why 
serum IgA was unable to inhibit IgE-allergen 
complex formation. In contrast to serum IgA, IgA 
from mucosal secretions may inhibit histamine 
release, as shown in patients receiving ragweed-
immunotherapy [40]. Increased levels of salivary, 
but not serum, IgA after receiving sublingual 
peanut immunotherapy was associated with higher 
peanut consumption [41]. Thus, allergen-specific 
IgA may block entry of allergens at mucosal sites 
or result in non-inflammatory IL-10 production 
when IgA binds to the Fcalpha receptor (CD89) 
[13]. In addition to IgA-mediated mucosal 
protection, systemic protection is mediated by 
allergen-specific IgG4 induced by allergen-specific 
immunotherapy. We hypothesize that mucosal 
Figure 4. The nasal combined score (NCS) of HDM-allergic patients is associated with the ratio of serum IgE 
and saliva IgA2. The NCS (table 1) is derived the PNIF recorded upon intranasal challenge in combination with 
maximally tolerated HDM-allergen dose that was injected in the nostrils with incremental doses. Increasing 
levels of serum IgE or decreasing levels of salivary IgA2 are correlated with increased allergic symptoms.
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IgA2 may protect against allergy at mucosal 
surfaces of the respiratory tract and that systemic 
protection is mediated by IgG4 (Figure 5).
The data presented here support the notion 
that detection of allergen-specific IgA in serum 
should be IgA1 and IgA2 subclass specific, and 
be accompanied by measurements in saliva. 
Eczema correlated with reduced levels of systemic 
(serum) HDM-specific IgA2, but not serum-IgA1 
or mucosal IgA1 and IgA2 (saliva). Interestingly, 
the association between eczema and decreased 
IgA levels in serum has been reported by Soothill 
and colleagues in the seventies of the previous 
century, but has been topic of debate since then 
and the underlying mechanism still needs to 
be revealed.[12, 32, 42]. It should be noted that 
eczema reported in our patients is not necessarily 
caused by house dust mite allergy, for it is difficult 
to identify the exact cause of this type of eczema. It 
is unclear how systemic IgA2 may protect against 
eczema, while this association was not found for 
HDM-specific serum-IgA1. Probably local tissue 
factors like a proliferation inducing ligand (APRIL) 
and B cell activating factor (BAFF or BLyS) that are 
expressed in the mucosa and skin are involved in 
causing eczema. APRIL enhances the production 
of IgA2, rather than IgA1, and its expression is 
reduced in the skin of patients with atopic eczema 
[43, 44]. Similarly, infants colonized with toxic 
Staphylococcus aureus produced increased levels 
of APRIL (4 months of age) and IgA and were less 
frequently sensitized to food (18 months of age) 
and less frequently developed eczema (18 months 
of age) [31]. Thus it is possible that eczema patients 
have a decreased ability to produce allergen-
specific IgA2 in skin, which may be reflected by 
decreased levels of allergen-specific IgA2 in serum.
To functionally differentiate between production of 
IgA1 and IgA2, different mechanisms of induction 
of the two subclasses are required. Indeed, different 
mechanisms for induction of IgA1 and IgA2 seem 
to exist (Chapter 6 and [44, 45]). In contrast to IgA1, 
the induction of IgA2 production may be more 
efficient under the influence of innate factors like 
Figure 5. Model explaining the different roles of mucosal IgA and serum IgG4 in prevention of mast cell or 
basophil degranulation. The increased levels of mucosal (salivary) IgA may prevent allergen-entry or result in 
non-inflammatory downstream immune responses upon binding of IgA-allergen complexes with myeloid cells. 
Allergen specific IgG4 can inhibit formation of IgE-allergen complexes that can be bound by mast cells, baso-
phils or CD23 on B cells and thereby prevent cell-degranulation and Th2 cell activation.
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APRIL and BAFF produced by mucosal dendritic 
cells, epithelial cells and probably also in the skin 
by keratinocytes[44, 46]. The same mechanism 
could explain why numbers of IgA2-producing B 
cells but not IgA1-producing B cells in jejunum 
increase with age in infants, due to prolonged 
exposure to bacterial ligands [27]. In line with this 
observation, limited exposure to microbes has been 
associated with allergic symptoms in sensitized 
children [47]. Dendritic cells play a central role in 
mucosal induction of IgA2 production. Allergens 
delivered by sublingual immunotherapy are taken 
up by mucosal oral Langerhans-type dendritic 
cells that respond by increased production of 
the tolerogenic cytokines TGF-ß and IL-10 [48]. 
Those cytokines are crucial for both induction of 
T regulatory cell-mediated oral tolerance and for 
production of IgA. Tolerogenic DCs are found 
across mucosal compartments and can be induced 
by local mucosal factors [49]. DC-mediated 
induction of allergen-specific IgA2 upon mucosal 
immunotherapy has not been investigated, but 
may be an important factor to explain the success 
of immunotherapy. In this respect, the observation 
that nasal birch-pollen-specific IgA2 (but not 
IgA1) was induced after immunotherapy, and that 
serum-levels of birch-allergen-specific IgA2 were 
linked to levels of nasal TGF-ß expression levels is 
promising [13]. In addition, the IgA2 induced by 
allergen immunotherapy may directly contribute 
to induction of tolerance as monocytes produce 
IL-10 upon binding of IgA-allergen complexes 
[13].
To conclude, allergen-specific IgA2 levels in serum 
and saliva are associated with reduced symptoms 
of allergy. As local production of IgA2 probably 
occurs under the influence of tissue factors, future 
work should focus on mechanisms to specifically 
increase allergen-specific IgA2 levels in serum and 
mucosal sites to protect against development of 
asthma and eczema. 
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chapter 5
The mucosal factors retinoic acid and TGF-ß1 
induced phenotypically and functionally
distinct DC types
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ABSTRACT
Non-inflammatory DC subsets are crucial to prevent massive inflammation in the intestines. We 
wanted to investigate whether the mucosal factors RA and TGF-ß1 can induce phenotypically and 
functionally distinct DC types.
DCs were differentiated from monocytes in the absence or presence TGF-ß1 and RA. Phenotype as 
well as responsiveness to bacterial ligands was studied in detail.
Compared to moDC, the expression the co-stimulating molecule CD86 and DC maturation marker 
CD83 were strongly reduced by RA and TGF-ß1. In addition, both RA and TGF-ß1 induced DC 
showed strongly decreased responsiveness to stimulation with bacterial ligands LPS and PGN, and 
produced significantly lower levels of the pro-inflammatory cytokines IL-12 and TNF-α compared 
to moDCs, whilst IL-10 production was not reduced significantly.
DCs differentiated under the influence of RA uniquely expressed markers related to intestinal hom-
ing (CD103 and integrin ß7). In addition, CCR7 that mediates homing to lymph nodes was ex-
pressed by DCs differentiated in the presence of RA, but also to a lesser extent by the other DC types. 
Further, whereas moDCs and TGF-ß1-derived moDCs expressed high levels of CD32, RA-derived 
DCs lacked CD32 expression but expressed high levels of CD64, suggesting that RA-DC may pri-
marily respond to soluble proteins and moDC and TGF-ß DCs to immune complexes.
The data presented here support the hypothesis that the mucosal factors TGF-ß1 and RA that can 
also be provided through dietary intake of dairy products, result in functionally and phenotypically 
distinct DC types with non-inflammatory properties. 
INTRODUCTION
the hematopoietic Fms-related tyrosine kinase 3 
ligand (Flt3l) for induction of CD103 DCs [7,8]. 
Other reports have demonstrated that RA is able to 
induce CD103 expression on human monocyte de-
rived DCs [3] or mouse bone marrow cells [9], but 
data on responsiveness to bacterial ligands is lack-
ing. Both DCs and CD4+ T cells can display tolero-
genic properties, which is reflected by expression 
of CD103 by DCs and forkhead box P3 (FoxP3) by 
T regs [1,3,5]. 
DC subsets exert different functional roles in the 
intestines, as evidenced by altered composition of 
the DC network in relation to disease. Increased 
numbers of CD11b+ DCs and decreased numbers 
of CD103+ DCs were observed after sensitization 
with peanut allergens in a mouse peanut allergy 
model [10]. DCs are also involved in the mecha-
nism underlying inflammatory bowel disease [11], 
The capacity of CD103+ DCs to induce peripheral 
tolerance by inducing FoxP3+ CD4+ Tregs has re-
ceived much attention [1,5]. Next to changes in 
A complex network of specialized DC subsets is 
involved in on the one hand inducing acute in-
flammatory responses upon invasion by patho-
gens, and on the other hand in inducing tolerance 
to harmless dietary and inhaled antigens and com-
mensal microbiota [1,2]. Knowledge on the role of 
local mucosal and dietary factors that induce these 
different DC types is still limited.
Intestinal epithelial cells have been shown to be 
able to induce tolerogenic DCs expressing integrin 
alpha E (CD103) [3]. Transforming growth factor 
ß (TGF-ß) and retinoic acid (RA) are major fac-
tors for conferring a tolerogenic environment in 
the mucosa by inducing regulatory T cells (Treg) 
and IgA-producing plasma cells [4,5]. Intestinal 
epithelial cells produce TGF-ß1 in steady state and 
can metabolize dietary vitamin A to retinoic acid. 
TGF-ß present in breast milk, has been associated 
with development of gut homeostasis and preven-
tion of allergy development in infants [6]. Murine 
but not human studies have indicated a role for 
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numbers of CD103+ DCs, expression of CD103 
Treg inducing capacity was lost in a mouse model 
of colitis [12]. Intestinal epithelial cells (IEC) are 
also important in the maintenance of intestinal 
homeostasis as IEC of patients suffering from 
colitis produce lower levels of Thymic stromal 
lymphopoietin (TSLP), TGF-ß1 and aldehyde de-
hydrogenase (ALDH). ALDH is involved in syn-
thesis of RA, and reduced expression of ALDG 
was concluded to be explanatory for the altered 
RA-dependent induction of Tregs in those patients 
[3,13]. 
Tolerogenic CD103+ DCs are discriminated from 
CX3CR1+ DCs for their different migratory ca-
pacity (homing to mesenteric lymph node) and 
location in the intestines [14] CX3CR1+ DCs lo-
cate close to the epithelium, whereas CD103+ DCs 
are more frequent deeper in the lamina proria. 
CX3CR1+ DC are abundantly found in the gut and 
sample soluble antigen and bacteria and have been 
shown to be able to protrude extensions through 
the epithelium into the lumen [15]. Complete ac-
tivation and differentiation of T cells in contact 
with antigen presenting DCs is determined by 
expression levels of costimulatory molecules like 
CD80 and CD86, and the production of  cytokines 
(TNF-α, IL-10, IL-12) and other soluble factors 
(e.g. RA). Next to induction of Tregs, TGF-ß and 
the metabolite of Vitamin A, RA, have been shown 
to play a role in the induction of IgA in vitro and 
mouse models, which is a major contributor to the 
first line of mucosal defence [4,16,17]. Vitamin A 
deficiency is associated with pathological signs in 
epithelia, which could be restored after supple-
mentation with vitamin A [18], but it is not known 
if the restoration of pathology was mediated by 
CD103+ DCs.
As data on the direct effects of RA and TGF-ß1 on 
DC phenotype and responses to bacterial ligands 
is strikingly limited, the current study aimed to 
identify how these mucosal factors affect DC phe-
notype and activation upon stimulation with bac-
terial ligand. Conventional monocyte derived DCs 
(moDC) were compared to moDCs that were dif-
ferentiated under the additional influence of TGF-
ß1 or RA. The expression of DC subtype specific 
cell surface markers, homing receptors, and IgG 
receptors was evaluated, as were their functional 
responses to stimulation by TLR ligands.
 
MATERIALS AND METHODS
PBMC and monocyte isolation
Peripheral blood mononuclear cells (PBMCs) ob-
tained from buffy coats of healthy blood donors 
(Sanquin Blood Bank Nijmegen, The Netherlands) 
were diluted 1:1 in IMDM (Gibco-BRL, Paisley, 
Scotland) and isolated by gradient centrifugation 
on Ficoll-Paque PLUS (Amersham Biosciences, 
Uppsala, Sweden) for 5 minutes at 200g and sub-
sequently for 15 min. at 500g (without brake at 
20ºC). The PBMCs were harvested from the Ficoll 
layer, gently resuspended in IMDM and washed 
two times in IMDM.
Freshly isolated PBMCs were labelled with Mi-
croBeads conjugated to mouse IgG2a monoclo-
nal anti human CD14 antibodies (130-050-201, 
Myltenyi Biotec,  Bergisch Gladbach, Germany) 
and incubated for 15 minutes at 4ºC, washed with 
MACS buffer (0.5% BSA, 2mM EDTA in PBS, pH 
7.2), centrifuged (10 min, 200g) and resuspended 
in MACS buffer. The MACS columns were placed 
in the quadroMACS (Myltenyi Biotec) and rinsed 
with MACS buffer. Subsequently, the cell suspen-
sion was added, the columns were rinsed three 
times with MACS buffer and removed from the 
quadroMACS; labelled cells were collected in a 
new tube by rinsing with MACS buffer and the 
supplied plunger.
Purity of the CD14+ cell population was between 
90 and 95%, as determined by flow cytometric 
analysis (FACS Canto II BD Biosciences, San Jose, 
CA, USA) by labeling the cells with mouse IgG2a 
anti human CD14 APC or an isotype control 
(clone M5E2, 555399 or 555576, BD Biosciences).
DC generation and stimulation
Isolated monocytes were cultured in RPMI (Lonza, 
Basel, Switserland) containing 10% standardized 
FCS (A15-551, PAA laboratories) and 1% pen/
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strep (Gibco, 15140) at a concentration of 1*106 
cells/ml. 50 ng/ml recombinant human GM-CSF 
(Peprotech, 300-03) and IL-4 (Peprotech, 200-04) 
were added and refreshed every second or third 
day. On day 7, expression of cell surface markers 
was analyzed using flow cytometry (FACS Canto 
II, BD Biosciences). Alternatively, DC subsets were 
generated by adding 10-5 M all-trans retinoic acid 
(Sigma Aldrich) or 10 ng/ml recombinant human 
TGF-ß1 (Peprotech) in addition to Il-4 and GM-
CSF. Like IL-4 and GM-CSF, RA and TGF-ß1 were 
refreshed every second or third day. Also TSLP (50 
ng/ml, Peprotech) was tested as factor for CD103 
induction.
After differentiation DCs were stimulated with 10 
ng/ml recombinant human IL-1ß (Peprotech) or 2 
µg/ml of LPS (S. typhimurium, L7261, Sigma, St 
Louis, USA), PGN (S. aureus, tlrl-pgnsa, Invivo-
Gen, Toulouse, France) or flagellin (S. typhimu-
rium, tlrl-stfla, InvivoGen).  Cell free supernatants 
were collected and stored at -80oC until analysis. 
DCs were collected and cell surface marker expres-
sion was analyzed. 
Cell Surface marker analysis
DCs were stained with antibodies against CD14 
(APC-H7, 560270, BD Biosciences), CD103 
(PE, 550260, BD Biosciences), CX3CR1 (PerCP-
eFluor710, 46-6099, eBioscience), HLA-DR (APC-
eFluor780, 47-9956-41, eBioscience), CD11b (PE-
Cy7, 25-0118, eBioscience), CD11c (V450, 560370, 
BD Biosciences), CD83 (FITC, 11-0839-42, eBio-
science), CD86 (V450, 560357, BD Biosciences), 
ß7 chain (APC, 551082, BD Biosciences), CCR7 
(FITC, 561271, BD Biosciences), CD209 (Per-
moDC RAmoDC TGFmoDC
CD14 - - -
HLA-DR ++ ++ ++
CD1a + - +
CD103 - + -
CX3CR1 - - -
CD11b ++ + +
CD11c ++ ++ +
CD86 + +/- +/-
CD83 + +/- +/-
FcRn - - -
CD16 - +/- -
CD32 + - ++
CD64 +/- ++ +
Table 1.  Basal expression of cell surface 
molecules
CP-Cy5.5, 558263, BD Biosciences), CD16 (PE, 
332779, BD Biosciences), CD32 (GTX74628, Ge-
neTex. Irvine, USA), CD64 (305015, BioLegend), 
FcRn (sc-271745, Santa Cruz, California, USA). 
For FcRn, CD32 and CD64 a secondary antibody 
labeled with FITC was used (goat anti mouse IgG/
IgM, 555988, BD Biosciences). Of each sample a 
control sample was analyzed, stained with control 
antibodies (same concentration as positive stain-
ing was used) of the same host species and isotype, 
conjugated with the same fluorochrome.
Cells were incubated at room temperature for 20 
minutes in the dark. Subsequently, cells were cen-
trifuged, supernatant discarded, 200 µl FACS Buff-
er (BD Biosciences) added, and analyzed for sur-
face marker expression by flow cytometric analysis 
(10 000 cells were analyzed using BD Canto II us-
Figure 1. Basal expression 
of CD11b and CD11c differs 
between DC subsets. Error 
bars indicate standard error. 
Significant differences are 
indicated. Significant differ-
ences are indicated in the 
diagrams.
5RA and TGF-ß1 - derived moDC subsets     73
ing DIVA software, BD). Data was batch processed 
and percentages and delta mean fluorescent inten-
sity (MFI) values (surface marker staining – iso-
type control staining) were obtained.
Human cytokine measurements
Human cytokine concentrations (IL-10, IL-12 and 
TNF-α, 558274, 558283 and 558273 respectively, 
BD Biosciences) in cell culture supernatants were 
determined using the cytometric bead array flex 
sets (BD Biosciences) and incubations were per-
formed in the recommended Protein Master Buff-
er Kit (BD Biosciences). Briefly, 50 µl supernatant 
was incubated with capture beads diluted in 50 µl 
Capture Bead Diluent for one hour at room tem-
perature in the dark. Next, PE Detection Reagent 
was diluted in 50 µl Detection Reagent Diluent, 
added and incubated for two hours at room tem-
perature in the dark. For the standard curve, the 
provided lyophilized recombinant cytokines were 
used and assayed together with the samples. After 
incubation the samples were centrifuged, superna-
tant discarded and 200 µl Wash Buffer was added. 
The samples were analyzed by flow cytometric 
analysis (FACS Canto II, BD Biosciences).
Statistical analysis
Statistical tests were performed in IBM SPSS Sta-
tistics v19. The independent samples t-test was 
used to test mean differences between DC types 
or treatments. Depending on equality of variances 
between test conditions, the p-value of equal or 
unequal variances assumed was reported.
 
RESULTS
Effects of RA and TGF-ß on DC differentiation
IL-4 and GM-CSF are generally used to generate 
DCs from monocytes. moDC are often used as 
model DC in studies on intestinal immunomodu-
lation. As the intestines contain several DC subsets, 
of which tolerogenic subsets are crucial for main-
taining homeostasis, we developed two additional 
DC subsets using the relevant mucosal factors RA 
and TGF-ß1. These factors were added to the dif-
ferentiating DCs in addition to IL-4 and GM-CSF. 
All three DC subsets expressed HLA-DR and 
lacked CX3CR1 and CD14 expression (Table 
1). Conventionally differentiated moDCs and 
TGF-ß1-derived DCs (TGFmoDCs) expressed 
CD1a, but RA-derived DCs (RAmoDCs) did not 
express CD1a (Table 1). 
All three DC types expressed CD11b and CD11c. 
Analysis of the MFI of CD11b revealed that 
TGF-ß1-derived DCs and even more so the RA-
derived DCs expressed reduced levels of CD11b 
compared to moDC (p=0.006 and p=0.001 re-
spectively, Figure 1A). CD11c expression was also 
Figure 2. Basal expression 
of MLN homing receptor 
CCR7 and ß7 chain of α4ß7 
complex is different between 
DC subsets (isotype cor-
rected). Error bars indicate 
standard error. Significant 
differences are indicated in 
the diagrams. p=0.004 p=0.011
p=0.003 p=0.012
p=0.007p=0.010p<0.001
 74    Chapter 5 
reduced (p=0.001 respectively p=0.006, Figure 
1B). This was more prominent for TGF-derived 
moDCs than for RA-derived moDCs, resulting in a 
significantly reduced CD11b/CD11c ratio for RA-
derived moDCs compared to moDCs (p=0.020, 
data not shown). 
As in vivo functionality of CD103+ DCs depends 
on co-expression of (α4)ß7 to adhere to E-cad-
herin and migrate to the intestine and on CCR7 
for homing to the MLN, we assessed expression 
of those cell surface markers on the different DC 
types. The percentage of CCR7-expressing cells 
doubled under the influence of RA but not under 
the influence of TGF-ß1 (Figure 2A). The MFI 
level of CCR7 was significantly higher on TGF-
derived moDC compared to moDCs, but not com-
pared to RA-derived moDCs. Addition of TGF-ß1, 
however, did not result in increased percentage of 
cells CCR7+ moDCs (Figure 2B). Apart from ex-
pression of CD103, the percentage (but not MFI) 
of DCs expressing the integrin ß7 was significantly 
higher for RA compared to moDC and TGF-ß1 
differentiated DCs (Figure 2C and 2D). 
The basal expression data of the three DC subsets 
are summarized in Table 1.
Differential expression of Fcγ receptors
Fc gamma Receptors (FcγR) have different affini-
ties for IgG. Low affinity FcγR (CD16) and high 
affinity FcγR (CD64) can bind to monomeric IgG 
whereas low affinity FcγR (CD32) binds to im-
mune complexes only [19]. CD32 was expressed by 
moDCs and TGF-derived moDCs, but not on RA-
derived moDCs (Figure 3). CD64 was expressed by 
all DC types, but its expression was highest on RA-
derived moDCs. FcγR expression pattern is simi-
lar for moDCs and TGF-derived moDCs, although 
expression of CD32 and CD64 seems to be higher 
on TGF-derived moDCs. RA-derived moDC have 
a different FcγR expression profile by expressing 
low levels of CD16 and high levels of CD64, but no 
CD32. Expression of the neonatal receptor (FcRn) 
could not be shown on any of the DC types.
Bacterial ligands reduce expression level of 
CD103 on RA-derived DCs
CD103 expression was induced by RA only and 
not by TGF-ß1 (Figure 4A). The integrin CD103 
binds to E cadherin expressed on epithelial cells 
when in complex with integrin ß7. CD103+ DCs 
are believed to migrate to the MLN upon activa-
tion, for which reduction of CD103 expression lev-
els may be essential, next to upregulation of CCR7 
which is responsible for homing to the MLN. RA-
derived DCs were stimulated with several bacte-
rial ligands and changes in CD103 expression level 
Figure 3. DC subtype specific expression of high 
affinity (E.g. CD64) and low affinity complex-binding 
(CD32) FcγR. Isotype controlled MFI values are 
shown. Error bars indicate standard error.
moDC RAmoDC TGFmoDC
CD14 - - -
HLA-DR ++ ++ ++
CD1a + - +
CD103 - + -
CX3CR1 - - -
CD11b ++ + +
CD11c ++ ++ +
CD86 + +/- +/-
CD83 + +/- +/-
FcRn - - -
CD16 - +/- -
CD32 + - ++
CD64 +/- ++ +
Table 1.  Basal expression of cell surface 
molecules
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were measured after 48 hours. Addition of bacte-
rial PGN (TLR 2/6 ligand) and LPS (TLR4 ligand) 
significantly reduced expression of CD103 (Figure 
4B).
DC subsets vary in expression of CD86 and 
CD83
Expression of co-stimulatory molecules is essen-
tial for complete activation of T cells. The per-
centage CD86-expressing cells was reduced in 
RA- and TGF-derived moDCs relative to moDC 
(p=0.013 respectively p=0.007), whereas the MFI 
of CD86 was only reduced in RA-derived moDCs 
(not significant, Figure 5). All CD83-expressing 
cells also expressed CD86 and comprise roughly 
half of the CD86+ cells. RA- and TGF-ß1-derived 
moDCs showed a reduced percentage of CD83+ 
cells compared to moDCs (p=0.002 respectively 
0.004), whereas the level of expression (MFI) was 
the same.
Although the percentage of basal expression of 
CD86 on TGF-ß1 and RA-derived moDCs was 
reduced, addition of bacterial ligands (48 hours) 
resulted in a pronounced upregulation of CD86 
expression on all DC types with most significant 
changes induced by exposure to LPS (Figure 6 and 
Table 2). However, after stimulation with the TLR 
ligands PGN and LPS the MFI of CD86 of RA- and 
TGF-derived moDC was still significantly lower 
compared to conventional moDCs, especially 
for RA-derived moDCs (Figure 6), indicating a 
state of non-responsiveness. Also, the percentage 
CD83+CD86+ cells upon activation with bacterial 
ligands, was significantly reduced when DCs were 
Figure 4. CD103 is expressed 
on RA-derived moDCs (A) 
and its expression is reduced 
after stimulation with bacterial 
ligands (B). Test of significance 
is performed on raw MFI data 
(left panel) or on normalized 
MFI data (right panel). Error 
bars indicate standard error of 
4 donors tested.
Figure 5. Basal expression of 
costimulatory molecule CD86 
and maturation marker CD83. 
All cells expressing CD83 co-
expressed CD86 (not shown). 
Data are corrected for isotype 
staining. Error bars show 
standard error of data obtained 
from 4 different donors. Signifi-
cant differences are indicated.
p=0.007
p=0.013
p=0.004
p=0.002
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differentiated in the presence of TGF-ß1 and RA. 
However, no differences in MFI of CD83 were ob-
served. 
Production of the proinflammatory cytokine 
TNF-α and IL-12 is reduced in RA and TGF-ß1 
– derived DCs
After stimulation with the bacterial ligands LPS 
and PG for 48 hours, cell culture supernatants 
were collected and cytokine production levels 
(TNF-α, IL-10, IL-12) were determined. Produc-
tion levels of all cytokines were decreased in cul-
tures with DCs differentiated in the presence of RA 
and TGF-ß1 (Figure 7). RA and TGF-ß1-derived 
moDCs, showed significantly reduced production 
of the pro-inflammatory cytokines TNF-α and IL-
12 compared to moDC (RA: p=0.017 and p=0.021 
respectively; TGF-ß1: p=0.013 and p=0.017 re-
spectively). TGF-derived moDC did not produce 
detectable IL-12, and strongly reduced amounts of 
Figure 6. Percentage and expression level of CD83 and CD86 is different between DC subsets after stimula-
tion with bacterial ligands for 48 hours (isotype corrected). P-values are indicated at the bottom of the figure. 
Error bars indicate standard error; of 4 donors tested. Similar results were obtained after stimulation for 24 
hours in independent experiments.
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IL-12 were produced by RA-derived moDCs when 
PGN or LPS was added. IL-10 production by RA- 
and TGF-derived DCs had a tendency to reduction 
upon stimulation with PGN, but this did not reach 
significance.
DISCUSSION
In this report we describe two DC subsets that can 
be induced by the mucosal ligands RA and TGF-
ß1. RA- and TGF-ß1-derived DCs were compared 
to the commonly used moDCs that are differenti-
ated with IL-4 and GM-CSF only. Addition of RA 
gave rise to a CD103 and integrin ß7-expressing 
subset that also expressed CCR7 and resembles 
non-inflammatory DCs observed in vivo.  DC dif-
ferentiated under the influence of IL-4 and GM-
CSF in the presence or absence of TGF-ß did not 
express CD103 and integrin ß7. Both differentia-
tion in the presence of RA or TGF-ß1 resulted in 
reduced responsiveness to bacterial ligands.
All three regimens used to differentiate peripheral 
monocytes seem to result in differentiation of im-
mature DC types as expression of CD14 was lost 
Figure 7. Cytokine production (y-axes, pg/ml) after stimulation with bacterial ligands LPS and PGN for 48 
hours. Error bars show standard error and significant differences are indicated at the bottom of the figure. 
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and HLA-DR, CD11b and CD11c up-regulated. 
Both CD103- and CD103+ DCs expressed CD209, 
but CD103+ DCs lacked CD1a. The in vitro dif-
ferentiated CD103+ DCs expressed CD11b, but at 
lower levels compared to CD103- moDCs. The cy-
tokine TSLP did not induce expression of CD103. 
CX3CR1 expression could also not be induced by 
differentiation of DCs in the presence of IL-1ß. 
Though progress has been made, until now, the pre-
cise factors differentially inducing CD11c+CD103+ 
and CD11lowCD103- DCs have not been revealed 
[20]. Though functional consequences of different 
expression levels of CD11b and CD11c by DCs are 
not understood well, CD11b may correlate with 
more inflammatory subsets, whereas CD11c might 
be more expressed on tolerogenic CD103+ subsets 
in vivo [21]. None of the moDCs generated, nor 
basally neither after addition of bacterial ligands, 
expressed CX3CR1. 
Compared to moDCs, differentiation using addi-
tional RA and TGF-ß1 resulted in reduced expres-
sion of CD86 and CD83 and reduced production 
of cytokines, indicating that these cells may have 
tolerogenic properties, which was confirmed by 
their reduced activation by TLR ligands. 
CD103+DCs are believed to migrate to the lymph 
node upon activation in a CCR7-dependent man-
ner [22]. CD103+ DCs present in the lamina pro-
pria and MLN express CCR7 [3,20], which also 
was found in a significant proportion of RA-de-
rived moDCs. Expression of ALDH does not de-
pend on TLR-signaling [23], which is in line with 
our finding that expression of CD103 was down-
regulated after stimulation with bacterial ligands. 
It can be envisaged that CCR7-dependent migra-
tion is more efficient when expression of CD103 
is reduced upon activation. Another effect of the 
downregulation of CD103 expression upon stimu-
lation with bacterial ligands may be that CD103+ 
DCs lose their non-inflammatory properties [12]. 
Another interesting difference observed between 
the three DC types was the level of expression of 
Fcγ receptors on the cell membrane. Addition of 
TGF-ß1 during differentiation resulted in a similar 
pattern as on moDC (CD32hi, CD16lo, CD32lo) but 
higher levels of both low affinity CD32 and high 
affinity FcγR CD64. RA however, resulted in a lack 
of CD32 and relatively high expression of CD64. 
This may implicate that moDCs and TGF-derived 
moDCs have a higher potency to bind to immune-
complexes including bacteria, whereas RA-derived 
moDCs may be specialized in binding soluble an-
tigens (e.g. dietary proteins). Immune complex 
binding (e.g. bacteria) by moDCs may preferen-
tially result in activation of T-cells, whereas those 
complexes bound by non-inflammatory TGF-de-
rived DCs may result in tolerance to those bacte-
ria. It has been established that ligation of CD64 
by antigen-IgG complexes could result in activa-
tion of T cells by DCs [24]. As RA-derived DCs 
show non-inflammatory characteristics, ligation of 
CD64 on RA-derived DC (CD103+) may result in 
induction of oral tolerance as those cells in vivo do 
migrate to the MLN and induce Tregs. Currently, 
data describing Fc gamma receptor expression of 
DC subsets is limited.
Like CD103+ DCs found in vivo, the RA-differen-
tiated DCs described here could induce increased 
percentages of FoxP3+ in allogeneic CD4+ cells 
under the influence of suboptimal doses of anti-
CD3 and anti-CD28 monoclonal antibodies (data 
not shown). This increased expression was not ob-
served when T cells were co-cultured with conven-
tional moDCs, and could be abrogated by blocking 
TGF-ß and RA simultaneously (data not shown). 
The different levels of cytokines produced by the 
DC types may result in differential skewing of T 
helper cells. Absence of production of Th1 induc-
ing IL-12 by TGF-derived DCs is beneficial for the 
moDC RAmoDC TGFmoDC
CD103 - ↓ -
CD83 ↑↑ ↑ ↑
CD86 ↑↑ ↑ ↑
IL-10 ↑↑ ↑ ↑↑
IL-12 ↑ - -
TNF-α ↑↑ ↑ ↑
Table 2.  Modulation of cell surface marker 
expression and cytokine production after 
stimulation with PGN or LPS.
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development for Th2 cells, also because IL-10 ex-
pression was largely maintained [25,26]. Recently, 
DCs have been identified as important players in 
induction of mucosally produced IgA. CD103+ 
DCs are a candidate IgA-inducing DC subset [9] 
as those cells are able to produce the major IgA 
switch factor TGF-ß, and RA which induces IgA 
plasma cell homing to the intestines [3,4]. For syn-
thesis of RA, humans depend on dietary intake of 
RA precursors. Those precursors are present in 
several dietary ingredients, including a number of 
vegetables like carrot (ß carotene) and cow’s milk. 
Induction of peripheral antigen specific FoxP3+ 
Tregs may indirectly depend on dietary intake of 
RA. Also TGF-ß is present in physiological rele-
vant amounts (several ng/ml) in cow’s milk. The 
bio-active form of TGF-ß1 and TGF-ß2 is identical 
between cow and human, and TGF-ß bioactivity is 
induced by acidic conditions in the stomach than 
inhibited [27]. Also bovine IL-10 is cross-reactive 
with the human IL-10R, though IL-10 is mainly 
present in colostrum and lacking in the majority of 
commercially available dairy products [28]. Pres-
ence of IL-10 during terminal differentiation into 
immature DCs gives rise to DCs with increase ca-
pacity to induce type 1 regulatory T cells [29,30]. 
Thus, several mucosal and dietary factors may con-
tribute to a non-inflammatory intestinal milieu. 
In conclusion, the RA- and TGF-ß1- differentiated 
DCs induce distinct mucosal DC subsets, includ-
ing CD103+ DC. The CD103+ DCs resemble the 
CD103+ DCs described in in vivo studies, and 
can advance widely used in vitro models as DC 
type with a different functional response to bacte-
rial ligands. Importantly, the expression of homing 
markers and Fcγ receptors differed between the 
DC types, suggesting different functional roles in 
intestinal immunity. Induction of these non-in-
flammatory DC types may very well be modulated 
by the dietary intake of vitamin A and TGF-ß. 
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ABSTRACT 
IgA forms a first line of defence against pathogens at mucosal surfaces and may also be involved in 
protection against allergy. The mucosal factors APRIL and BAFF, supplemented with TGF-ß1, IL-
10 and retinoic acid are crucial for induction of IgA. Humans produce two subclasses of IgA, IgA1 
and IgA2. We aimed at identifying the role of mucosal factors in the differential regulation of T-cell 
independent production of IgA1 and IgA2.
B cells were isolated from peripheral blood of healthy donors and stimulated for 7 days with differ-
ent combinations of cytokines. Cell culture supernatants were analysed for IgA1 and IgA2 levels, and 
expression of plasma cell (CD38) and homing markers (α4ß1, α4ß7) was analysed by flow cytometry.
The highest levels of IgA1 were observed after stimulation with BAFF and IL-10, and the highest 
levels of IgA2 were observed when APRIL instead of BAFF was added. Addition of TSLP inhibited 
the production of IgA1 and IgA2. The vitamin A metabolite retinoic acid (RA) increased the ex-
pression of the plasma cell marker CD38 and subsequently also increased production of IgA1 and 
IgA2. When the factors RA and IL-10 were combined IgA-secreting plasma cells that also expressed 
intestinal-homing integrin ß7 were induced.
Together, these data demonstrate that the differential production of IgA1 and IgA2 is under the 
influence of APRIL and BAFF. RA and IL-10 can initiate differentiation of peripheral B cells into 
mucosal-homing IgA plasma cells. Our data provide insight into the regulation of mucosal IgA pro-
duction and provide a mechanistic explanation for the association observed between reduced levels 
of IgA2 and APRIL and increased levels of TSLP seen in allergic eczema. 
INTRODUCTION
IgA is the dominant immunoglobulin produced in 
mucosal tissues.  The presence of IgA in the mucosa 
is crucial for the first line of defence against patho-
gens and regulation of the composition of intesti-
nal microbiota. In contrast to rodents, humans can 
produce two subclasses of IgA (IgA1 and IgA2). Of 
the two IgA subclasses, especially IgA2 seems to 
be associated with protection against allergy (Pi-
lette et al., 2007) [den Hartog et. al., submitted]. It 
is likely that IgA1 and IgA2 are induced by differ-
ent mechanisms (Kitani and Strober, 1994). Fac-
tors inducing IgA class switch recombination have 
been identified, but data on regulation of differen-
tial production of IgA1 and IgA2 is limited.
IgA production can be initiated in a T helper cell-
dependent (TD) and T helper cell-independent 
(TI) fashion. The most important IgA-inducing 
factor identified under TD conditions is TGF-ß, 
which is involved in class switch recombination 
to both IgA1 and IgA2 (Islam et al., 1991). TGF-
ß is produced by a number of cells like T regula-
tory cells (Tregs), epithelial cells and dendritic 
cells (DCs), and even by B cells themselves. In the 
presence of T cells, IL-10 can enhance IgA produc-
tion, but IgA class-switch recombination (CSR) is 
dependent on TGF-ß (Zan et al., 1998). Activation 
of B cells by T-helper cells also induced affinity 
maturation in addition to class switching (Bemark 
et al., 2012).
To our current understanding TI induction of IgA 
largely depends on innate tissue factors and DCs. 
The TNF-α family members a proliferation induc-
ing ligand (APRIL) and B cell activating factor 
(BAFF) can substitute CD40 ligation in cases of TI 
induction of IgA, and are produced by epithelial 
cells and DCs of both intestinal and respiratory 
tract (Hardenberg et al., 2007; He et al., 2003; He et 
al., 2007; Kato et al., 2006; Litinskiy et al., 2002). In 
the mucosal tissues TGF-ß and IL-10 are produced 
constitutively, in addition to retinoic acid (RA) 
that is synthesized from retinal by both epithelial 
cells and mucosal DCs (Duester, 1996; Guilliams 
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et al., 2010; Molenaar et al., 2011). IL-10 has been 
reported to enhance IgA CSR, and to induce CSR 
to IgA2 in the presence of the TNF-α family mem-
ber APRIL and in the absence of TGF-ß and Th 
cells (He et al., 2007). Dietary-derived RA affects 
accessibility of the IgA locus on the genome and is 
essential for induction of IgA plasma cell homing 
to the intestines in mice (Mora and von Andrian, 
2009; Tokuyama and Tokuyama, 1999).
IgA production is crucial to confer mucosal pro-
tection against pathogens, and appears to be in-
volved in protection against allergy (Kulis et al., 
2012; Pilette et al., 2007). Thymic stromal lym-
phopoietin (TSLP) has been implicated in the 
induction of Th2 cells and has been shown to be 
increased in skin of patients with atopic dermati-
tis. TSLP is primarily produced by epithelial cells 
and keratinocytes. An association between eczema 
and decreased levels of serum-IgA and APRIL has 
also been observed. The aim of this study was to 
identify the role of the innate cytokines APRIL, 
BAFF and TSLP, and the mucosal cytokines IL-10 
and TGF-ß, and dietary derived RA on IgA1 and 
IgA2 production and the expression of plasma cell 
as well as homing markers.
RESULTS
IL-10, but not TGF-ß1, increases IgA1 and IgA2 
secretion by peripheral blood B cells
TGF-ß1 has been identified as a major inducer of 
IgA class switch recombination under the influ-
ence of CD40L expressed by Th cells. IL-10 and 
RA have also been implicated to enhance IgA pro-
duction. To determine the role of TGF-ß and IL-10 
on IgA1 and IgA2 production in the absence of T 
cells, these cytokines were added to B cells in the 
presence or absence of RA and incubated for sev-
en days. Compared to medium, addition of IL-10 
but not TGF-ß1 increased the production of IgA1 
(p=0.050) and IgA2 (p=0.056) by peripheral blood 
B cells, which was slightly enhanced when RA was 
also present (p=0.010 and p=0.018, compared to 
medium) (Figure 1A and 1B). TGF-ß1 and RA 
alone or added together did not enhance produc-
tion of IgA1 and IgA2. These data show that IL-10 
alone, but not TGF-ß1, could enhance secretion of 
IgA1 and IgA2.
Figure 1. IgA1 (A and 
C) and IgA2 (B and D) 
production by peripheral 
B cells upon stimulation 
with TGF-ß1, IL-10 and 
RA (A and B) or APRIL 
and BAFF (C and D) 
after incubation for 7 
days. Error bars indicate 
standard error and 
p-values of (borderline) 
significant differences 
are shown. Data shown 
is of 5 to 8 healthy 
donors.
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BAFF and APRIL differentially induce IgA1 and 
IgA2 production
APRIL and BAFF are produced in mucosal tissues 
and skin, and have been identified as factors in-
ducing IgA production, class switching,  as well as 
plasma cell survival. In order to study the coopera-
tion between BAFF and APRIL with TGF-ß1 and 
IL-10 on differential regulation of IgA1 and IgA2 
production, these cytokines were added to periph-
eral B cells in different combinations. 
Addition of BAFF alone significantly increased 
levels of IgA1 (p=0.050), but not of IgA2, in super-
natant of peripheral B cells after 7 days of culture 
(Figure 1C and 1D). The presence of APRIL abro-
gated the increased production induced by BAFF. 
No significant increase of IgA2 production was 
observed after addition of APRIL or BAFF, or a 
combination thereof.
Addition of TGF-ß1 enhanced the production of 
IgA2 in the presence of APRIL (p=0.036), but not 
in the presence of BAFF (Figure 2). When also 
BAFF was added, the increased production of IgA2 
in the presence of APRIL and TGF-ß1 was inhib-
ited. This synergistic effect of TGF-ß1 with APRIL 
or BAFF was not observed for IgA1. In contrast 
to IgA2, IgA1 levels increased in the presence of 
BAFF alone, whether TGF-ß1 was present or not 
(Figure 2). 
When the combination of IL-10 and BAFF was add-
ed to freshly isolated B cells, a strongly increased 
production of IgA1 was observed (p<0.001). This 
increased production of IgA1 was reduced when 
APRIL also was added, but IgA1 production was 
still significantly increased (p=0.027) compared 
to medium (Figure 2C). In contrast to IgA1, pro-
duction of IgA2 was slightly increased when IL-10 
was added together with APRIL (p=0.061), but not 
with BAFF.
Together, these data demonstrate that IgA1 pro-
duction is optimal in the presence of BAFF and IL-
10, whereas highest levels of IgA2 were observed in 
the presence of APRIL and TGF-ß1or IL-10.
TSLP inhibits secretion of IgA1
As TSLP levels are increased and IgA levels are de-
creased in patients with eczema, the role of TSLP 
on IgA production was studied. The addition of 
TSLP to B cells strongly inhibited the production 
of IgA (Figure 3). The inhibition of IgA1 produc-
tion was observed independent of presence or ab-
Figure 2. IgA1 (A and C) 
and IgA2 (B and D) pro-
duction upon stimulation 
with APRIL and BAFF 
and TGF-ß1 (A and B) 
or IL-10 (C and D) after 
incubation for 7 days. Er-
ror bars indicate standard 
error and p-values of 
(borderline) significant 
differences are shown. 
Data shown is of 5 to 8 
healthy donors.
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sence of APRIL and BAFF (Figure 3A). Inhibi-
tion of IgA2 production was observed in the 
absence of APRIL and BAFF, the presence or 
APRIL alone, and the presence of APRIL and 
BAFF, but not in the presence of BAFF alone 
(Figure 3B). These data show that the Th2 
skewing factor TSLP inhibits IgA1 and IgA2 
production, which might affect the protective 
role of mucosal IgA against allergy, especially 
in eczema where TSLP is increased.
RA induces plasma cell differentiation of 
IgA-B cells
IgA+ B cells need to differentiate into plasma 
cells to secrete high levels of immunoglobulins, 
in order to confer mucosal protection against 
pathogens or allergens. Therefore the effect of 
mucosal factors on the induction of expression 
of the plasma cell marker CD38 on IgA1+ as 
well as IgA2+ B cells was studied. Expression 
of CD38 was significantly enhanced by RA 
(p=0.001). Addition of TGF-ß1 partly inhib-
ited RA-induced expression of CD38, whilst 
CD38 expression was maintained or even in-
creased when IL-10 was added in addition to 
RA (Figure 4A). Addition of RA to B cells re-
sulted in induction of CD38 expression of the 
majority of IgA1 and IgA2 membrane-positive 
B cells, indicating differentiation of IgA1+ as 
well as IgA2+ plasma cells by RA (Figure 4B).
Figure 3. The inhibition effect of TSLP on IgA1 (A) and IgA2 (B) production upon stimulation of B cells with 
APRIL and BAFF after incubation for 7 days. Error bars indicate standard error and p-values of (significant) 
differences are shown. Data shown is of 2 to 4 healthy donors.
Figure 4. Modulation of plasma cell marker CD38 
expression after stimulation with TGF-ß, IL-10 and RA 
after incubation for 7 days (A). Error bars indicate stand-
ard error and p-values of differences are shown. Data 
shown is of 5 till 8 healthy donors. The majority of IgA1 
and IgA2 positive B cells express CD38 after stimulation 
with RA in the presence of APRIL (B).
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RA enhances secretion of IgA1 and IgA2 in the 
presence of IL-10
As RA induced the expression of plasma cell 
marker CD38, experiments were performed to 
demonstrate if actual production levels of IgA1 
and IgA2 were also enhanced by RA. Addition 
of RA to peripheral blood B cells in the presence 
of IL-10 resulted in increased production of both 
IgA1 and IgA2 (Figure 1B). This synergistic effect 
of RA was not observed when TGF-ß1 was added 
instead of IL-10. The combination of IL-10 and RA 
enhanced production observed after stimulation 
with APRIL or BAFF alone (Figure 5). The syner-
gistic effect of IL-10 and RA with APRIL or BAFF 
alone was inhibited when both APRIL and BAFF 
were added (data not shown). The highest levels 
of IgA1 production were observed when RA and 
IL-10 were added to B cells together with BAFF. 
IgA2 production however, was maximal when RA 
and IL-10 were added together with APRIL. These 
data indicate that induced expression of CD38 by 
B cells results in IgA-secreting plasma cells in the 
presence of IL-10, but not TGF-ß1. 
Induction of mucosal-homing markers on IgA1 
and IgA2 plasma cells by RA and IL-10 
In addition to induction of IgA-secreting plasma 
cells, homing properties of B cells are required for 
effective mucosal protection by IgA. All cultured 
peripheral B cells expressed integrin ß1, regardless 
of the absence (data not shown) or presence of any 
of the factors tested (Figure 6A). Expression of in-
tegrin ß7 however, was increased after stimulation 
with APRIL or BAFF alone, but not when APRIL 
and BAFF were added together (Figure 6B). Inte-
grin ß7 expression was induced when B cells were 
cultured in the presence of IL-10 and RA, but not 
in the presence of TGF-ß1 and RA, or any of those 
factors alone (Figure 6C). The majority of B cells 
expressing integrin ß7 also expressed CD38 after 
stimulation with APRIL, RA and IL-10 (Figure 
6D). Expression of both integrin ß7 and CD38 on 
B cells was further increased by IL-10 and RA, sug-
gesting the induction of intestinal-homing plasma 
cells. Also IgA1 and IgA2 positive B cells expressed 
CD38 and integrin ß7. Together our data indicate 
that IL-10 and RA are involved in induction of 
intestinal-homing IgA1+ and IgA2+ plasma cells, 
whereas under these T-cell independent condi-
tions no profound role for TGF-ß1 was observed.
DISCUSSION
Although it has been known for decades that IgA1 
and IgA2 production levels vary between different 
mucosal tissues and compartments, knowledge on 
Figure 5. Effect of RA on IgA1 (A) and IgA2 (B) production upon stimulation with APRIL or BAFF and TGF-ß1 
or IL-10 after incubation for 7 days. Error bars indicate standard error and p-values of (significant) differences 
are shown on top of the graph. Data shown is of 5 to 8 healthy donors.
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differential regulation of production of IgA1 and 
IgA2 in humans is still limited (He et al., 2007; 
Kitani and Strober, 1994). In this study the com-
bination of BAFF and IL-10 promoted IgA1 pro-
duction, whereas APRIL and IL-10 promoted IgA2 
production. Upon further addition of RA the plas-
ma cell marker CD38 was induced and secretion of 
IgA1 and IgA2 was increased. The combination of 
IL-10 and RA induced expression of receptors for 
homing to the intestines by IgA-producing B cells.
A significant amount of IgA production in the in-
testines is induced  upon triggering by bacterial 
ligands, and occurs independently of Th cells (Be-
mark et al., 2012). The advantage of TI IgA induc-
tion over TD IgA induction may the time required 
to initiate production as no T cells are involved. 
IgA plasma cells induced in the absence of T cells, 
but in the presence of APRIL and BAFF may stay 
local in the tissue (Figure 6) and be relatively 
short-lived and unable to induce systemic antigen-
experienced B cells. However, factors like APRIL 
and BAFF have also been identified as crucial for 
survival of long-lived IgA plasma cells (Benson et 
al., 2008; O'Connor et al., 2004).  
That factors differentially regulating IgA1 and 
IgA2 may exist has been known for a long time, 
based on the observation of different distribution 
of IgA1+ and IgA2+ B cells through the body (Cra-
go et al., 1984). In addition to TGF-ß, IL-10 has 
been implicated before as inducer of IgA2 produc-
tion when stimulated with anti-CD40 monoclonal 
antibodies or CD40 ligand, or when B cells were 
stimulated with APRIL and IL-10 (He et al., 2007; 
Kitani and Strober, 1994). In line with this, we 
also observed highest levels of TI IgA2 production 
under the influence of APRIL and IL-10, whereas 
TI IgA1 production was highest in the presence 
of BAFF and IL-10. Addition of BAFF alone sig-
nificantly increased IgA1 production, which was 
further enhanced in the presence of IL-10, but not 
TGF-ß1. To increase production of IgA2, the pres-
ence of APRIL and TGF-ß1 or IL-10 was required. 
Figure 6. Expression of integrin ß1 and 
ß7 by B cells (A) and modulation of ß7 
expression (B,C). Error bars indicate 
standard error, and p-values are shown. 
Expression of ß7 and CD38 (D) or ß7 
and IgA1 and IgA2 (E) on the membrane 
of B cells that are positive (black dots) or 
negative (grey dots) for CD38. Isotype 
control (iso) and surface marker staining 
of APRIL (or APRIL, IL-10 and RA, panel 
A) stimulated B cells is shown.
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When APRIL and BAFF were added together, the 
production of IgA1 in the presence of BAFF and 
the production of IgA2 in the presence of APRIL 
and other factors were inhibited. 
Depending on the location of the B cell and the 
differentiation stage, different receptors for BAFF 
and APRIL are expressed on B cells, of which some 
bind to both APRIL and BAFF (TACI), while oth-
ers bind with higher affinity to APRIL (BCMA) 
or BAFF (BAFF-R) alone (Bossen and Schneider, 
2006; Darce et al., 2007). Future studies should 
confirm if membrane expression or intra cellular 
signalling of those receptors is influenced by IL-10 
and RA, and to what extent IgA plasma cell dif-
ferentiation is affected by those receptors. The data 
presented here identify factors enhancing IgA1 
and IgA2 production by a mixed population of 
freshly isolated peripheral B cells. Therefore, the 
IgA1 and IgA2 production observed originates 
from a combination of de-novo induced IgA1+ and 
IgA2+ B cells, and B cells that were already com-
mitted to IgA1 or IgA2 production before the start 
of the cell culture experiments. Increased produc-
tion of IgA1 by BAFF alone might well be caused 
by IgA plasmablasts that are sensitive to stimula-
tion with BAFF, whereas IgA2 induction more 
likely depended on de-novo CSR under the influ-
ence of APRIL. As our aim was not to identify fac-
tors for IgA CSR, a heterogeneous population of 
B cells was used in order to resemble more closely 
IgA production upon activation of heterogeneous 
B cell populations in vivo. Future studies should 
identify which process (e.g. CSR) and what B cell 
development stage contributes most to IgA1 and 
IgA2 production.
In order to confer IgA-mediated protection at mu-
cosal surfaces, regulation of expression of hom-
ing molecules is required to guide the cells to ap-
propriate sites in the body. Expression of integrin 
α4ß7 by mouse B cells was shown to be abrogated 
in the presence of a RA inhibitor (LE540), and the 
presence of IgA+ B cells in the gut is dependent on 
dietary vitamin A (Mora et al., 2006). Based on our 
data and a literature report describing induction 
of CD38 plasma cells under the influence of IL-10 
and RA under T cell dependent conditions, similar 
mechanisms seem to exist in humans (Dullaers et 
al., 2009; Morikawa and Nonaka, 2005). Our data 
indicate that neither RA alone nor IL-10 alone, but 
the synergism of IL-10 and RA induced integrin 
α4ß7 expression. Integrin α4ß7 binds to MAd-
CAM-1, which is expressed in the intestines but 
seems to be lacking in the respiratory tract (Xu 
et al., 2003). However, homing of lymphocytes to 
respiratory tissue is mediated by, amongst others, 
integrin α4ß1, which was expressed on all B cells 
in our cultures (Xu et al., 2003). To our current 
understanding of plasma cell homing pathways, 
intestinally-induced B cells (α4ß1+α4ß7+) may mi-
grate to a variety of other mucosal sites, including 
the respiratory tract, whereas B cells activated in 
the respiratory tract (α4ß1+) preferably migrate 
back to the VCAM-1 expressing respiratory tract 
rather than the intestines (expressing MadCAM-1) 
(Rott et al., 2000; Xu et al., 2003). As a result, anti-
genic challenges in the gut could result in systemic 
dissemination of antigen-specific B cells confer-
ring protection against subsequent encounter of 
those antigens.
Recently, Pilette et. al. described that upon specific 
allergen immunotherapy allergen-specific IgA2 B 
cells were induced in the nasal mucosa, but not 
IgA1 B cells (Pilette et al., 2007). Immunotherapy 
has been shown to increase the numbers of aller-
Figure 7. Hypothetical 
model explaining the 
association observed 
between allergy and al-
lergic eczema with TSLP 
and APRIL.
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gen specific Tregs (Jutel et al., 2003). Until, now 
there is no evidence showing that Tregs preferen-
tially induce IgA2 and not IgA1. This induction of 
IgA2 upon allergen specific immunotherapy may 
well be mediated by local tissue factors like APRIL 
and IL-10. In addition to correlation with absence 
of allergy, serum IgA2 levels were associated with 
the presence of eczema in house dust mite allergic 
patients (den Hartog et. al., submitted). A double 
blinded randomized dose-response study where 
house dust mite allergic patients received immu-
notherapy, showed a reduction of eczema after im-
munotherapy (Werfel et al., 2006). Together these 
findings may need further study to reveal if aller-
gen-specific serum IgA2 levels are causally related 
to the absence of eczema in sensitized individu-
als. A possible underlying mechanism (Figure 7) 
could be the reduced production of APRIL in pa-
tients suffering from eczema, in combination with 
increased expression of TSLP (Chen et al., 2011; 
Lee et al., 2010; Lundell et al., 2009). Here we have 
shown that APRIL is involved in induction of IgA2 
production, whereas TSLP may inhibit IgA2 pro-
duction. APRIL and TSLP are constitutively pro-
duced in the mucosa and skin and therefore induc-
tion or inhibition of IgA2 production may occur 
both in the intestine and skin (Demehri et al., 2009; 
Soumelis et al., 2002). TSLP has been implicated in 
both intestinal Th2 skewing and progression of ec-
zema into asthma (Blázquez et al., 2010; Demehri 
et al., 2009; Soumelis et al., 2002). The fact that nu-
merous B cells are present in the intestine is widely 
known. However, B cells expressing α4ß1 can also 
migrate to the skin, at least under inflammatory 
conditions (Geherin et al., 2012). Consequently, 
factors produced in the skin may affect B cell IgA 
production, also because induction of CSR (not 
necessarily CSR itself)  is being reported in differ-
ent tissues that are not organized lymphoid tissues 
like Peyers patches or lymph nodes (Cameron et 
al., 2003; Chvatchko et al., 1996; Payne et al., 2011). 
An alternative mechanism underlying the asso-
ciation between IgA levels and absence of eczema 
could be induction of IgA production in early life. 
Indeed, colonization with toxic Staphylococcus 
aureus has been associated with increased levels of 
APRIL and IgA in serum, and reduced numbers 
of infants with eczema later in life (Lundell et al., 
2009). In line with this, an association has been 
found between bacterial exposure, secretory IgA 
levels in saliva and reduced clinical symptoms in 
infants (Böttcher et al., 2002; Fagerås et al., 2011). 
In addition to these environmental factors, genetic 
factors like polymorphisms in IL-10 and TGF-ß 
promoter regions have been associated with in-
creased incidence of eczema (Hobbs et al., 1998).
In summary, this study shows that mucosal and 
T cell independent IgA1 and IgA2 production is 
optimal under the influence of BAFF and APRIL 
respectively, which may explain the different lev-
els of IgA1 and IgA2 observed in different tissues. 
In addition, the data presented here may help to 
explain the observed association between allergic 
eczema and IgA2 and APRIL induced by mucosal 
and skin factors.
MATERIALS AND METHODS
PBMC and B cell isolation
Peripheral blood mononuclear cells (PBMCs) ob-
tained from buffy coats of healthy blood donors 
that provided informed consent (Sanquin Blood 
Bank Nijmegen, The Netherlands) were diluted 1:1 
in IMDM (Gibco-BRL, Paisley, Scotland) and iso-
lated by gradient centrifugation on Ficoll-Plaque 
PLUS (Amersham Biosciences, Uppsala, Sweden) 
for 5 minutes at 200g and subsequently for 15 min. 
at 500g (without brake, 20ºC). The PBMCs were 
harvested from the Ficoll layer, resuspended and 
washed two times in IMDM.
Freshly isolated PBMCs were incubated with 
CD19 MicroBeads  (130-050-201, Myltenyi Bio-
tec, Bergisch Gladbach, Germany) for 15 minutes 
at 4ºC, washed with MACS buffer (0.5% BSA, 
2 mM EDTA in PBS, pH=7.2), centrifuged (10 
min, 200g) and resuspended in MACS buffer. The 
MACS columns were placed in the quadroMACS 
(Myltenyi Biotec) and rinsed with MACS buffer. 
Subsequently, the cell suspension was added, the 
columns were rinsed three times with MACS buff-
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er and removed from the quadroMACS; labelled 
cells were collected in a new tube by rinsing with 
MACS buffer and the supplied plunger.
Purity of the CD19+ cell population was between 
90 and 95%, as determined by labelling the cells 
with CD19-antibodies or isotype control (561121 
or 560787, BD Biosciences), followed by flow cy-
tometric analysis (FACS Canto II BD Biosciences, 
San Jose, CA, USA).
B cell cultures
B cells were cultured at a concentration of 0.5-1 
million cells/ml in 48 wells plates in RPMI supple-
mented with 10% FBS and 1% pen/strep. Stimuli 
were added and incubated with the cells for 7 days 
at 37oC in a humidified environment and 5% CO2. 
Stimuli were used as follows: All-trans RA 10-5M 
(Sigma Aldrich, St. Louis, MO, USA), 10 ng/ml 
TGF-ß1, 20 ng/ml IL-10, 125 ng/ml APRIL and 
BAFF (all from Peprotech, Rocky Hill, NJ, USA). 
Cell culture supernatants were collected and stored 
(-20oC) until use. Cells were harvested, centri-
fuged and stained for flow cytometric analysis.
IgA1 and IgA2 ELISA
ELISA plates (Greiner Bio One, Alphen a/d Rijn, 
The Netherlands) were coated with 0.2 or 1.0 µg/ml 
Polyclonal goat anti human IgA (2050-01, South-
ern Biotec). Plates were washed (0.05% tween in 
PBS) once and blocked with biotin free casein 
(UCBD, SDT reagents, Baesweiler, Germany). Af-
ter blocking plates were washed three times and 
undiluted cell culture supernatants or 50 ng/ml 
IgA1 or IgA2 (16-16-090701-1M or 16-16-090701-
2M, Athens Research, Athens, Greece) was added 
in 1:2 block and wash buffer respectively. The IgA1 
and IgA2 antibodies were serially diluted to obtain 
a standard curve. Plates were washed and 1/5000 
or 1/2000 biotinylated anti IgA1 or IgA2 was add-
ed (Southern Biotec). Plates were washed 6 times 
and 1/10 000 streptavidin poly HRP 80 (SDT rea-
gents) was added and covered. 100 µl TMB (SDT 
reagents) was added. Plates were developed until 
wells developed clear colours, without obtaining 
too much back ground signal, stopped with acid 
and measured at 450 nm and 650 nm as reference. 
Calibration curve was calculated using 4-param-
eter logistic fit. Incubations were performed for 1 
hour at room temperature on a shaker.
Flow cytometric analysis
B cells were stained with CD19 (V500,  BD Bio-
sciences, Franklin Lakes, NJ, USA), CD38 (BV421, 
BD Biosciences), IgA1 (FITC, Southern Biotec, 
Birmingham, AL, USA), CD29 (ß1) (PE,  BD Bio-
sciences), ß7 (PerCP-Cy5.5,  BioLegend, San Die-
go, CA, USA), CD27 (PE-Cy7,  BD Biosciences), 
IgA2 (APC, Miltenyi Biotec, Germany), or the re-
spective isotype controls: Mouse IgG1 conjugated 
to V500, PE, BV421, PE-Cy7 ( BD Biosciences), 
mouse IgG1 FITC (0102-02, Southern Biotec),, 
Rat IgG2a PerCP-Cy5.5 (400532, BioLegend),),  or 
mouse IgG1 APC (130-092-214, Miltenyi Biotec). 
At least 10 000 events within the cells gate were 
collected using BD FACS Canto II (BD Bioscienc-
es). Data were batch processed and values reported 
corrected for background staining (FACS Diva 
software).
Statistical analysis
Data were entered in IBM Statistics version 19. 
Data were square root transformed to improve dis-
tribution of the data. Differences were tested using 
the two independent samples T-test or generalized 
linear models.
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ABSTRACT
In this study the interplay between intestinal microbiota and functional maturation of the antibody 
response during avian ontogeny was investigated. The IgM, IgG and IgA CDR3 spectratypes succes-
sively changed over time. However, IgA VH pseudogene usage remained the same over time. Flow 
cytometric analysis of the fecal microbiota revealed that in the first weeks of life maximally 30 per-
cent of fecal bacteria were coated with IgM, and from day 35 onwards up to 70% of fecal microbiota 
were coated by IgA. No coating with IgG was observed. Microbiota composition was transiently 
changed (day 14-42) and related to IgA expression levels but not to deviations of CDR3 spectratypes 
from the normal distribution. The results obtained indicate that endogenous humoral immunity 
plays a limited role in the first four weeks post-hatching. We hypothesize that modification of the 
naive IgA CDR3 repertoire is not required to recognize the majority of intestinal bacteria.
 
INTRODUCTION
Immunoglobulin M and A in the gut are essential 
for the first line of defense against infections in 
vertebrates(1, 2). Initially, neonates receive protec-
tive maternal antibodies either via egg yolk (aves) 
or via the placenta and milk (mammals). Avian 
maternal antibody levels will decline and reach 
negligible levels within three weeks post-hatch. In 
aves maternal derived antibodies are mainly of the 
IgG class whilst novel findings indicate that mater-
nal-derived IgA might be present in the intestinal 
tract of hatchlings (3).
Primary activation and maturation of the intesti-
nal humoral immune system is at least partly de-
pendent on (commensal) intestinal microbiota, as 
shown by a poorly developed immune system of 
animals grown in germ-free conditions(1, 2, 4-9). 
Naive B cells express IgM and initial intestinal 
body defense depends exclusively on IgM, which 
like IgA can be transported across the gut epitheli-
um into the lumen by the polymeric immunoglob-
ulin receptor (pIgR)(10, 11). This is demonstrated 
by pIgR-/-mice, which lack IgM and IgA in the in-
testinal lumen. Lack of secretory IgA at mucosal 
surfaces results in increased mucosal leakiness as 
shown by the presence of serum proteins in mu-
cosal secretions of pIgR-/- mice, and in increased 
vulnerability to mucosal infections as compared to 
normal genotypes(12-14). 
In mammals, intestinal microbiota are believed to 
be recognized by T cell independent and poly-spe-
cific antibodies, as well as T cell-dependent high 
affinity IgA(15), (16, 17). These poly-specific an-
tibodies can belong to either IgM or IgA classes. 
Data on the role of the antigen-binding repertoire 
maturation in intestinal immunity is limited. Mat-
uration of the antibody repertoire into functional 
binding antibodies may be required to confer pro-
tection to the host against pathogens and influence 
microbial composition in the intestinal lumen. 
This antibody repertoire is largely determined 
by the complementarity determining region 3 
(CDR3). The CDR3 length distribution of antibod-
ies of unstimulated or highly heterogeneous popu-
lations of B cells can be approximated by a normal 
distribution (18, 19). Thus deviations from the 
normal distribution could indicate activation of a 
selective subset of B cells resulting in increased ex-
pression of antibodies with a certain CDR3 length. 
Especially plasma cells are highly productive and 
hence important determinants of the intestinal 
IgA CDR3 repertoire. CDR3 length could affect 
the shape of the antigen recognition region and 
consequently its binding specificity (20-23). The 
CDR3 diversification process in chickens is differ-
ent from that described in mammals: in chickens, 
the CDR3 encoding domain consists of a single 
VH-gene, combined with a D (used from a set of 
15 D genes) and one J gene(24). After recombina-
tion of the heavy chain gene, the variable domain 
is subsequently diversified by somatic gene conver-
sion of variable pseudogene segments into the 3’ 
end of the heavy chain gene(25, 26). CDR3-diver-
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sification in combination with antibody produc-
tion levels determines the ability to coat microbes 
by binding to surface molecules. 
Currently, data describing the maturation of the 
intestinal IgA-CDR3 repertoire in relation to mi-
crobial composition during ontogeny is limited. In 
the current study, we investigated if the microbial 
composition is related to the CDR3 repertoire of 
the various immunoglobulin isotypes. Addition-
ally, the functionality of IgM, IgG or IgA in the 
intestines during ontogeny was investigated by 
analyzing the percentage of bacteria coated with 
immunoglobulins. Finally, we assessed age related 
changes in microbiota composition and their as-
sociation with local cytokine production and the 
CDR3 repertoire diversity.
 
MATERIALS AND METHODS
Animals
Commercially obtained eggs of Lohman Brown 
chickens were incubated at 41ºC and 65% humid-
ity and allowed to hatch in climate respiration 
cells. Hatchlings were housed in groups of five per 
cage. 100 mg ileum tissue was collected at days 4, 
7, 21, 35, 49 and 70 after hatch from 10 chickens at 
each time point, based on experience from previ-
ous experiments. The performed experiments were 
reviewed and approved by the Animal Experimen-
tation Committee of Wageningen University, The 
Netherlands, according to Dutch law. 
RNA isolation and cDNA synthesis 
Total RNA extraction from ileum tissue samples 
was performed using TRIzol® reagent (Lifetech-
nologies, Breda, The Netherlands) according to the 
manufacturer’s recommendations. RNA concen-
trations were determined by spectrophotometric 
analysis and equalized by dilution in DEPC water. 
RNA was checked by agarose gel electrophoresis 
for integrity and treated with DNase I  for 15 min 
at RT (Invitrogen, Breda, The Netherlands, 18068-
015) and inactivated using EDTA (65°C for 10 
min). 300 ng random hexamers, 1 μl 10 mM dNTP 
mix, 4 μl 5× first strand buffer, 2 μl 0.1 M DTT 
and 10 U RNase inhibitor (Invitrogen, 15518-012) 
were added and incubated for 10 min at 37 °C. 200 
U Superscript RNase H− reverse transcriptase (RT; 
Invitrogen, 18053-017) was added and incubated 
for 50 min at 37 °C.
Spectratyping
The universal forward primer (CACCATCTC-
GAGGGACAAC, FAM-labeled) was located at 
the VH gene segment (genbank M30319.1), 97 bp 
upstream of the CDR3 region and could amplify 
the complete CDR3-repertoire. Pseudogenes 57-
12 and 57-3 contain substitutions in the area cov-
ered by the forward primer, and might depending 
on the part used from the pseudogene, not be am-
plified in our PCR. The reverse primers (GGTG-
CATGGTGACGAAAAG (X01613.1) for IgM, CA-
GAGGGAGGAGCTGGTAGA (S40610.1) for IgA 
and GGGTCCCCGAAACTCTGC (X07174.1) for 
IgG were located downstream of the CDR3 region 
at the isotype specific constant part of the heavy 
chain. 
PCR was performed with 1 µl cDNA, 0.4 µM for-
ward and reverse primer, 6 µl ABGene Master Mix 
(Applied Biosystems, Foster City, U.S.A) and 4 µl 
de-ionized water. The PCR program consisted of 
a preheating step (10 min, 95ºC), 36 cycles at 58 
ºC and 10 min extension. One µl PCR-product (20 
ng/µl) was diluted in 9 ul formamide (Applied Bio-
systems) with GeneScan™  600LIZ® Size Standard 
and analyzed on a DNA Analyzer 3730 (Applied 
Biosystems). A dilution experiment showed that in 
samples with high expression of Ig, the cDNA sam-
ple could be diluted 10 000 times to result in simi-
lar spectratype profiles. Data files were imported 
in ABI PRISM® GeneMapper v4.0 (Applied Bio-
Systems) and batch processed to extract product 
size and relative frequency data which was further 
processed in MS Excel (Microsoft corp., U.S.A.). A 
cut off value was used to eliminate background sig-
nal and minor PCR artifacts. Peaks of spectratype 
profiles needed to be separated by three nucleo-
tides, yield sufficient signal to discriminate multi-
ple peaks. Each spectratype profile was standard-
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ized by dividing the area under a single peak by the 
total area of all peaks of that spectratype diagram.
The average CDR3 lengths were calculated: 
∑
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, where   and zi 
is frequency of product size xi. For each sam-
ple, CDR3 length was used as x   and ‘s’ 
was estimated using the following formula: 
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. The obtained   and ‘s’ values were inserted in the 
formula describing the normal distribution (18). 
The variability between the standardized spec-
tratype data and the normal distribution was cal-
culated: sum of squares of X = SS =   (Figure S1).
Ig expression was very low in a number of samples, 
which resulted in too low frequencies of CDR3 
regions (eg IgG day 70). Those samples were not 
further analyzed.
Sequencing
Immunoglobulin sequences were PCR amplified 
using the same procedure as described for spec-
tratyping, but different reverse primers were used 
for IgA and IgG (AGGAGGGTCACTTTGGAG-
GT respectively CTCTTCCCTTCCCTCCAATC). 
3 µl PCR product was used for ligation in pGEM-
T Easy Vector (Promega, Madison, USA, Quick 
protocol, 3). After transformation and incubation 
overnight at 37ºC 40 – 50 positive clones were col-
lected and a colony-PCR was performed. 1 µl colo-
ny suspension, 12 µl 2x ABgene Master Mix, 0.5 µl 
forward and reverse primers (10 µM, T7 forward 
and Sp6  reverse) and 11 µl MQ (5 min at 95ºC, 30 
cycles of 1 min at 55ºC, 10 min extension), ampli-
cons were checked on 1% agarose gel and purified 
using SephacrylTM S-400 (GE Healthcare, 17-
0609-01). On the purified product a dual sequence 
reaction (same program as colony PCR) was per-
formed (using either T7 or Sp6, 1.6 µM), puri-
fied again and analyzed on a DNA Analyser 3730 
(Applied Biosystems) using 1µl sequence reaction 
product and 9 µl formamide. 
Sequence analysis
A number of VH pseudogenes have been pub-
lished (26).  The same position of the start of the 
CDR3 region was used as proposed by Reynaud 
et. al.(26). CDR3 sequences were blasted with 
the following settings: nucleotide blast, database, 
other: nucleotide collection (nr/nt), Organism: 
gallus (taxid: 9030), entrez query: pseudogene NO 
mRNA NO cDNA, discontinuous mega blast. The 
three scores with the lowest E-value describing a 
germ line pseudogene were exported and used for 
further analysis in Excel). To select the best fit-
ting pseudogene, query coverage was multiplied 
by the sequence identity and the pseudogene with 
the highest score was selected. The dendrograms 
of the germ line pseudogenes and obtained CDR3 
sequences were made with MEGA 4, using the 
neighbor joining p-distance model.
Microbial Community Profiling (MCPC)
Mid sections of ileum were opened with a sterile 
scalpel, rinsed in cold PBS and sampled by mov-
ing rigid nylon brushes (Servoprax GmbH, Wesel, 
Germany) up and down over a length of 3 cm. 
Brushes were stored at -20 °C until further use. 
Bacterial DNA was isolated by putting the ny-
lon brushes  in 6 M guanidine thyocyanate, 0.6% 
Tween-20 (v/v), 10 mMEDTA, 50 mM Tris-HCl, 
pH 6.5 and 2 g of zirconia beads (<0.1 mM, Bio-
spec Instruments, Bartlesville, OK, USA). The 
bacteria were physically disrupted by shaking for 4 
minutes in a MiniBeadbeater-96™ (Biospec Instru-
ments), followed by heating for 5 minutes at 90oC 
and centrifugation (1 min, 10.000 g). 200 µl of the 
supernatant was used for DNA isolation according 
to Carter and Milton (1993)(27), with minor mod-
ifications (omission of the final acetone wash step). 
Terminal restriction fragment polymorphism 
(T-RFLP) analysis was essentially performed as 
described by Liu et al. (1997)(28). The 16S rRNA 
genes were amplified by PCR using fluorescently 
labeled primers 8f (6-FAM) and 926r (NED). The 
PCR reaction was performed in 15 µl containing 
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1x PCR buffer (Applied Biosystems), 62.5 µM, 
deoxynucleoside triphosphate (Applied Biosys-
tems), 1.5 mM MgCl2, 0.5 µM of each primer, 
0.5 U Taq DNA polymerase (Promega) and 1 µl 
of DNA sample. The PCR program consisted of 5 
min at 94 °C, followed by 35 cycles (45s at 56°C), 
and a final extension at 72°C for 5 min. The PCR 
amplicons were digested using MspI and HinpII 
(New England Biolabs, Ipswich, MA, USA). The 
digested reaction products were size separated on 
36 cm capillary electrophoresis POP4 gel matrix 
(ABI 3100, Applied Biosystems). The size standard 
marker MapMarker 30–1000, ROX labeled (Bio-
ventures, Murfreesboro, TN, USA) was added to 
each sample for accurate sizing. Fragment length 
analysis was performed using GeneScan software 
(Applied Biosystems).
Flow cytometry of coated microbiota
0.5 g feces and 4.5 ml filtered PBS was homog-
enized and centrifuged for 2 min at 2000 g. The 
supernatant (1 ml) was collected, centrifuged for 
10 min at 9000 g to generate the bacterial pellet. 
The pellet was washed twice in PBS, fixed in 4% 
para-formaldehyde and stored at 4°C overnight. 
The cells were recovered by centrifugation for 10 
min at 9000 g. The pellet was washed twice with 
PBS, resuspended in 1 ml PBS-ethanol (1:1) and 
stored at -20°C until further use.
Bacteria were stained with monoclonal FITC con-
jugated mouse IgG1 anti chicken IgG (Southern 
Biotec), IgM or IgA. Monoclonal mouse IgG1 anti 
chicken MCAM was used as isotype control. Just 
before cytometric analysis (BD FACS Canto II) 
samples were loaded with 1 µl 1 mg/ml propidium 
iodide (Sigma) to identify the microbiota. Mother 
daughter gates were applied for forward plus side-
ward scatter, subsequently for PI staining (PerCP-
Cy5.5 channel) and finally for Ig coating (FITC 
channel).
qRT-PCR
5 μl cDNA and forward and reverse primer (500 
nm each) were added to 12.5 μl SYBR® Green PCR 
Master Mix (Applied BioSystems) and filled up 
with demineralized water to a final volume of 25 
μl. The primer sequences used for qRT-PCR are 
listed in Table S3. All primer sets allowed DNA 
Figure 1. Total and vaccine-specific serum levels of antibodies in chickens during the first 70 days following 
egg hatching. No autologous antibodies are produced as IgM (initially produced isotype) is absent the first 
days after hatch (A). IgG antibodies that are initially present are maternally derived (B). Also circulating IgA is 
self-produced. Natural antibodies (Nabs) against Keyhole limpet hemocyanin (KLH) (D) initially originate from 
the mother and are subsequently endogenously produced. Data is shown of ten animals per time point. Error 
bars show standard error.
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amplification efficiencies between 94% and 100%. 
RQ-PCR (10 min 95°C, 40 cycles of 15s 94°C, 30s 
59°C and 36s 72°C, followed by 15s at 95°C, 1 min 
at 59°C) was carried out on an Applied BioSystems 
7500 real-time PCR machine (Applied BioSystems, 
The Netherlands). After each run, melting curves 
were collected by detecting the fluorescence from 
60 to 90 °C at 1 °C intervals. Relative expression 
was expressed as 2−ΔCt. Primers used are indi-
cated in Table S1. Gene expression analysis was 
performed on ileum tissue samples and from the 
same animals as the microbiota profiling analysis. 
Statistical analysis
Data were entered in PASW Statistics 19 (SPSS 
Inc., Chicago, USA). General Linear Model (mul-
tivariate) was used to test the CDR3 length and SS 
change over time. An independent samples dou-
ble sided T-Test was used to test the overall CDR3 
length differences between isotypes. 
Figure 2. Changes in spectratype-based deviation from the normal distribution (sum of squares) (A) and 
CDR3 length (B) with age, by isotype. A) Sum of squares of normalized spectratypes show changes of 
spectratype profiles upon antigenic stimulation. Box plots show median (horizontal bar), the interquartile range 
(box), 1st and 4th percentiles (line bars), and outliers (o ) or extreme outliers (*). CDR3 length is indicated by 
the number of nucleotides. P-values result from running a generalized linear model; dashed lines indicate time 
points included in the statistical model.
B
A
7Ontogeny of IgA production and repertoire in relation to microbiota     99
To study age-related changes in microbiota com-
position and to relate microbiota composition to 
mRNA expression levels of several immune re-
lated genes, principal component analysis (PCA) 
respectively redundancy analysis (RDA) (29) was 
performed using CANOCO® software (version 
4.5, developed by Cajo J.F. ter Braak and Petr S 
Milauer) (30). Square root transformed MCPC 
data (Peak areas) were used as response variables. 
Log-transformed values of immune related gene 
expression data (previously published(31)) were 
used as environmental variables (29). Cage was 
used as a covariate in CANOCO. RDA was per-
formed focusing on inter-sample correlation, and 
an unrestricted Monte Carlo Permutation Test 
(499 permutations) was applied to decide whether 
gene expression had a significant effect on the mi-
crobiota composition. Diagrams were plotted as 
biplots using CanoDraw for Windows. 
 
RESULTS
The CDR3 length distribution changes during 
ontogeny
During different stage in ontogeny maternal-de-
rived and endogenously produced antibodies can 
be detected in serum, reflecting humoral immu-
nity of the neonate. Analysis of antibody levels in 
serum showed that maternally derived antibodies 
mainly consists of IgG. Titers of natural antibod-
ies against keyhole limpet hemocyanin (KLH) dis-
appeared within three weeks post hatch and with 
age gradually increased again. Strikingly, kinetics 
of autologous antibody serum levels are similar to 
intestinal expression profiles of immunoglobulin 
isotypes (Figures 1 and S1).
CDR3 spectratype profiles can be approximated 
by a normal distribution, which can be deduced 
from the normalized length distribution shown 
in Figures S1 and S2. Polyclonal expansion of spe-
cific B cells results in deviations from the normal 
distribution, whilst at a polyclonal background. 
The deviation of the spectratype profile from the 
normal distribution (sum of squares, SS) of the dif-
ferent isotypes tested was calculated using normal-
ized spectratype data (Figures S1 and S2). The SS 
for IgM spectratypes was highest at days 4 and 7 
after hatch, reached a nadir at day 35 (Figure 2A). 
The SS for IgG was low until day 35 but increased 
after day 49. The SS for IgA was average at days 
4 and 7, low at days 21 and 35, increased at day 
49 and was maximal at day 70. With aging, the SS 
numerically decreased for IgM, but changes were 
not significantly different (p=0.125). SS increased 
for IgG (p=0.007) and IgA (not significant for all 
ages, days 21 till 70, p=0.001). Age dependent 
changes in spectratype profiles are also shown in 
a principal component analysis (PCA) (Figure S3), 
which indicates deviating CDR3 profiles of indi-
vidual chickens by placing the individual animal 
away from the center of the plot. Spectratyping 
IgA CDR3 sequences for animals aged 4 and 7 days 
succeeded, but originates from relatively low num-
bers of plasma cells and hence copies of Ig genes.
As CDR3 length could affect the shape of the an-
tigen recognition region and the binding specific-
ity, this length was calculated from our spectratype 
data. The data shown in Figure 2B reflects the aver-
age isotype-specific CDR3 length produced in situ. 
The average CDR3 length of IgM decreased by 6 
nucleotides during the experimental period from 
approximately 37 to 31 nucleotides (p<0.001). The 
CDR3 length of IgG did not change with age (de-
crease by 33 to 30 nucleotides). IgA CDR3 length 
was approximately 30 nucleotides, which did not 
change with age.
Regardless of age, IgM and IgG had a significant-
ly longer mean CDR3 region compared to IgA 
(p<0.001 respectively p<0.001). IgM CDR3 was 
longer than IgG CDR3 length in the period from 
day 4 until day 21 (p=0.009). 
IgA CDR3 sequences do not reveal major chang-
es during ontogeny
Since age-related differences in peak distribu-
tion of IgA spectratypes (Figures 2A and S3) were 
found, we studied whether IgA CDR3 regions were 
different at the sequence level between immuno-
logical immature (7 days of age) and mature chick-
ens (70 days of age). 
 100    Chapter 7 
0.005
0.005
Day 7 of age 
Day 70 of age 
0.005
0.01
0.002
Figure 3. Dendrograms of IgA CDR3 sequences. The NJ joining p-distance model (consensus 500 bootstraps) 
was used. Branches corresponding to partitions reproduced in less than 50% of bootstrap replicates have 
been collapsed. Animals aged 7 days have numbers Dendrograms of IgA CDR3 sequences are shown of two 
animals aged 7 days (top) and three animals aged 70 days (bottom). All dendrograms show more divergent 
CDR3 sequences and identical CDR3 sequences, no apparent age differences were observed.
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164 IgA-CDR3 sequences were obtained, which 
were variable in size and nucleotide composition. 
Sequences with the same size also differed in their 
nucleotide composition. Of each chicken, 60% to 
89% of the sequences obtained were unique whilst 
the sequences remaining were identical to any of 
the other sequences. In the dendrograms (Figure 
3), several clades containing highly similar IgA 
CDR3 sequences are visible in the dendrogram. 
CDR3 sequences of the same size ended up in both 
the same as well as in different clades of the den-
drogram, indicating that both similar as well as 
divergent CDR3 sequences of the same size were 
obtained. 
Although the improved draft genome sequence 
is available (build 8), the complete annotation of 
the VH pseudogene sequences of the Ig locus ap-
peared not to be present. Only eighteen out of the 
estimated 70-90 pseudogenes have been identified 
and are available (26). To compare pseudogene 
sequence composition, a dendrogram was con-
structed also including the VH1 gene (Figure 4A). 
The VH1 gene is clearly distinct from the pseudo-
genes. Pseudogenes VH15-9, VH57- 5, VH57-12 
and VH57-15 did not group with other pseudo-
genes. Pseudogenes VH15-5, VH57-3, VH57-10 
and VH57-16; VH57-4 and VH57-11; VH57-1 
and VH57-13 clustered closely together. 
To assess if pseudogene usage was selective, CDR3 
sequences obtained were blasted against germline 
nucleotide sequences to identify which pseudo-
gene could have been used. The pseudogene with 
the highest coverage and sequence similarity was 
selected, identifying which of the currently known 
Figure 4. Dendrogram of genomic pseudo-
gene sequences using the same procedure 
used for Figure 3 (A), and approximated 
pseudogene usage by 2 chickens of 7 days 
and three chickens of 70 days old (B). CDR3 
sequences were blasted against pseudo-
genes published. Pseudogenes with highest 
coverage and similarity were selected.
B
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pseudogenes most closely resembled the obtained 
cDNA CDR3 sequences (Figure 4B). Pseudogene 
VH15-9 occurred most frequently (approximately 
40% of the cases), followed by VH57-13, VH15-3, 
VH57-6, VH15-8, VH15-2, VH15-7 and VH57-1. 
Pseudogenes VH15-5, VH57-3 – 5, VH57-10 – 12 
and VH57-15 did not appear in our results. This 
indicates restricted use of pseudogenes. No differ-
ences were found between animals at the age 7 or 
70 days. As not all pseudogenes have been identi-
fied, no accurate counts of point mutations could 
be obtained. 
Microbial composition is temporarily changed
To study the interplay between the gut microbiota 
and expression of immune related genes, bacte-
rial 16S rRNA genes were analyzed by PCR-am-
plification and subsequent enzymatic digestion (T-
RFLP) resulting in ribotypes identifying microbial 
composition differences between animals. Because 
chickens had to be sacrificed to perform this analy-
sis at each time point ten different chickens were 
analyzed.
The ileal microbiota composition was highly vari-
Figure 5. Number of similar 16S peaks between age 
of at least 7 chickens per age group. Higher numbers 
as indicated by color in the legend indicate more 
similarity between profiles characterizing microbiota 
composition. Data should be read where ages inter-
sect. Maximum 60 out of 580 ribotypes were present 
in 7 animals or more between different age groups, 
showing that microbiota composition is highly variable 
between animals and time points. 
Figure 6. PCA analysis of intestinal mi-
crobiota composition in ileum at differ-
ent ages. Variance explained by PCA is 
fitted at the x axis (component 1) and y 
axis (component 2). Separate clustering 
of animals indicate different microbiota 
profiles. Data were derived taking hous-
ing units into account (cage). Percent-
ages along axes indicate explained 
variance.
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able over time. Presence or absence of products of 
a specific size was used to directly compare simi-
larity between age groups (Figure 5). T-RFLP of 
chickens at day 4 had very low numbers of similar 
peaks (10-20 similar for 7 or more chickens per age 
group, out of a total of 580 ribotypes) compared to 
other ages. Chickens at the age of 7 days showed 
relatively high similarity with chickens of the ages 
28, 42, 49 and 70 days. Chickens aged 10 and 35 
days had low similarity with chickens at other ages, 
suggesting shifts in microbial composition. Chick-
ens of day 21, 28 and 42, and chickens of day 42 
and 49 had more similar T-RFLP profiles.
Next to these differences, the microbial compo-
sitions transitionally changed during the period 
from 14 until 42 days of age as analyzed by prin-
cipal component analysis (PCA, Figure 6). PCA 
analysis allows evaluation of complex data 
Figure 7. Antibody coating of fecal microbiota. Example of FACS staining showing staining for PI (A) and 
daughter gatings for isotype control (B), IgM (C), IgG (D) and IgA (E). Panels F-H show the percentage of 
microbiota coated by IgM (F), IgG (G) and IgA (H); line bars indicate standard errors derived from data from 9 
chickens (average). Panel I shows cumulative percentage of coated bacteria.
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sets by statistically explaining as much variance in 
the data set as possible in the first and subsequent 
components (displayed on x and y axes respective-
ly, Figure 6). Data of individual animals is plotted 
in relation to those components. Most variance in 
microbiota composition is explained along the x 
axis and second most on the y-axis. As microbiota 
composition can be affected by housing conditions, 
analysis accounted for cage. Animals aged 4 to 10 
days cluster together with animals at the age of 49 
and 70 days at the right part of the graph, whereas 
animals of intermediate age (14 till 42 days) mainly 
cluster at the left part. This indicates a temporar-
ily distinct composition of the ileum microbiota in 
animals aged 14 to 42 days. 
 
Microbial coating with host Ig shows maturation 
of intestinal humoral immunity
The IgA immune response can be considered to 
be mature when it is able to exert its function by 
for instance binding to the intestinal microbiota, 
which depends on IgA production levels and an-
tigen-repertoire. The fecal microbiota was stained 
with either FITC conjugated anti-chicken IgM, 
IgG, IgA or isotype control and analyzed by flow 
cytometry (Figure 7). No IgG was detected on fecal 
microbiota. Percentage of IgM stained bacteria de-
creased slightly with age (not significant). Bacterial 
coating by IgM was increased at day 14 compared 
to day 3 (p=0.052) and 17 (p=0.012). The percent-
age of IgA stained microbiota increased with age, 
up to 55-70 percent on average (p<0.001). Bacte-
ria at days 3 and 7 were only coated with IgM and 
from day 35 onwards bacteria were mainly coated 
with IgA. FACS data from days 17 till 28 showed 
fluctuations of IgM and IgA coating.
Cytokine mRNA expression levels correlate with 
ileum microbiota
As the microbial composition changed during the 
experimental period and expression levels of im-
mune related genes were temporarily elevated from 
10-42 days compared to the days before and after 
this period (previously published (31)), the ques-
Figure 8. RDA analysis of microbial composition and immune gene expression, taking housing units into ac-
count. Gene expression depicted are significantly (p<0.05) related to microbiota composition, except for IL-4 
and IL-12 (p=0.06). Expression of IgM, IgG, IL-2 and iNOS is not shown (p>0.10). Percentages along axes 
indicate variance in microbiota composition explained by immune gene expression. Direction of arrow indicate 
correlation in animals having a specific microbiota profile. Arrows opposite to each other indicate negative cor-
relation, perpendicular arrows indicate that variables are not correlated.
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tion arose whether the variability in the composi-
tion of the ileum microbiota could be explained 
by the expression levels of these immune-related 
genes  (Figure 8).  Eighteen percent of the total 
variability in the microbial profile can be related 
to the immune gene expression pattern as deter-
mined by the Monte Carlo permutation test.  Only 
the immune genes that significantly explained 
part of the variability in the 16S rRNA gene RFLP 
profile are shown in the plot. The directions of ar-
rows indicate to what microbial communities gene 
expression levels are associated and the length of 
the arrow the amount of association. Positive re-
lations were found between the intestinal micro-
bial composition and expression levels of IL-10 
(p=0.004), IFN-γ (p=0.002), IL-1ß (p=0.03), TGF-
ß (p=0.002), pIgR (p=0.02) and IgA (p=0.002) and 
a tendency with IL-4 (p=0.06) and IL-12 (p=0.06). 
No relation was found between expression levels of 
IgM, IgG, IL-2 or iNOS (p>0.10) and the ileum mi-
crobiota composition. In general, immune genes 
ordinated to the left part of the diagram together 
with microbiota composition of animals aged 14 
until 42 days (Figure 8). Immune gene expression 
did not associate positively with microbiota com-
position of animals early or later in our experi-
ment, but only with the transiently changed micro-
biota composition. Composition of the microbial 
community did not correlate with the degree of 
deviation from the normal distribution of CDR3 
repertoire profiles. 
DISCUSSION
Our data show that 5-7 weeks are required for in-
testinal humoral immunity in chicken to mature 
into a functional microbiota-binding IgA response. 
The observation that coating of bacteria with IgA 
was observed at earlier ages than increased SS 
of IgA CDR3 spectratypes and that no profound 
changes in CDR3 sequences were observed, indi-
cate that IgA production levels but not changes in 
CDR3 repertoires are required to coat the intesti-
nal microbiota.
In mucosal IgA production, we can distinguish be-
tween antibody production itself and the variation 
of the IgA antigen recognition repertoire. In the 
early period (day 4 and 7), only IgM spectratypes 
showed clonally expanded CDR3 regions, while 
the spectratypes for IgG (day 49) and IgA (day 49 
and 70) had clonally expanded CDR3 regions later 
in ontogeny. Clonally expanded CDR3 regions 
could be caused by a combination of proliferation 
and activation of existing B cells and differentia-
tion or influx of B cell subsets. However, changes in 
CDR3 spectratype profiles reflect the CDR3 length 
distribution of all B cells in the tissue sample ana-
lyzed, and do not reveal which B cell subset is a 
major contributor to the CDR3 repertoire. Because 
of their approximately 1000-fold higher Ig-produc-
tion rate compared to naïve B cells, plasma cells are 
the main contributors to spectratype profiles (32). 
The CDR3 length of IgM decreased with increas-
ing age and the IgA and IgG CDR3 length did not 
change with age. At day 70 the three isotypes had 
similar CDR3 lengths. The CDR3 length affects 
the three dimensional shape of the antigen bind-
ing sites (33). Longer CDR3 domains may result in 
poly-specific antibodies, and recently it was pub-
lished that pneumococcal vaccination resulted in 
decreased CDR3 lengths (23, 34). Different pseu-
dogenes were used to generate the IgA CDR3 rep-
ertoire, with a preference for pseudogene VH15-9. 
Interestingly, there was no evidence for differential 
pseudogene usage between individual chickens or 
between chickens of different age (7 or 70 weeks 
post hatch). The unchanged pseudogene usage 
suggests that age of the animals and intestinal 
microbioata composition, and probably environ-
mental factors in general, may have limited effect 
on pseudogene usage. These results should be con-
firmed when more pseudogenes have been identi-
fied and could be combined with analysis of muta-
tions in the CDR3 region. Restricted variability in 
gene usage in intestinal CDR3 repertoires has also 
been published for rodents (35). VH-pseudogenes 
used by intestinal B cells may be selected for rec-
ognition of microbial surface molecules. However, 
the IgA CDR3 repertoire does not only depend on 
pseudogene usage, but also on somatic mutations. 
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Though not observed from our spectratype data 
and pseudogene usage, the CDR3 repertoire might 
be slightly different between animals aged 7 or 70 
days.  We conclude that the IgA CDR3 repertoire 
modification does not seem to depend on differen-
tial pseudogene usage at different ages.
Intestinal IgA regulates the composition of the 
intestinal microbiota. Therefore we hypothesized 
that regulation of the microbiota by IgA may de-
pend on the antigen specificity of IgA and there-
fore maybe related to the IgA CDR3 repertoire. 
However, we found no relation between the 
CDR3 repertoire and the microbial composition, 
whereas the IgA expression level was related to the 
microbial composition. Functional coating of fe-
cal microbiota with IgA was significant from five 
weeks post hatch and later. Ileum IgA expression 
level data correlated with pIgR expression data 
and were consistent with functional IgA coating 
of fecal microbiota data. We found that functional 
coating of microbiota with IgA, preceded changes 
in CDR3 repertoire as determined by spectratyp-
ing. It should be noted, however, that the CDR3 
repertoire analysis was performed on mRNA from 
ileum, while bacterial coating was analyzed by flow 
cytometry on stool samples. In addition, bacteria 
binding the J-chain could contribute to numbers 
of bacteria found to be positive for secretory Ig. 
That bacterial coating preceded CDR3 repertoire 
changes suggests that coating of intestinal micro-
biota is independent of functional maturation of 
the ileal IgA CDR3 repertoire and that the initial 
IgM and IgA repertoire is already able to recog-
nize large numbers of intestinal bacteria. This 
hypothesis corroborates the observation by Stoel 
et.al and Harris et.al. (35, 36), that the majority of 
IgA controlling the commensal microbiota in the 
intestines undergoes limited changes in the CDR3 
region. We did not study if IgA binds to specific 
species or groups of bacteria. It is still possible that, 
dependent on the CDR3 repertoire, different spe-
cies at different time points were coated. 
Because functional IgM levels are relatively low 
and maternal-derived IgA in the gut is limited 
just after hatch, more adherence of bacteria to the 
epithelium and translocation of bacteria may oc-
cur in avians where to our current understanding 
less maternal IgA or IgM is available compared to 
mammals. Lack of IgA results in increased translo-
cation of bacteria, which coincides with increased 
expression of IgG (11, 12, 37). During this period, 
de microbiota composition is temporally changed 
and therefore IgG specificities may be biased to-
wards transiently dominant and translocating bac-
teria. Increased IgA levels later in life is believed to 
prevent translocation of bacteria, and IgA present 
in sufficient amounts inhibits IgM mediated classi-
cal complement activation and dose-dependently 
inhibits IgG mediated complement activation(38, 
39). Though maternally derived antibodies can be 
readily detected systemically, no IgG coating of fe-
cal microbiota was observed. This implies a limited 
role for maternal IgG in recognizing intestinal mi-
crobiota and that the role of IgG might be more re-
stricted to protection against translocated bacteria. 
It would be interesting to identify to what extent 
IgG specific immunity is initiated to translocating 
bacteria in this transitional period.
The transiently increased expression of innate and 
T helper cell cytokines likely reflects this increased 
activation of the host’s immune system. As in the 
same period the microbial community underwent 
temporally changes, cytokine expression data was 
hypothesized to relate to the composition of the in-
testinal microbiota. Indeed the analysis of the ep-
ithelia-adherent ileal microbiota composition was 
correlated with increased immune gene expres-
sion. Our data suggest that the period from 2-6 
weeks post hatch with features of low inflamma-
tion (31) is the main immune-inducing window. 
Immune gene expression was decreased in chick-
ens of 7 weeks and older (31). This reduction in 
immune activation may indicate that homeostasis 
was established between 7 to 10 weeks post hatch. 
It is interesting to note that especially at day 35 a 
change is observed in microbiota composition and 
IgA production. A role for IgA in immune homeo-
stasis has been observed before (14). The present 
study, however, shows that initiation of IgA pro-
duction during ontogeny significantly contributes 
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to microbiota composition and establishment of 
homeostasis.
We conclude that chickens have only minor levels 
of functional immunoglobulins of all three iso-
types in the gut lumen in the first weeks post-hatch. 
From the second week post-hatch, the microbiota 
composition changed, which correlated with en-
hanced immune gene expression and subsequent 
return to a microbial community resembling the 
initial community. The changes and correlations 
observed between microbial community and host 
cytokine and IgA gene expression suggest a two-
way interplay between host immune system and 
microbiome: initially microbiota initiate immune 
activation, while later in life IgA is binding large 
amounts of microbiota. IgA production seems to 
be initiated prior to maturation of the CDR3 rep-
ertoire and these initially formed IgA molecules 
are able to bind to microbes. Therefore, our data 
indicate that levels of IgA expression rather than 
IgA CDR3 repertoire are important in controlling 
the intestinal microbiota.
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Gene Genbank no Primer Product size (bp)
28S DQ018756 F: GGCGAAGCCAGAGGAAACT 62
R: GACGACCGATTTGCACGTC
IL-1 AJ245728 F: CAGCAGCCTCAGCGAAGAG 86
R: CTGTGGTGTGCTCAGAATCCA
IL-2 AF033563 F: TTCAAAATATCGAAAAGAACCTCAAG 51
R: CGGTGTGATTTAGACCCGTAAGAC
IL-4 AJ621249 F: GTGCCCACGCTGTGCTTAC 82
R: AGGAAACCTCTCCCTGGATGTC
IL-10 AJ621614 F: CGCTGTCACCGCTTCTTCA 88
R: TCCCGTTCTCATCCATCTTCTC
IFN-γ Y07922 F: GTGAAGAAGGTGAAAGATATCATGGA 71
R: GCTTTGCGCTGGATTCTCA
TGF-β4 M31160 F: ACCTCGACACCGACTACTGCTT 86
R: ATCCTTGCGGAAGTCGATGT
IgA S40610 F: GTCACCGTCACCTGGACTACA 192
R: ACCGATGGTCTCCTTCACATC
IgG X07174.1 F: ATCACGTCAAGGGATGCCCG 118
R: ACCAGGCACCTCAGTTTGG
IgM X01613.1 F: GCATCAGCGTCACCGAAAGC 98
R: TCCGCACTCCATCCTCTTGC
PIgR AY233381 F: GGATCCGACGTGCAGATCCAGCTCCTTCGT 247
R: TCACCATCATCGACTTCCCAGAGCAGG
INOS U46504 F: TGGGTGGAAGCCGAAATA 241
R: GTACCAGCCGTTGAAAGGAC
Table S1.  Primers used for RT-qPCR
inflammatory activity of human IgA antibodies and their 
Fabα fragments: inhibition of IgG-mediated complement 
activation. European Journal of Immunology 19: 2243-
2249.
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Figure S1. Panel A shows a cartoon of Ig expression kinetics in ileum based on previous findings (Lammers 
2010) and the samples points of Ig expression, spectratyping, sequencing (IgA), microbial community profiling 
(MCPC) and flow cytometric analysis of fecal bacteria (FACS). Panel B shows the experimental procedure of 
spectratyping and data analysis.
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Figure S2. Heat maps of standardized spectratype profiles of IgM (A), IgG (B) and IgA (C), of all chickens 
tested. X axes show age (days post hatch), y axes peak number (product size) and the color coding shows the 
relative amount a peak contributes to the total repertoire. Use of e.g. green or purple colors indicates clonal 
expansions.
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Figure S3. IgM, IgG and IgA CDR3 repertories changed successively with age. PCA analysis of CDR3 reper-
toires was performed of chickens of different ages. Each individual animal is depicted and an envelope drawn 
through most extreme individuals. The more a spectratype deviates from normality the more the individual 
ends up away from the center of the graph, where the axes intersect.
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ABSTRACT
Cytokines can be functionally active across species barriers. Bovine IL-10 has an amino acid se-
quence identity with human IL-10 of 76.8%. Therefore, the aim of this study was to evaluate whether 
bovine IL-10 has immunomodulatory activities on human monocytes and dendritic cells. 
Peripheral blood monocytes were isolated from healthy donors, and used directly or allowed to dif-
ferentiate to dendritic cells under the influence of IL-4 and GM-CSF. Recombinant bovine IL-10 
inhibited TLR induced activation of monocytes, and dose-dependently inhibited LPS-induced acti-
vation of monocyte-derived DCs comparable to human IL-10. By using blocking antibodies to either 
bovine IL-10 or the human IL-10 receptor it was demonstrated that inhibition of monocyte activa-
tion by bovine IL-10 was dependent on binding of bovine IL-10 to the human IL-10R. 
These data demonstrate that bovine IL-10 potently inhibits the activation of human myeloid cells in 
response to TLR activation. Bovine IL-10 present in dairy products may thus  potentially contribute 
to the prevention of necrotizing enterocolitis and allergy, enhance mucosal tolerance induction and 
decrease intestinal inflammation and may therefore be applicable in infant foods and in immu-
nomodulatory diets.
 
INTRODUCTION
Dietary components are capable of modulating 
intestinal immune responses [1,2]. Dairy prod-
ucts, including cow’s milk, are widely consumed in 
Western societies and contain a wide range of im-
munoprotective factors such as immunoglobulins, 
lactoferrin, anti-microbial enzymes and cytokines. 
Bovine IL-10 was found to have an amino acid se-
quence identity of 76.8% with human IL-10, indi-
cating that bovine IL-10 may exert functional ef-
fects on human immune cells [3,4,5,6]. Therefore, 
bovine IL-10 present in dairy and dairy related 
products could potentially have immunomodula-
tory activity in the human consumer. Functional 
cross species activity of cytokines  has been re-
ported for chicken IFN-γ and turkey IL-2 [5,6], 
and both porcine IL-2 and human IL-2 were re-
ported to enhance proliferation of human, bovine, 
porcine and murine cells in vitro [3]. Also, human 
IL-10 is functionally active on a mouse mast cell 
line, but mouse IL-10 was not functionally active 
on a human B cell line [7]. Together these findings 
indicate that cytokines can be functionally active 
across species. The potential cross-species bioac-
tivity of IL-10 depends mostly on the sequence 
identity of the IL-10 receptor (IL-10R) binding 
sites [4] and three dimensional structure of the 
proteins involved. 
Biologically active IL-10 binds to the IL-10R, 
which is expressed on monocytes, macrophages, 
dendritic cells (DCs), NK cells, T cells and B cells. 
IL-10 is bound as a homodimer at two sites by both 
the IL-10R1 dimer and the IL-10R2 dimer, result-
ing in four IL-10/IL-10R interaction sites [8,9,10]. 
The IL-10R1 dimer binds the IL-10 molecule with 
high affinity; subsequently, this complex is rec-
ognized by the low affinity IL-10R2 dimer. IL-10 
bound to IL-10R1 activates phosphorylation of 
Jak1 and Tyk2, which leads to Signal Transducer 
and Activator of Transcription 3  activation [11]. 
Signal Transducer and Activator of Transcription 
3 translocates to the nucleus and activates Sup-
pressor of Cytokine Signalling-3  [11,12], resulting 
in suppression of MyD88 - NFκB activated TLR-
inducible cytokines like IL-1β, IL-6 and TNF-α 
[13,14,15,16,17]. These cytokines are selectively 
inhibited by IL-10 in a dose-dependent manner 
[18,19].
IL-10 is a potent cytokine and essential in con-
trolling excessive immune responses to infec-
tions, thereby reducing immunopathology [20]. 
T cell dependent and T cell independent IgA class 
switching and production can be initiated by IL-
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10 in secondary immune organs and in the lamina 
propria [21,22,23]. IL-10 is involved in tolerance 
induction and immune regulation in both the in-
nate and adaptive immune system. IL-10 can also 
inhibit homing of DC’s to the draining lymph 
node [24], and IL-10 treated DCs can induce tol-
erance [25]. The maturation and activation in-
duced expression of CD40, CD80 and CD86 by 
macrophages and DCs can be inhibited by IL-10 
[26,27], affecting the ability to stimulate T cells. 
Indeed, IL-10-exposed APCs fail to induce IFN-γ 
production by Th1 cells [28,29]. 
IL-10 can directly regulate T cell responses and 
has been shown to be related to successful aller-
gen immunotherapy [30,31,32]. IL-10 excreted by 
transfected Lactococcus lactis in the lumen of the 
intestine of mice can induce IL-10 production by 
cells of the Peyers patch and prevent allergic sensi-
tization to food [33]. Next to this, in a neonatal rat 
model, decreased necrotising enterocolitis (NEC) 
correlated with increased in situ IL-10 production 
[34]. These findings show the potential signifi-
cance of the presence of IL-10 in the intestine.
In this report, we investigated whether bovine 
IL-10 could exert functional activity on human 
monocytes and dendritic cells. Bioactive bovine 
IL-10 could potentially be used for the preven-
tion of inflammatory diseases as NEC and allergy 
in infant nutrion, or in immunomodulating diets 
for patients suffering from intestinal inflammatory 
disorders. We show that bovine IL-10 is recognized 
by the human IL-10 receptor and dose-dependent-
ly inhibits cytokine production and surface marker 
expression during LPS induced DC maturation.
MATERIALS & METHODS
IL-10 sequence analysis
IL-10 sequences were obtained from the online da-
tabases of NCBI (http://www.ncbi.nlm.nih.gov/) 
and UniProt (http://www.uniprot.org/). Existing 
signal peptide data or signalP 3.0 (http://www.cbs.
dtu.dk/services/SignalP/) were used to identify 
IL-10 signal peptides, which were removed before 
performing the sequence alignment. Sequence 
alignment was done in BioEdit (version 7.0.9.0) 
using ClustalW Multiple Alignment with default 
settings. Subsequently, the amino acid sequence 
identity was calculated using the sequence identity 
option in BioEdit. Accession numbers of the IL-
10 sequences are: Human, UniProt, P22301; Bo-
vine, UniProt, P43480, Epstein-Barr virus (EBV), 
UniProt, P03180; Rat, NCBI, EDM09836; Sheep, 
NCBI, CAA82546; Mouse, NCBI, AAI37845; Pig, 
NCBI, CAL29498 and Papiine herpesvirus 1 (Pa-
pHerp), NCBI, AAF23949.
Three-dimensional modeling of bovine IL-10
The dimeric structure of human IL-10 (PDB en-
try: 1j7v, resolution 2.9 Å) was used as a template 
to model the dimeric bovine IL-10 protein using 
the program MODELLER (version 9v8 [35,36]), 
which incorporates the CVFF force field [37]. Ste-
reochemical quality of the homology models was 
assessed using the program PROCHECK [38]. 
Protein folding quality was verified using the pro-
gram PROSAII [39], which independently evalu-
ates the compatibility of each residue to its envi-
ronment.
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) 
were diluted 1:1 in IMDM (Gibco-BRL, Paisley, 
Scotland) and isolated by gradient centrifugation 
on Ficoll-Plaque PLUS (Amersham Biosciences, 
Uppsala, Sweden) for 5 minutes at 200g and sub-
sequently for 15 min. at 500g (without brake at 20 
ºC). The PBMCs were harvested from the Ficoll 
layer, gently resuspended in IMDM and washed 
two or three times in IMDM. 
Monocyte isolation and stimulation
Monocytes from freshly isolated PBMCs were la-
beled with MicroBeads conjugated to mouse IgG2a 
monoclonal anti human CD14 antibodies (130-
050-201, Myltenyi Biotec, Germany), and isolated 
using the quadroMACS (Myltenyi Biotec) accord-
ing to the manufacturers descriptions. Briefly, cells 
were incubated with MicroBeads for 15 minutes at 
4ºC, washed with MACS buffer, centrifuged and 
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resuspended in MACS buffer. The MACS columns 
were placed in the quadroMACS and rinsed. Sub-
sequently, the cell suspension was added, rinsed 
and the columns removed from the quadroMACS; 
labeled cells were collected in a new tube by rins-
ing with MACS buffer and the supplied plunger. 
Purity of the CD14+ cell population was between 
90 and 95%, as determined by flow cytometric 
analysis (FACS Canto II  BD Biosciences, San Jose, 
CA, USA) by labeling the cells with mouse IgG2a 
anti human CD14 APC or an isotype control 
(clone M5E2, 555399 or 555576, BD Biosciences). 
Myltenyi Biotec indicated that clone M5E2 was not 
used on the microbeads used for isolation of the 
cells. After MACS sorting monocytes were resus-
pended in IMDM + 1% Yssels medium [40] + 1% 
penicillin and streptomycin (Gibco). 
Recombinant bovine IL-10
The recombinant bovine IL-10 was produced in 
house. Therefore the bovine IL-10 cDNA sequence 
encoding the mature part of the protein was cloned 
in pET15bGW essentially as described previously 
for rhinoceros IFN-γ [41]. Vector pET15bGW en-
codes for an N-terminal tag containing 6 histidine 
residues (his6-tag) under control of a T7 promoter. 
This tag enables purification of recombinant pro-
tein by immobilized metal affinity chromatog-
raphy (IMAC). Protein production, purification 
by IMAC endotoxin removal and refolding was 
essentially performed as described previously for 
carp CXCL8 chemokines [42]. The sequence of re-
combinant bovine IL-10 used in the cell culture ex-
periments is identical to the bovine IL-10 sequence 
showed in Figure 1 (NCBI database), as was con-
firmed by sequencing the IL-10 coding insert of 
the vector (Baseclear, Leiden, The Netherlands).
IL-10R inhibition
Monocytes were stimulated with 1 µg/ml LPS (S. 
enterica, Sigma Aldrich, St Louis, USA), 2 µg/
ml peptidoglycan (S. aureus, Fluka, Buchs Swit-
zerland) and 2 μg/ml flagellin (S. typhimurium, 
InvivoGen, Toulouse, France). Human (200-10, 
Peprotech, London) or bovine IL-10 was used at 
a concentration of 10 ng/ml. To block the biologi-
cal activity of recombinant bovine IL-10, 50 μg/
ml total chicken IgY isolated from egg yolks of 
chicken immunized with recombinant bovine IL-
10 was used. Antibodies isolated from egg yolks 
of non-immunized chicken (50 μg/ml) were used 
as a negative control. To block the human IL-10R, 
5 μg/ml rat IgG2a anti human IL-10R (CDw210) 
(Clone 3F9, 556011, BD Biosciences) and an iso-
type control (554687, BD Biosciences) were used. 
Antibodies were added to the cells and incubated 
at 37ºC and 5% CO2 for 30 minutes prior to addi-
tion of other stimuli. Monocytes were stimulated 
with different TLR ligands with or without bovine 
IL-10 for 24 hours at 37ºC and 5% CO2. LPS and 
a widely used dose [12,19] of 10 ng/ml human 
or bovine IL-10 were added and incubated for 24 
hours at 37ºC and 5% CO2. Cell culture superna-
tants were collected and stored at -80ºC for later 
cytokine analyses.
DC generation and stimulation
Monocytes for DC generation were purified from 
freshly isolated PBMCs by density centrifugation 
using Percoll (GE Healthcarespec. grav. 1.130 ± 
0.005 g/ml, <25 mOsm/kg H20). Standard isotone 
Percoll was prepared by adding 1 part PBS to 9 
parts Percoll and used to make three layers of dif-
ferent densities of Percoll (2.5 ml 60%, 5.0 ml 45% 
and 2.5 ml 34.2% in HBSS in a 15 ml tube). Cells 
(in HBSS + 10% FBS) were gently added on top 
of the Percoll layers (max 40*106 cells) and centri-
fuged at 18-22ºC for 45 minutes at 1750g without 
brake. Monocytes were collected and transferred 
to a new tube, centrifuged again (20 minutes at 
1000g) and washed two times with 1% FBS in PBS 
(Gibco, 16000-044). Isolated monocytes were cul-
tured in FBS free CellGroD medium (CellGenix, 
2005) with pen/strep (Gibco, 15140) at a concen-
tration of 1*106 cells/ml. 40 ng/ml recombinant 
human GM-CSF (Peprotech, 300-03) and 20 ng/
ml recombinant human IL-4 (Peprotech, 200-04) 
were added and refreshed every second day. On 
day 6, expression of surface markers was analyzed 
using flow cytometry (FACS Calibur, BD Bio-
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sciences).
On day 6, DCs were stimulated with 50 ng/ml (or 
1000 ng/ml, data not shown) LPS (S. enterica, Sig-
ma Aldrich, St Louis, USA) for 48 hours in the ab-
sence or presence of IL-10. Cell free supernatants 
were collected and stored at -80ºC until analysis. 
DCs were collected and cell surface marker expres-
sion was analyzed.
Cell Surface marker analysis
DCs were stained with FITC or PE labeled mouse 
IgG1 antibodies anti human CD40 (FITC), CD80 
(PE), CD83 (FITC, ), CD86 (FITC), CD1a (PE), 
MR (CD206, PE) or HLA-DR (PE) (555588, 
557117, 556910, 555657, 555807, 555954, 555812, 
BD Biosciences) or isotype controls (PE 555749, 
FITC 555748, BD Biosciences), according to the 
manufacturers descriptions. Cells were incubated 
at room temperature for 30 minutes in the dark. 
Subsequently, cells were centrifuged, supernatant 
discarded, 200 μl FACS Buffer (BD Biosciences) 
added, and analyzed for surface marker expression 
by flow cytometric analysis.
Human cytokine measurements
Human cytokine concentrations in cell culture su-
pernatants were determined using the cytometric 
bead array flex sets (BD Biosciences) and incuba-
tions were performed in the recommended Protein 
Master Buffer Kit (BD Biosciences). Briefly, 50 μl 
supernatant was incubated with capture beads in 
50 μl Capture Bead Diluent for one hour at room 
temperature. Next, PE Detection Reagent in 50 μl 
Detection Reagent Diluent was added and incubat-
ed for two hours at room temperature in the dark. 
For the standard curve, the provided lyophilized 
recombinant cytokines were used and assayed to-
gether with the samples. After incubation the sam-
ples were centrifuged, supernatant discarded and 
200 μl Wash Buffer was added. The samples were 
analyzed by flow cytometric analysis (FACS Canto 
II, BD Biosciences).
Bovine IL-10 ELISA
A bovine IL-10 specific capture ELISA was devel-
oped in house using an anti-bovine IL-10 specific 
monoclonal (MCA2110, AbD Serotec, Oxford, 
UK) as a capture antibody and biotinylated anti-
bovine IL-10 IgY as a detecting antibody. The 
anti-IL-10 IgY had been affinity purified against 
in house produced recombinant bovine IL-10 cou-
pled to CNBr-activated Sepharose 4B from eggs of 
chickens that had been immunized repeatedly with 
recombinant bovine IL-10.  
Statistical analysis
Statistical analysis was performed with PASW Sta-
tistics SPSS version 17.0.3. Cytokine production 
levels upon stimulation with bacterial ligands vary 
greatly between donors. Therefore we tested the in-
hibitory capacity within the donor. We performed 
a generalized linear model after logarithmic trans-
formation of the cytokine data: cytokine produc-
tion level = donor (stimulus * inhibitor). Stimulus 
(LPS, PGN or Flagellin) and inhibitor (whether IL-
10 was added or not) were included as fixed fac-
tors (this will compare groups) and the interaction 
term (*) tests the effect of the inhibitor in relation 
to the stimulus used.
Statistical analysis of the dose-dependent modu-
lation of DC surface marker expression levels by 
bovine IL-10 was performed using a one by one 
correlation model: surface marker expression level 
or cytokine concentration = bovine IL-10 concen-
tration.
The bioactivity between bovine and human IL-10 
was compared using a univariate general linear 
model: cytokine production = IL-10 source (bo-
vine or human) * IL-10 concentration. Low p-
values would indicate a difference between human 
and bovine IL-10.
 
RESULTS
  
Identification of human IL-10R binding sites in 
bovine IL-10
In order to make a more detailed comparison pos-
sible of potential interactions between bovine IL-
10 and human IL-10R, IL-10 sequences of different 
species were aligned and the IL-10R binding sites 
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Figure 1. Comparison of human and bovine IL-10 in the human IL-10R. A: ClustalW sequence alignment 
of IL-10 from different species. IL-10 sequences were retrieved from the NCBI and Uniprot databases and 
analyzed for signal peptides (SignalP 3.0) which were removed from the sequences before performing the 
alignment (18 amino acids for human and bovine IL-10). At the top left the overall sequence identity is shown. 
In grey (Ib) and black (Ia) background shading the IL-10 receptor 1 binding sites are indicated as published by 
Josephson [8]. The underlined residues indicate > 5 Å2 surface area in IL-10RA site I. At the bottom of each 
row the consensus (*) sequence is shown; “.” and “:” indicated homologous amino acids. B: Bovine IL-10 was 
modeled using human IL-10 in the human IL-10/IL-10R complex as template. The human IL-10R is shown in 
green and amino acid substitution between human and bovine IL-10 are depicted in cyan. Cysteine residues 
are colored yellow, the amino acid colored red (indicated with an arrow for one of the two IL-10 chains) is His 
44, which is and amino acid substitution in close contact with the human Il-10R. C: The same model as in B, 
but displayed using spheres.
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indicated (Figure 1). IL-10 sequences were ob-
tained from the NCBI and Uniprot online databas-
es, and SignalP 3.0 was used to identify signal pep-
tides. Next, signal peptides were removed from the 
sequences before performing the ClustalW Multi-
ple Alignment. Data on the IL-10R binding sites 
(obtained from Josephson [8]), were in line with 
the receptor binding sites reported by Reineke [9]. 
The IL-10R binding sites in IL-10, as published by 
Josephson, are indicated in Figure 1A, with black 
(Ia) and grey (Ib) background colors. The interac-
tions between IL-10 and the IL-10R are largely de-
termined by residues of IL-10 in close contact with 
the receptor. Therefore, residues burying a surface 
area of more than 5 Å2 into human IL-10R1 [8] 
are underlined in Figure 1A, allowing evaluation 
of potential consequences of sequence differences 
between human and bovine IL-10 in the human 
IL-10R binding sites. 
Human and bovine IL-10 were found to have an 
amino acid sequence identity of 76.8% (Figure 
1A). Twenty-nine percent (11 out of 38) of the 
amino acid substitutions are present in the first 
20 amino acids of the IL-10 sequence. The IL-10R 
binding site Ia (amino acid residues 138-149) is 
identical for human and bovine IL-10. Divided 
over the three other IL-10R binding sites, bovine 
IL-10 contained nine amino acid substitutions 
compared to human IL-10 (summarized in Table 
1). Seven of the nine different residues bury more 
than 5 Å2 in the IL-10R binding site and therefore 
are expected to contribute to the binding of IL-10 
to the IL-10R. Three amino acid substitutions had 
a different polarity, and different hydrophobicity 
indexes. These three non-homologous substitu-
tions occurred in the Ib IL-10R binding sites and 
two of them buried more than 5 Å2 in the IL-10R 
binding site. Six of the nine amino acid substitu-
tions had similar polarity and none had opposite 
(positive versus negative) polarity.
To support the linear peptide analysis, a 3D model 
of bovine IL-10 bound to the human IL-10R was 
built, based on the available crystal structure of 
the human IL-10/IL-10R complex (Figure 1B). No 
structural differences apart from some side chain 
orientations are observed between the model of 
bovine IL-10 and the crystal structure of human 
IL-10. The majority of amino acid substitutions be-
tween human and bovine IL-10 are located at the 
surface of the IL-10 molecule. The IL-10R binding 
site of IL-10 does not contain any amino acid sub-
stitutions, except for one histidine residue (His 44) 
substitution. Analysis of the 3D model showed that 
this histidine is located in a pocket of the recep-
tor (Figure 1C) and is not likely to impair IL-10R 
binding. 
Bovine IL-10 exerts functional effects on human 
monocytes through binding to the IL-10R
In order to investigate the bioactivity of bovine IL-
10 on the human immune system, we tested the ef-
fect of bovine IL-10 on freshly isolated monocytes 
from three healthy donors. These freshly isolated 
monocytes were stimulated with different bacte-
rial ligands: peptidoglycan (PGN), flagellin and li-
popolysaccharide (LPS) in the presence or absence 
of bovine IL-10. 
Monocyte cell cultures were 90-95% pure, as de-
termined by flow cytometry for CD14 (data not 
shown). Addition of recombinant bovine IL-10 
Binding site Ib Ia Ia Ib
(residues) (20-28) (34-46) (138-149) (151-159)
No. residues 9 13 12 9 43
Substitutions 3 2 0 4 9 (21 %)
- Homologous 2 2 - 3 7 (78 %)
Substitutions >5 Å2 2 2 - 3 7
- Homologous 1 2 - 2 5 (71 %)
Total
Data are obtained from a ClustalW Multiple alignment as shown in Figure 1A. Of the 
amino acid substitutions and the substitution burying >5 Å2 in the human IL-10R [9] 
the number of homologous amino acid substitutions is indicated.
Table 1.  Summary of bovine IL-10 amino acid substitutions in human IL-10R 
binding sites. 
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significantly inhibited PGN, flagellin and LPS in-
duced IL-1β (p<0.001) and TNF-α (p<0.001) pro-
duction by monocytes as tested on three different 
donors (Figure 2A). We suggest that bovine IL-
10 potently inhibits TLR induced activation. The 
5-fold inhibition of TNF-α and IL-1β production 
by monocytes was comparable between bovine 
and human IL-10 (Figure 2B and Table 2).
Additional experiments were performed to con-
firm that inhibition of TLR-induced cytokine pro-
duction by monocytes was specifically caused by 
bovine IL-10. Therefore, IL-10 blocking antibodies 
or isotype control antibodies were pre-incubated 
with bovine IL-10 and LPS, and subsequently add-
ed to the monocytes. Addition of IL-10 blocking 
antibodies in combination with bovine IL-10 com-
pletely restored the IL-1β and TNF-α production 
by LPS stimulated monocytes; which was not ob-
served when the isotype control was used (Figure 
2C). 
The comparison of the sequence of bovine IL-10 
with the IL-10R binding sites on the sequence of 
human IL-10 (Figure 1), confirmed that bovine IL-
10 could potentially bind to the human IL-10R. To 
investigate whether the functional effect of bovine 
IL-10 is indeed through the binding of bovine IL-
Figure 2. Bovine IL-10 can regulate TLR ligand 
induced cytokine production by monocytes by binding 
the IL-10R. Figures 2B-2D are box plots, showing 
the median (black horizontal bar), 50% data range 
(box) and 99% data range (error bars). On the x-axes 
is the addition indicated (+) of TLR stimuli (panel A), 
or 10ng/ml LPS (B-D), 10 ng/ml IL-10 (A-D), bovine 
IL-10 or human IL-10R blocking antibodies (anti 
bIL-10 or IL-10R) or isotype control (C-D).  A: Freshly 
isolated monocytes were stimulated for 24 hours 
with different ligands (lipopolysaccharide (LPS); 
Flagellin (Flag); peptidoglycan (PGN)) with or without 
recombinant bovine IL-10. IL-1β (p<0.001) and TNF-α 
(p<0.001) were significantly inhibited by the three 
bacterial ligands tested. Data (pg/ml) is shown for 
three different donors. B: Human monocytes were stimulated with LPS and either human (white box) or bovine 
(hatched box) IL-10 was added to compare the inhibitory capacity of bovine IL-10 with human IL-10. C: To 
confirm that the response is specifically inhibited by bovine IL-10 a blocking antibody and an isotope control 
were pre-incubated with bovine IL-10 and LPS and subsequently added to the monocytes. IL-1β and TNF-α 
production (pg/ml) is shown of three different donors. D: In order to proof that the bioactivity of bovine IL-10 is 
mediated through the IL-10R, monocytes were pre-incubated with IL-10R blocking antibodies and subsequent-
ly stimulated with LPS and bovine or human IL-10. Data is shown of 3 different donors.
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10 to the human IL-10R, additional experiments 
were performed with an human IL-10R blocking 
antibody (anti human CDw210). PBMC derived 
monocytes from three different donors were iso-
lated and pre-incubated with the IL-10R blocking 
antibody or isotype control. Following this incu-
bation, LPS and bovine IL-10 were added. Block-
ing the IL-10R completely restored the IL-1β and 
TNF-α production of LPS stimulated monocytes, 
proving that bovine IL-10 binds to the human IL-
10R (Figure 2D). Addition of the isotype control 
resulted in TNF-α and IL-1β production levels 
similar to IL-10 inhibited monocytes. The re-
sults obtained with the IL-10R blocking antibody 
showed a similar inhibition as the results from the 
bovine IL-10 blocking antibody.
These results clearly demonstrate that bovine IL-
10 inhibits TLR induced cytokine production by 
human monocytes, through binding to the human 
IL-10R.
Bovine IL-10 inhibits LPS-induced DC activa-
tion
After testing the bioactivity of bovine IL-10 on 
human monocytes, experiments with DCs were 
performed to test if bovine IL-10 is bioactive on 
other antigen presenting myeloid cells that are po-
tent T helper cell inducers. Freshly isolated mono-
cytes were differentiated into immature DCs under 
the influence of human IL-4 and GM-CSF. These 
Figure 3. Bovine IL-10 dose-dependently inhibits DC surface marker expression and cytokine production. A: 
Typical example of raw data of flow cytometric analysis. Data shown is CD80 expression during LPS induced 
DC maturation of one donor. The solid line indicates CD80 staining and the dashed line the isotype control. On 
top of the graphs is indicated whether medium, LPS or LPS plus different doses of IL-10 (ng/ml) were used.  
B: Bovine IL-10 dose-dependently modulates DC surface marker expression (CD83, p=0.002; CD40, p=0.030; 
CD80, p=0.018) during LPS induced maturation. Relative values are shown from three different donors. 
Mean fluorescent intensities were divided by the isotype control and expressed relative to the positive control 
(LPS, without IL-10), which was set at 100%. C: Recombinant bovine IL-10 dose dependently modulates the 
production of cytokines by human DC’s during LPS induced maturation (IL-12, p=<0.001; TNF-α, p<0.001; 
IL-1β, p<0.001, IL-10, p<0.001). Raw data is shown from three different donors tested. For each cytokine, a 
negative control (no LPS, no IL-10) is shown at the left. Data is shown in panels B and C are from three differ-
ent donors, error bars indicate standard error. On the x-axes the addition of LPS and bovine IL-10 (ng/ml) is 
indicated.
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immature DCs from three different donors were 
maturated with 50 ng/ml LPS in the presence of 
several concentrations of bovine IL-10. The LPS-
induced cytokine production and cell surface 
marker expression were characterized by flow cy-
tometric analysis.
A typical example of raw flow cytometry data is 
shown in Figure 3A (CD80). Maturation mark-
er CD83 and activation markers CD40, CD80 
and CD86 were up-regulated after stimulation 
with LPS. Expression of CD83 (p=0.006), CD40 
(p=0.030), CD80 (p=0.018) and CD86 (p=0.012) 
were dose-dependently down-regulated by bovine 
IL-10 (Figure 3B).  Expression of mannose recep-
tor (MR) (p=0.002) was up-regulated with increas-
ing doses of bovine IL-10. The expression of HLA-
DR was not influenced by bovine IL-10 or LPS. The 
expression of CD1a was inhibited after stimulation 
with LPS, and not affected by bovine IL-10 (data 
not shown). Addition of bovine IL-10 alone did 
not affect any of the analyzed surface marker ex-
pression levels (data not shown). 
Cell culture supernatant of LPS (50ng/ml) stimu-
lated DCs were analyzed for IL-12p70, TNF-α, 
IL-1β and IL-10 levels. Bovine IL-10 dose-depend-
ently down-regulated the production of IL-12p70 
(p<0.001), TNF-α (p<0.001), IL-1β (p<0.001) and 
IL-10 (p=0.001) as shown in Figure 3C. Similar re-
sults were obtained for DC’s stimulated with 1000 
ng/ml LPS (data not shown). On both, DCs and 
monocytes, 10 ng/ml bovine IL-10 could almost 
completely inhibit TLR dependent activation.
These data clearly show that bovine IL-10 dose-
dependently inhibits LPS induced surface marker 
expression and cytokine production by DCs.
Bovine and human IL-10 are equally effective in 
inhibiting LPS-induced DC activation
As bovine IL-10 is able to dose-dependently mod-
ulate DC responses, a comparison of the bioactiv-
ity of bovine IL-10 and human IL-10 was made, to 
verify if bovine IL-10 is equally potent as human 
IL-10 on human dendritic cells. Compared to the 
previous experiment, a wider range of IL-10 con-
centrations was used in combination with 10 ng/
ml LPS. Expression of CD40, CD80, CD83, CD86, 
HLA-DR, CD1a, MR and TNF-α and IL-12p70 
production was determined for three different do-
Figure 4. Dose-dependent 
inhibition during LPS-induced 
DC maturation is comparable 
for human and bovine IL-10. 
Data shown are from 3 dif-
ferent donors tested, error 
bars indicate standard error. 
A: Dose dependent inhibi-
tion of CD83 (p=0.753) and 
CD86 (p=0.936) by human 
and bovine IL-10. Data were 
divided by the isotype control 
and expressed relative to the 
positive control of only LPS, 
which was set at 100%. B: 
Dose dependent inhibition 
of TNF-α (p=0.916) and IL-
12p70 (p=0.962) production 
by human and bovine IL-10, 
shown in pg/ml.
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nors. 
Human and bovine IL-10 were both equally potent 
in inhibiting LPS induced CD83 (linear regression 
of the difference between human and bovine IL-
10: p=0.753 and CD86: p=0.936) expression by 
LPS stimulated DCs (Figure 4A and Table 2). Also 
expression of CD40 (p=0.995), CD80 (p=0.971), 
HLA-DR (p=0.841), CD1a (p=0.873) and MR 
(p=0.881) was not differentially modulated be-
tween human and bovine IL-10 (data not shown). 
Likewise, the TNF-α (p=0.916) and IL-12p70 
(p=0.962) production was equally modulated by 
human and bovine IL-10 (Figure 4B). From Table 2 
it appears that bovine and human IL-10 show simi-
lar inhibitory capacity for all parameters tested.
Based on these data, we conclude that bovine and 
human IL-10 are equally potent in inhibiting LPS 
induced DC activation.
Bioavailability of bovine IL-10
As applications of bovine IL-10 in humans would 
depend on the bioavailability we analyzed milk 
and colostrum samples for IL-10 levels by ELISA 
and performed an in vitro assay to assess the sur-
vival of IL-10 in the upper digestive tract. 
In colostrum samples, a range of 150 – 3000 pg/ml 
of IL-10 was detected in 56 samples from 10 dif-
ferent cows, but in commercially available milk no 
significant IL-10 levels were detectable (data not 
shown).
To evaluate the survival of bovine IL-10 in the hu-
man upper digestive tract, IL-10 was incubated in 
an electrolyte solution containing pepsin. IL-10 
was dissolved in a protein matrix and incubated 
for 1 (adults) or 2 (infants) hours at different pH 
(pH 3 for adults, pH 4 for infants) to resemble re-
spectively the infants and adult stomach. After this 
incubation 50-60 percent of the IL-10 was still de-
tectable under the conditions of an infant’s stom-
ach and 20% for adults (data not shown).
DISCUSSION
Dairy products form an important part of the 
Western diet, and are a potential source of im-
munomodulatory ingredients. Bovine milk con-
tains cytokines like IL-10 that can have functional 
effects on immunological structures in the gut 
mucosa. IL-10 can exert bioactivity when present 
in the lumen of the gut [33] and therefore, con-
sumption of IL-10 may potentially modulate in-
nate immune responses in the intestine. The data 
presented here demonstrate that bovine IL-10 is 
able to modulate TLR induced cytokine produc-
tion by human monocytes. Bovine IL-10 binds to 
the human IL-10R and is able to dose-dependently 
modulate LPS-induced DC activation, similar to 
human IL-10. This is in line with the results of a 
detailed analysis of the cytokine receptor binding 
sites, and with 3D modeling of the human IL-10R/
bovine IL-10 complex.
The recombinant bovine IL-10 used here exerted 
similar inhibitory capacity and dose-dependency 
on dendritic cells as human IL-10. The effects not-
ed with human IL-10 are in line with IL-10 studies 
published before [13,15]. These results demon-
strate that the amino acid substitutions between 
human and bovine IL-10 do not affect the interac-
tion between bovine IL-10 and the human IL-10R. 
Other amino acid substitutions in IL-10 may how-
bo hu bo hu bo hu bo hu bo hu bo Hu
0 100 100 100 100 100 100 100 100 100 100 100 100
0.25 102.9 52.5 143.9 92.1 130.5 128.7 106.3 105.6
0.75 30.8 49.0 88.0 74.7 125.5 114.4 83.4 99.2
2.2 28.0 16.3 55.2 25.1 125.2 60.6 99.3 83.7
6.7 8.9 6.4 13.1 4.6 90.9 72.0 67.9 62.2
20 1.5 2.1 0.9 1.3 38.2 26.2 51.0 47.3
10 30.3 23.0 14.2 6.1
IL-1β TNF-α
IL-10 (ng/ml)
Table 2. Percentage inhibition of DC and monocyte activation of human and bovine IL-10.
Average percentage (3 donors, Figure 4) of IL-12 and TNF-α production and CD83 and CD86 expression by DCs and IL-1β and 
TNF-α production by monocytes (4 donors, Figure 2B) is shown compared to cells only stimulated with LPS (DC’s 10 ng/ml, 
DC monocytes
IL-12 Tnf-α CD83 CD86
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ever decrease IL-10 functionality. An extensive 
genomic analysis of the IL-10 gene and flanking 
regions of 94 Ulcerative colitis and 94 Crohn dis-
ease patients revealed polymorphisms in the IL-10 
coding gene, of which one (R159) was in the recep-
tor binding site, as reported by Josephson [8,43]. 
However, it has not been studied in detail if this 
polymorphism indeed affects IL-10 – IL-10R inter-
actions in colitis patients.  
As far as we know, the IL-10R expression and sig-
nal transduction is similar for monocytes and DCs 
with regard to TLR-dependent activation and cy-
tokine production [11,12,44]. Indeed, our results 
show that cytokine production by monocytes and 
DCs could be equally well modulated by bovine 
IL-10. Involvement of the human IL-10R in the bi-
oactivity of bovine IL-10 implies that all cell types 
like T cells, B cells and NK cells expressing the IL-
10R are probably also modulated by bovine IL-10. 
Monocytes and DCs are antigen presenting cells 
(APC) that are involved in downstream activation 
of T cells. The modulation by bovine IL-10 of TLR-
induced cytokine responses and surface marker 
expression on DCs will in turn affect their ability 
to activate CD4+ T helper cells. T helper cells need 
co-stimulation of CD28 by CD80 (B7-1) or CD86 
(B7-2). Bovine IL-10 reduced the upregulation of 
CD80 and CD86 by human DC’s and therefore 
is likely to reduce T helper cell activation [45]. In 
addition, bovine IL-10 also modulated IL-12 pro-
duction, which affects Th1 versus Th2 skewing. 
As shown in figure 3C, this downregulation of cy-
tokines was more prominent for proinflammatory 
cytokines (IL-1β, TNF-α, and IL-12), suggesting 
that bovine IL-10 may dampen Th1 development. 
The prevention of upregulation of CD40 by bovine 
IL-10 prevents activation of DCs by CD40L from 
activated T cells and will reduce the activation of 
naive T cells by DCs. Moreover, bovine IL-10 can 
bind to the IL-10Rs expressed on T cells and di-
rectly inhibit their activation [45,46,47].
IL-10 and TGF-β both play a role in tolerance in-
duction [48,49] and have complimentary suppres-
sive activity [50]. The presence of intact IL-10 could 
enhance the success of allergen immunotherapy, as 
the presence of IL-10 with an antigen at mucosal 
sites induces tolerance to that allergen [33]. The 
presence of IL-10 in the lumen resulted in elevated 
levels of IL-10 producing cells in the Peyers patch 
[33]. IL-10 in the lumen may be detected by DCs 
that protrude their dendrites through the epithe-
lial cell layer to sample antigens [41,51] and mouse 
epithelial cells were proven to express the IL-10R 
[52]. In individuals tolerant to mucosal antigens, 
more IL-10 dependent regulatory CD4+ cells are 
present in the periphery and sublingual allergen 
immunotherapy induced TGF-β and IL-10 de-
pendent induction of T regulatory cells [50]. CD4+ 
cells activated in the presence of IL-10 become an-
ergic and can acquire antigen specific regulatory 
activities [30,53]. 
IL-10 is essential to develop healthy intestinal im-
munity [54]. That IL-10 present in the lumen can 
exert biological activity is shown in a mouse model 
of autoimmune encephalomyelitis and diabetes 
where orally administered IL-10 effectively en-
hanced tolerance induction [33]. In addition  oral 
administration of  TGF-β has proven to be func-
tionally active in the intestine when using a mouse 
model [55]. Likewise, results from our in vitro ex-
periment suggest that bovine IL-10 is able to sur-
vive and therefore may be bioactive, particularly in 
the upper digestive tract of infants.  Like in bovine 
colostrum, IL-10 is present in human breast milk 
in comparable concentrations ranging from 40 pg/
ml till 3 ng/ml [56,57,58]. As infant nutrition is 
based on resembling breast milk as much as possi-
ble, bovine IL-10 could be considered as a replace-
ment for the IL-10 present in human breast milk.
Interestingly, the development of necrotizing en-
terocilitis (NEC) in premature infants is associated 
with lower levels of IL-10 in breast milk [59]. In 
addition, IL-10 knockout mice develop a pheno-
type resembling NEC [54]. Necrotizing entero-
colitis induced in rats can be reversed by human 
breast milk as well as IL-10 [34,60], and increased 
cytoplasmic IL-10 levels in epithelial cells in rats 
correlated with protection to NEC [34]. Moreo-
ver, injection of rats with induced NEC with anti 
TNF-α antibodies reduced incidence and severity 
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[61]. IL-10 might have similar local effects as IL-10 
is a potent regulator of TNF-α production.
From a meta-analysis of the literature, breastfeed-
ing was concluded to be associated with a reduced 
risk for the development of allergy in the first dec-
ade of life [62]. The effect of breastfeeding may in-
crease with duration of breastfeeding [62]. Next to 
IL-10, TGF-β is present in both human and bovine 
milk. TGF-β1 and TGF-β2 amino acid sequence 
identity between cow’s and human is 95% respec-
tively 98% after removing the signal peptide, and 
100% in their cleaved form (own analysis, data not 
shown), and therefore are likely to be bioactive in 
humans. Prolonged application of a low dose of 
a cytokine could exert functional activity, as has 
been published for IL-2 [63]. Likewise, application 
of bovine IL-10 or TFG-β in infant nutrition over 
a long period may contribute to the prevention of 
allergy. Administration of bovine IL-10 is mainly 
expected to be advantageous for individuals with 
inflammatory diseases, but not for immune-com-
promised individuals as IL-10 may further inhibit 
immune activation. Additional administration of 
IL-10 should be done carefully. This requires fur-
ther study.
Although several in vivo studies have shown IL-
10 bioactivity after oral administration, a poten-
tial drawback of applying bovine IL-10 in infant 
nutrition is that to exert its biological effect in the 
intestines, bovine IL-10 administered through the 
diet has to pass the acidity and digestive enzymes 
of the human upper digestive tract. Another chal-
lenge would be to adapt current food processing 
procedures that currently affect the biological ac-
tivity of IL-10 [56]. We do not expect that anti bo-
vine IL-10 antibodies will appear when bovine is 
administered orally, and since bovine IL-10 is bio-
active it can inhibit immune cell activation which 
is a prerequisite for the development of specific 
antibodies.
We conclude that bovine IL-10 exerts biological 
activity comparable to human IL-10 on human 
monocytes and DC’s. These findings may have im-
plications for the induction of immune tolerance 
in the intestinal mucosa in patients with intestinal 
inflammatory diseases, and for the prevention of 
NEC and allergy in infants.
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ABSTRACT
Bovine milk from non-immunized cows contains pathogen-specific as well as allergen-specific im-
munoglobulins that may contribute to mucosal immunity in the gastro-intestinal tract. The aim of 
this study was to identify if bovine IgG is capable of modulating the activity of human myeloid cells 
through binding to Fc gamma receptors (FcγR).
To this aim monomeric bovine IgG or IgG in complex with LPS was added to monocytes and den-
dritic cells, and binding of bovine IgG to human myeloid cells was studied. Bovine IgG was shown 
to bind to human monocyte-derived dendritic cells, but not to freshly isolated monocytes. Pre-com-
plexing of bovine IgG to LPS increased the binding of IgG to the DCs. This binding could be inhib-
ited by blocking monoclonal antibodies (mAbs) to CD32 (low affinity FcγRII, binds complexes) and 
by mAbs to CD64 (high affinity FcγRI, binds soluble IgG-antigen). Bovine IgG enhanced IL-10 and 
TNF-α production by DCs in the presence of LPS, and also increased the expression of activation 
and maturation markers CD40, CD80, CD86 and CD83. Bovine IgG did not bind to freshly isolated 
monocytes, and as a result it inhibited the response of monocytes to LPS. 
In conclusion, bovine IgG can bind to human IgG receptors and modulate myeloid cell activation by 
bacterial ligands. Therefore, IgG from bovine milk may contribute to immunity to pathogens and 
may also play a role in induction of oral tolerance to allergens. 
INTRODUCTION
Immunoglobulins with a wide range of antigen 
specificities are present in breast milk as well as 
bovine milk [1, 2]. These specific antibodies (Abs) 
protect neonates against infectious agents that the 
mother has already been exposed to [3, 4]. Bovine 
immunoglobulins are able to bind to a wide range 
of antigens, including pathogenic and non-patho-
genic microbes, and inhaled or ingested antigens 
and allergens [3]. Therefore, it would be useful to 
evaluate if Abs from cow’s milk can enhance an-
timicrobial immunity in humans, or promote the 
induction of tolerance to allergens in neonates 
[5]. Immunoglobulins can have different isotypes, 
like IgM, IgG and IgA, resulting in different effec-
tor functions. Effector functions of antibodies are 
neutralization, antibody-dependent cellular cyto-
toxicity, Fc-receptor mediated phagocytosis and 
induction of downstream activation or inhibition 
of myeloid cells and B cells. The type of effector 
function induced by Abs is dependent on the Fc 
receptor, or complement factor, they can bind to. 
Human breast milk contains high levels of sIgA, 
especially in the first weeks postpartum, whereas 
levels of IgG are about ten-fold lower compared to 
IgA and IgM [6]. Immunoglobulins in cow’s milk 
are mainly of the IgG class, of which the majority is 
IgG1 [7, 8]. In bovine milk IgG1 levels are strongly 
increased around birth.
Even though the pathogens to which cows and 
humans are exposed may vary, bovine pathogen-
specific immunoglobulins can cross-react with 
conserved structures on human pathogens. Bovine 
and human pathogens share common pathogen 
associated molecular patterns like LPS, PGN and 
double stranded RNA, that enable cross-reactive 
binding of bovine immunoglobulins with human 
pathogens. Specific bovine IgG in colostrum has 
been detected against numerous bacterial and viral 
pathogens  [9, 10].The functionality of those Abs 
was illustrated for example in a study that could 
show decreased diarrhoea and frequency after 
treatment of HIV-infected patients  that suffered 
from recurrent diarrhoea with colostrum of non-
immunized cows [9]. Similarly, a bovine colostrum 
protein concentrate of non-immunized cows that 
consisted of more than 65% IgG was able to sig-
nificantly reduce Escherichia coli-associated diar-
rhoea in infants in a placebo controlled study [11]. 
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Myeloid antigen-presenting cells (APC), like 
monocytes, macrophages (MΦ) and dendritic cells 
(DC), express multiple Fc gamma receptors (FcγR) 
with varying affinities for human IgG [12]. Both 
activation-inducing and inhibitory IgG recep-
tors have been described, which are differentially 
regulated by IFN-γ and IL-4 [13]. Upon binding 
of  the Fc chains of Ig-complexes, FcγR trigger-
ing induces various effector functions, including 
phagocytosis, antibody-dependent cell-mediated 
cytotoxicity, differentiation, cytokine production, 
and even cross-presentation of antibody-coated 
antigens [14]. FcγR-mediated uptake of antigens 
may be especially beneficial by potentiating Th 
cell activation when only low concentrations of 
antigen are present [15]. Activation of APC via 
Toll-like receptors (TLR) or FcγR is a requirement 
for efficient adaptive immune responses upon in-
fection as APC take up, process and present an-
tigens to T cells resulting in T cell activation and 
differentiation. Myeloid cells have variable abili-
ties to stimulate T cells. Monocytes can both initi-
ate pro-inflammatory responses, and differentiate 
further into different DC subsets [16, 17]. DCs are 
especially efficient antigen presenting cells that are 
able to activate naïve T cells and induce T helper 
cell differentiation into different effector Th cells, 
like Th1 and Th2 [18]. Four types of human IgG 
Fc receptors have been identified to date, that have 
low affinity (CD16 and CD32) and high affinity 
(CD64) to IgG and bind to larger immune com-
plexes and soluble IgG-bound antigen respectively 
[19, 20]. In addition to classical FcγRs that selec-
tively binds IgG the neonatal FcR (FcRn) has been 
identified [21].  FcRn is expressed on various cells 
of the intestinal mucosa, including epithelial cells, 
and bi-directional transport of human IgG over 
the epithelial cell wall has been shown to occur [21 
]. This bidirectional transport both enables anti-
body-mediated protection at mucosal surfaces and 
antigen sampling of immune complexes present in 
the intestinal lumen, and processing for induction 
of specific immunity or tolerance.
The aim of the current study was to identify if bo-
vine IgG can interact with FcγR expressed on hu-
man monocytes and dendritic cells, and if this re-
sults in functional activation of these cells.
MATERIALS AND METHODS
Preparation of bovine colostrum
Bovine colostrum (LF200, La Belle, Washington, 
USA) was dissolved at 10 mg/ml in sterile PBS 
(Mg2+/Ca2+-free; Lonza), incubate 30 minutes at 
37°C and Centrifuged for 10 minutes at 1000g at 
room temperature. Supernatants were sterile fil-
tered through a 0.45 µm filter and stored at 4oC. 
Purification of bovine colostrum-derived immu-
noglobulins  
Commercially available colostrum sample (Colos-
trum 35% IgG, Reflex Nutrition, UK) was diluted 
in 0.75 M (NH4)2SO4 loading buffer (two-fold di-
lution). Additional (NH4)2SO4 was added to ob-
tain a final concentration of 0.75 M (NH4)2SO4. 
The sample was loaded onto an AFFI-T™ column 
(Kem-en-Tec) and eluted with 0.05 M Tris-HCl pH 
8.9 elution buffer. The sample was diluted with 0.02 
M NaPi pH 7.0 loading buffer (four-fold dilution) 
and loaded on a protein G column (5 ml; Amer-
sham). Sample was eluted with 0.1 M glycine-HCl 
pH 2.7 elution buffer and neutralized with 1 M 
Tris-HCl pH 9.0 neutralizing buffer, followed by 
dialyzation against PBS (3x 1L). Sample was steri-
lized (0.2 µm filter) and absorbance at A280 nm 
was measured (GeneQuant; Amersham) to deter-
mine protein concentration and stored at 4oC.
Isolation of human monocytes  
PBS (Mg2+/Ca2+-free; Lonza) supplemented with 
0.1% BSA (Sigma) and 2.0 U/mL heparin (Leo 
Pharma) was added to buffy coat blood (blood 
bank Sanquin, Amsterdam) resulting in a final 
volume of 120 mL. The diluted blood was layered 
onto Lymphoprep gradient (1.077 g/mL; Axis 
Shield) and centrifuged for 15 minutes at 1000g at 
RT (no braking). Peripheral blood mononuclear 
cells (PBMC) were harvested and washed in excess 
of PBS/0.1% BSA by three centrifugation steps, i.e. 
10 minutes at 750g, 5 minutes 500g, and 10 min-
utes 250g at RT (last step, no braking). The pellet 
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(PBMC) was placed onto a Percoll gradient (stock 
1.130 g/mL; GE Healthcare) consisting of 1.076, 
1.057, and 1.045 g/mL layers and subsequently 
centrifuged for 45 minutes at 1,750g at RT (no 
braking). Enriched monocytes were washed (low 
density fraction) in excess of PBS/0.1% BSA (5 
minutes 500g RT).
  
Activation of human monocytes 
106 monocytes/ml were allowed to adhere for 1.5 
hour at 37˚C in serum-free CellGro DC culture 
medium (CellGenix) supplemented with 50 µg/
mL gentamycin (Gibco). After 1.5 hour of incuba-
tion non-adhering lymphocytes were removed by 
washing 4 times with PBS containing 0.5% BSA. 
Subsequently, 250 µg/mL or 50 µg/mL bovine IgG1 
was added from colostrum and purified bovine 
immunoglobulins with or without 1 ng/ml LPS 
from Escherichia coli (serotype 055:B5; Sigma) to 
monocytes. In addition, 50 or 250 µg/ml human 
IgG (Jackson ImmunoResearch) with or without 1 
ng/ml LPS was added. Non-stimulated monocytes 
and 1000 ng/mL LPS treated monocytes were in-
cluded as negative and positive controls respec-
tively. Cells were incubated for 2 days in a 5% CO2 
incubator at 37˚C. After 2 days supernatants were 
collected and stored at -20˚C until determination 
of cytokine levels.
Generation and activation of human immature 
monocyte-derived DC 
0.5x106 monocytes/ml were added to a culture 
flask and allowed to adhere. After adherence non-
bound cells were removed and serum-free CellGro 
DC culture medium (CellGenix) supplemented 
with 50 µg/mL gentamycin (Gibco) and 20 ng/mL 
GM-CSF (PeproTech) and 20 ng/mL IL-4 (Pepro-
Tech) was added to monocytes. Cells were incu-
bated for 5 days in a 5% CO2 incubator at 37˚C. 
Medium containing IL-4 and GM-CSF was re-
freshed at day 2. 
After 5 days of differentiation immature DCs were 
harvested and adjust to 1.0x106 DC/mL in Cell-
Gro DC medium supplemented with gentamycin 
and 20 ng/mL GM-CSF and 20 ng/mL IL-4. 250 
µg/mL or 50 µg/mL bovine IgG1 from colostrum 
and purified bovine immunoglobulins with or 
without 100 ng/ml LPS from Escherichia coli (se-
rotype 055:B5; Sigma) were added to the DCs. 
Also human IgG (Jackson ImmunoResearch) at 
250 µg/mL or 50 µg/mL with or without 100 ng/
ml LPS were tested. Non-stimulated DC and 100 
µg/mL polyI:C (Sigma) treated DC (PeproTech) 
were included as negative and positive controls 
respectively. Stimulated cells were incubated for 2 
days (5% CO2 incubator at 37˚C). After 2 days su-
pernatants were collected and stored at -20˚C until 
determining cytokine levels. DCs were harvested 
for analysis of surface activation markers.
 
Determination of surface activation markers on 
human DC 
After 2 days of DC activation DCs were collected, 
washed in PBS/BSA/NaN3 at 4°C, and adjusted to 
105 DC/100 μL in PBS/BSA/NaN3 at 4°C per tube. 
5 μL mouse anti-human CD40, CD80, CD83, and 
CD86 antibodies conjugated to FITC or to PE (Bec-
ton & Dickinson) were added to 1 * 105 DC/100 
μL/tube. Mouse IgG1 isotype controls conjugated 
to FITC or to PE (Becton & Dickinson) were in-
cluded to determine non-specific background 
staining. Cells with antibodies were incubated for 
30 minutes at 4°C, washed (3 minutes 500g) in ex-
cess (4 mL/tube) of PBS/BSA/NaN3 at 4°C. Cells 
were resuspended to 105 cells/200 μL in PBS/BSA/
NaN3/2% formaldehyde at 4°C and incubated for 
30 minutes at 4°C. MFI of 10,000 events were re-
corded to determine DC surface activation mark-
ers using a flow cytometer (Becton & Dickinson).   
Determination of IL-10 and TNF-α levels 
Supernatants from cell cultures were serially dilut-
ed in IMDM (Lonza), i.e. for IL-10 determinations 
at 1:5, 1:10 and 1:50, and for TNF-α determination 
at 1:10, 1:50 and 1:250. IL-10 and TNF-α levels in 
diluted supernatants were measured according to 
manufacturer’s instructions (ELIPAIR from Dia-
clone). IL-10 and TNF-α standards were also di-
luted in IMDM.
Binding of bovine and human IgG to myeloid cells
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250 µg bovine IgG1/mL from colostrum and pu-
rified bovine immunoglobulins, and 250 µg na-
tive  (monomeric) or denatured (20 minutes at 
65°C; to mimic immune complexes) human IgG 
/mL (Jackson ImmunoResearch) was added to 
enriched monocytes and immature DCs (1 * 105 
cells/100 μL) in PBS/BSA/NaN3 at 4°C. Cells with 
immunoglobulins were incubate for 30 minutes 
at 4° C, followed by washing (3 times; 3 minutes 
500g) in excess (4 mL/tube) of PBS/BSA/NaN3 at 
4°C. Cells were resuspended to 1 x 105 cells/100 μL 
PBS/BSA/NaN3 at 4°C and 10 µl 1:10 sheep anti-
bovine IgG (Bethyl), 10 µl 1:10 sheep anti-bovine 
IgA (Bethyl), and 10 µl 1:10 sheep anti-bovine IgM 
(Bethyl), or 10 µl 1:10 goat anti-human IgG-FITC 
(Jackson ImmunoResearch) was added and incu-
bated for 30 minutes at 4°C. Cells were washed (3 
minutes 500g) in excess (4 mL/tube) of PBS/BSA/
NaN3 at 4°C and resuspended to 1 x 105  cells in 
100 μL PBS/BSA/NaN3 at 4°C. 10 µl 1:10 donkey 
anti-sheep IgG-FITC (Jackson ImmunoResearch) 
was added and incubated for 30 minutes at 4° C. 
Cells were washed and resuspended 105 cells/200 
μl PBS/BSA/NaN3 containing 2% formaldehyde at 
4°C. Cells were incubated for 30 minutes at 4° C 
and analysed for MFI (10,000 events) MFI to de-
termine Ig binding using a flow cytometer (Becton 
& Dickinson).   
FcR Blocking
Immature moDCs were incubated with blocking 
antibodies to CD32 (clone AT10, GeneTex), CD64 
(clone 10.1, BioLegend, San Diego, CA, USA) (or 
IgG1 isotype control, clone MOPC-21, BioLegend 
for 30 minutes on ice. Cells were washed (ME-
DIUM) and 100 µl 1 µg/ml monomeric (µg/ml) 
or bovine IgG in complex with 1ng/ml LPS was 
added and incubated for 30 minutes on ice. Cells 
were washed again and incubated with 1:100 sheep 
anti-bovine IgG (Bethyl), washed and incubated 
with 1:100 FITC conjugated donkey anti-sheep 
IgG (Jackson). Cells were incubated 30 minutes 
on ice, washed and resuspended in 200 µl FACS 
buffer (PBS, 0.5% BSA, 0.5 mM EDTA). MFI was 
determined of 10 000 events recorded (BD FACS 
Canto).
RESULTS AND DISCUSSION
Binding of bovine Ig to human monocytes and 
dendritic cells
Knowing that bovine milk and milk-derived prod-
ucts contain immunoglobulins of various subclass-
es that can bind to pathogens and allergens that are 
also encountered by humans, the ability of bovine 
Ig to bind to human monocytes was studied. Bo-
vine IgG (250 µg/mL), IgA (31 µg/mL), and IgM 
(125 µg/mL) and purified bovine immunoglobu-
lins did not bind significantly to freshly isolated 
human monocytes (data not shown).
In contrast, bovine IgG (250 µg/mL) from colos-
trum as well as purified immunoglobulins did 
clearly bind to immature monocyte-derived DC 
(Figure 1). The binding of bovine IgG to moDC 
was dose dependent (data not shown). Bovine IgA 
and IgM bound only marginally to moDCs. The 
Figure 1. Binding of bovine IgG (A), of bovine IgA (B), and of bovine IgM (C) from 
colostrum (red histograms) and purified bovine immunoglobulin (blue histograms) 
on human monocyte-derived immature DC. Dotted black histograms represent 
background staining. Data from one representative donor of two is shown.
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lack of CD89/FcαRI expression by these immature 
DC (data not shown) indicates that the low level of 
binding of bovine IgA was most likely non-specific. 
However, involvement of other known human IgA 
and IgM receptors like asialoglycoprotein recep-
tor, CD71/transferrin receptor, and Fcα/µR cannot 
be excluded as some of those receptors have been 
identified on myeloid cells [22, 23].
Bovine IgG binds to human FcγR
Having observed that bovine IgG binds to human 
moDCs, experiments were designed to identify to 
which human FcγR expressed on moDC bovine 
IgG could bind. IgG that was allowed to form com-
plexes with LPS resulted in increased binding of 
bovine IgG to human moDCs compared to mono-
meric bovine IgG, suggesting binding of immune 
complexes (Figure 2A). There is an optimal ratio 
between antigen and IgG for formation of immune 
complexes. Titration of LPS with bovine IgG re-
sulted in a bell-shaped curve with optimal binding 
of IgG-LPS complexes to DCs at a ratio of 1 µg of 
bovine IgG and 1 ng/ml of LPS. This binding of 
bovine IgG could partially be inhibited by block-
ing monoclonal antibodies (mAbs) directed at the 
low affinity FcγRII (CD32), but also by mAbs to 
the high affinity FcγRI (CD64) (Figure 2B). These 
data suggest that monomeric bovine IgG can bind 
to the high affinity human FcγRI, and that bovine 
IgG immune complexes could bind to the human 
low affinity FcγRII.
The monomeric bovine IgG did not bind to mono-
cytes, likely because FcγRI (CD64) on freshly iso-
lated monocytes were already saturated with mon-
omeric human IgG. moDCs however, have CD64 
on the membrane without bound IgG, which ex-
plains that bovine IgG was bound by moDCs and 
not monocytes. Binding of complexed bovine IgG 
to freshly isolated monocytes could be possible as 
CD32 does not bind to soluble monomeric IgG 
present in blood. The observation that bovine IgG 
binds to FcγRI and FcγRII on DCs strongly sug-
gests that bovine IgG may also bind to FcγRI and 
FcγRII expressed on other cell types. FcγRI and 
FcγRII are differentially expressed on dendritic 
cells in the mucosal tissues. Therefore, dietary 
bovine IgG may mediate uptake of allergens and 
pathogenic and non-pathogenic bacteria and vi-
ruses. Depending on the expression levels of acti-
vating and inhibitory FcγR, inflammatory or non-
inflammatory downstream immune responses may 
be initiated leading to the production of protective 
IgG or IgA antibodies. This may be influenced by 
which type of DC the FcγRs are expressed.
Effect of bovine immunoglobulins on IL-10 and 
TNF-α production by human monocytes 
Minimal binding of bovine IgG to monocytes was 
observed. To study if bovine IgG could modulate 
LPS-induced cytokine production by monocytes, 
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Figure 2. Binding of bovine IgG-LPS immune complexes to human moDCs. 1 µg bovine IgG was 
incubated with different doses of LPS and subsequently added to moDCs (A). IgG –LPS immune com-
plexes were added to moDC in the presence or absence of IgG receptor blocking antibodies (B). Ctr 
shows background staining, boIgG mono is monomeric bovine IgG and boIgG complex shows bovine 
IgG pre-incubated with LPS prior to addition to the DCs. Blocking of CD32 and CD64 was performed 
with LPS-IgG complexes. For both panels an example of three experiments is shown.
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bovine IgG with and without LPS was added to 
freshly isolated monocytes and incubated for 48 
hours. Human monocytes secreted substantial IL-
10 and TNF-α upon exposure to LPS (Figure 3). 
The cytokine secretion levels reached their plateau 
at a 1000 ng/mL LPS, while 1 ng/mL LPS was sub-
optimal (n=3; dose response curves not shown).
Interestingly, the cytokine responses evoked by 1 
ng/ml LPS were significantly inhibited by co-in-
cubation with purified bovine immunoglobulins. 
This finding strongly suggests that the anti-LPS 
specific antibody pool recognized and neutralized 
a bioactive moiety of LPS.
Bovine immunoglobulins synergistically en-
hance the activation of human moDC by LPS 
As discussed above, bovine IgG-LPS complexes 
could bind to human moDCs. To check if this re-
sults in enhanced responses of the moDC to LPS, 
bovine IgG alone or in combination with LPS 
was added to immature moDC. Human imma-
ture DC showed no, or only a minimal IL-10 and 
TNF-α production after stimulation with 100 ng/
ml LPS or bovine immunoglobulins alone (Figure 
4). However, the combination of 100 ng/mL LPS 
with purified bovine immunoglobulin resulted in 
a strong synergistic increase of IL-10 and TNF-α 
secretion by the moDCs (Figure 4). This observa-
tion indicates that immune complexes consisting 
of bovine LPS-specific immunoglobulin and LPS 
could activate human moDC via a FcR-signaling 
pathway. This is consistent with the observation 
that IgG-LPS complexes result in increased bind-
ing to DC compared to monomeric IgG (Figure 2). 
Consequently, binding of IgG immune complexes 
seem to result in activation of these DCs.
The induction of increased expression levels of ac-
tivation- and maturation markers by stimulation 
of moDC with LSP- bovine IgG immune com-
plexes varied between the donors tested. However, 
in agreement with the demonstrated synergism 
on cytokine secretion from human immature DC, 
bovine immunoglobulins in combination with 100 
ng/mL LPS also synergistically increased CD83 
and CD86 expression on immature DC (Figure 
4B).  Apart from CD86 and CD83 bovine IgG also 
increased expression of CD40 and CD80, but this 
effect was less prominent (data not shown). CD83 
expression is associated with expression of MHC 
class II, which is required for antigen presenta-
tion by DCs to T cells [24]. These data suggest that 
bovine IgG may mediate FcyR-facilitated antigen 
presentation to T cells, as was previously demon-
strated for human IgG [25].
Two previous reports have shown cross-species 
binding of bovine IgG to human Fc receptors. 
Loimaranta et al demonstrated that immuniza-
tion of cows with Streptococcus mutans and S. 
sobrinus resulted in increased specific Ab levels in 
bovine colostrum-derived whey that could medi-
ate phagocytosis by human monocytes, eosino-
phils and neutrophils [26]. In a more recent paper, 
colostrum-derived bovine IgG from HIV-1 enve-
lope gp140 vaccinated cows was shown to dose-
dependently bind to FcγRs on human neutrophils, 
monocytes and NK cells, and was able to induce 
antibody dependent cellular cytotoxicity by mono-
cytes via signalling through the activation-induc-
ing FcγRIIa (CD32a) [1]. The data presented here 
confirm these previous reports, and extend these 
Figure 3. Effect of purified bovine immunoglobu-
lin, in the absence or presence of a suboptimal 
concentration of LPS (1 ng/mL), on IL-10 and 
TNF-α production from human monocytes. Data 
from one representative donor of three is shown.
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findings by showing that the presence of bovine 
IgG enables DCs to respond more vigorously to 
LPS (Figure 4). 
In addition to classical FcγR, the non-classical 
IgG-binding neonatal receptor FcRn is expressed 
in the intestines of neonates, which is involved in 
induction of oral tolerance to allergens in mice [5]. 
Binding of bovine IgG to human FcRn does occur, 
but is relatively low compared to binding of hu-
man IgG [27]. We have not been able to show the 
presence of FcRn on the moDC used in this study, 
which does not exclude a functional of FcRn ex-
pressed in the intestine of humans, in which FcRn 
is expressed constitutively [28].
Bovine IgG-antigen complexes formed in the in-
testinal lumen are expected to be bound and sub-
sequently taken up by mucosal FcγR-expressing 
DCs, that can protrude their extensions through 
tight junctions between epithelial cells into gut lu-
men [29]. In addition, goblet cells have been re-
ported to deliver luminal antigen to tolerogenic 
CD103+CDd11c+ DCs [30]. Immune complexed 
antigens that are internalized via CD32 on im-
mature DC are known to be presented far more 
efficiently to T lymphocytes than non-complexed 
antigens [31], suggesting that bovine IgG-antigen 
immune complexes may also play a functional role 
in immune defence in the intestine as they can also 
bind to CD32. In addition to intestinal pathogens 
or food allergens, airway pathogens and allergens 
may be encountered by intestinal DCs, as airway 
content can be swallowed and be bound by immu-
noglobulin in the intestinal lumen [32]. 
Induction of immune responses by bovine IgG 
requires formation of complexes of bovine IgG 
with a pathogen or allergen. Specific IgG against 
many different bacterial pathogens has been found 
in milk of non-immunized cows, including IgG 
specific for Yersinia enterocolitica, Campylobac-
ter jejuni, Escherichia coli and toxins thereof [33, 
34]. Also rotavirus-specific IgG is present in cow’s 
milk [2]. Interestingly, bovine milk also contains 
specific immunoglobulins against rye-grass pol-
len, house dust mites, Aspergillus mould and 
wheat proteins [35]. Levels of specific IgG in bo-
vine milk can be strongly increased by vaccination 
of the cows. In addition to Fc yR-mediated facilita-
tion of immune responses, vaccination results in 
Figure 4. Effect of colostrum and purified bovine immunoglobulin, and of human monomeric IgG, with or 
without 100 ng/ml LPS, on IL-10 and TNF-α (A) production and activation marker CD86 and maturation 
marker CD83 expression (B) by human monocyte-derived immature DC after 2 days. Data from one of 
three donors is shown.
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strongly increased levels of pathogen-specific IgG 
that can neutralize pathogens in the intestinal lu-
men, thereby offering passive protection against 
infections. For in vivo application of the results 
reported here, bovine immunoglobulins need to 
resist industrial processing and the upper diges-
tive tract. Bovine IgG is likely to resist the stomach 
milieu of infants [36] which has milder conditions 
(e.g. pH) compared to adults. Indeed several stud-
ies have demonstrated that delivering passive pro-
tection against human rotavirus by feeding a colos-
trum formula from vaccinated cows to infants can 
prevent rotavirus infections [37].
Bovine immunoglobulin preparations from im-
munized cows have also been applied successfully 
in treatment of infants that already suffered from 
rotavirus-induced gastroenteritis [38]. Likewise, 
an immunoglobulin concentrate from cows hyper 
immune for Escherichia coli has been shown to 
protect infants against diarrhoea[39].
CONCLUSION
Bovine colostrum-derived IgG and IgG-LPS com-
plexes bind to FcγRI and FcγRII expressed by 
human moDC, resulting in cytokine production 
and upregulation of activation- and maturation-
markers. 
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The mucosal immune system has been studied extensively, but research relating to the role of mucosal B 
cells in allergy is limited. This chapter discusses the relevance of B cell responses in allergy, with empha-
sis on mechanisms of IgA induction in mucosal tissues. Reports evaluating if and how IgA may protect 
against allergy are scarce, especially for mucosal IgA. In this chapter, interaction between the different 
antibody-isotypes and allergens are discussed. The potential role of dietary ingredients as modulator of 
the mucosal immune system, as opposed to dietary ingredients causing allergy, is considered. Subse-
quently, the concept of potential mucosal mechanisms contributing to prevention or protection against 
allergy are discussed, leading to a new hypothesis about the protective role of mucosal IgA and the dif-
ference between IgA1 and IgA2 in protection against allergy.
I SEROLOGICAL DIAGNOSIS OF ALLERGY: BEYOND ALLERGEN-SPECIFIC 
 IGE LEVELS
Epitopes of allergens
Tropomyosin is the major shell fish allergen that 
is recognized in a cross-reactive manner between 
different animal species by serum IgE [1-9]. Cross-
reactivity can be determined in vitro by inhibition 
assays. IgE-binding epitopes identified in both 
crustacean and molluscan tropomyosin cover 
similar surface areas on the molecule [10]. Tech-
niques to identify IgE-binding epitopes vary. The 
methods that are used most frequently rely on lin-
ear synthetic peptides, and enzymatic digestion of 
native tropomyosin followed by ELISA analysis. 
The latter technique was used by Ishikawa et. al [5, 
11] to identify epitopes in molluscan species. Us-
ing this technique, only one IgE-binding epitope 
was identified for tropomyosin of see snail (Tur 
c 1) and oyster (cra g 1). The lack of detection of 
other IgE-binding epitopes may be caused by the 
limited number of sera used or indicate limited al-
lergenicity of those molluscan allergens compared 
to shrimp tropomyosin, where five IgE-epitope re-
gions have been identified. 
For tropomyosin, a common sequence motif 
(LEXXL) has been proposed, as it appeared to be 
present in all IgE epitopes identified [10]. Howev-
er, this motif is also present in human tropomyosin 
and therefore unlikely to be a key determinant in 
allergic responses to shrimp tropomyosin; no sero-
logical analysis was performed on human tropo-
myosin (Figure 1).
IgE-binding epitopes have been identified in tro-
pomyosin in a variety of species. Those epitopes 
are distributed over the surface of the protein, 
and therefore enable crosslinking of IgE immo-
bilized on FcεRI on mast cells and basophils. For 
IgE crosslinking at least two epitopes are required 
that should be at least  8-10 nm (80-102 Å) and is 
estimated to be at maximum 20-24 nm apart from 
each other [12]. An interesting finding from our 
tropomyosin 3D model (Chapter 2) was the re-
gional distribution of the five IgE-binding epitopes 
identified. IgE-binding epitopes on tropomyosin 
were located at a distance of approximately 70 Å 
apart from each other, whereas the Fab fragment 
binding to allergens is about 50 Å and therefore 
steric hindrance is limited allowing binding of 
up to five IgE-molecules to shrimp tropomyosin 
simultaneously. This finding shows that serologi-
cal analysis at the level of IgE epitopes is relevant 
to predict aller genicity of allergens and potential 
cross-reactivity. Currently the usefulness of com-
ponent resolved diagnosis using recombinant al-
lergen proteins is being discussed in the literature 
[13]. A complicated analysis may be difficult to ap-
ply in clinical settings, whereas selection of a num-
ber of allergens in relation to IgE-epitope reactivity 
may greatly enhance specificity of diagnostic tests. 
Systemic versus local allergen-specific Ig
For most allergies, presence of allergen-specific 
IgE is a prerequisite to develop allergy, whereas 
sensitized individuals can have varying clinical 
symptoms and these may even be absent. As a 
result, detection of allergen-specific IgE in serum 
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has high sensitivity, whilst specificity can be lim-
ited. An important explanation for lack of specific-
ity of serological detection of allergen-specific IgE, 
is the presence of blocking antibodies like IgG4 
(Figure 2) [14, 15]. Reduced mast cell and basophil 
degranulation has been observed after specific im-
munotherapy prior to visible serological changes 
in the ratio between IgG4 and IgE [16]. This could 
be due to the suppressive effect of induced mu-
cosal tolerance mediated by DCs and Tregs. Pro-
duction of anti-inflammatory cytokines like IL-10 
and TGF-ß may inhibit activation of mast cells and 
basophils or other cellular compartments, like Th2 
cells and eosinophils [17]. 
An alternative, but poorly explored explanation for 
early clinical protection against allergy during spe-
cific immunotherapy, may be the increase in aller-
gen-specific IgA at mucosal surfaces (Figure 2) due 
A
B
Figure 1. ClustalW Alignment of tropomyosin sequences of black tiger shrimp, blue mussel and human (A) 
and a 3D model of IgE Fab fragments binding to tropomyosin (B). The IgE epitope regions identified in shrimp 
are shaded and the identified common motive LEXXL is boxed, and is shown to be present in human tropo-
myosin too. The 3D model (B) indicates that multiple IgE molecules can bind simultaneously to tropomyosin, 
as discussed in more detail in chapter 2.
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to the tolerogenic cytokines IL-10 and TGF-ß that 
are crucial for Treg induction and IgA production 
[17]. Induction of tolerance and production of IgA 
both occur locally in the mucosa [18, 19]. The fact 
that the majority of IgA is being produced locally 
in the mucosa could suggest that the antigenic 
specificities between systemic and local IgA may 
vary as these IgA molecules may originate from 
different lymphoid tissues (Chapter 4). Indeed 
different antigen specificities have been observed 
between serum and mucosal fluids like saliva, but 
no epitope studies that compare allergen-epitope 
specificity between serum and mucosal fluids have 
been performed [20-22]. This finding is consistent 
with the observation that systemically induced al-
lergen-specific B cells are not migrating efficiently 
to peripheral mucosal sites compared to mucosally 
induced IgA-producing B cells [23]. Also homing 
between different mucosal compartments is differ-
entially regulated. IgA plasma cells induced in the 
gastro-intestinal tract are believed to disseminate 
to all mucosal sites by expressing integrin α4ß1 
and α4ß7, whereas IgA plasma cells induced in the 
respiratory tract mainly migrate back to the respir-
atory tract (due to lack of expression of α4ß7) (dis-
cussed in chapter 6). That different antigen-spec-
ificity repertories exist between serum and saliva 
could implicate that protection against allergy by 
IgA would be possible when allergen-specific IgA 
would be present at the mucosal surface where the 
allergen is encountered. Indeed, the ratio of sys-
temic IgE over IgA2 in saliva correlated better to 
clinical symptoms of house dust mite allergic pa-
tients, compared to the ratio of IgE over IgA2 in se-
rum (Chapter 4). Next to the differences in antigen 
specificity between serum-IgA and mucosal secre-
tions, production levels of IgA are much higher in 
mucosal than systemic tissues. In addition, IgA1 
levels are higher in serum, whereas jejunum and 
especially colon IgA2 levels are higher [22, 24], in-
dicating differential regulation of IgA1 and IgA2 
production between systemic and local compart-
ments. In conclusion, IgA1 and IgA2 production is 
differentially regulated in different tissues and dif-
ferent antigen-repertoires exist between different 
tissues, which could have functional implications 
for protection against infections as well as allergies.
mucosa systemic 
IgA 
IgE 
IgG(4) 
Legend A B 
Figure 2 Isotypes causing or inhibiting allergy. A IgE causes allergy, IgG4 is able to block IgE-allergen interac-
tions, and IgA is proposed in this thesis to be able to protect against allergy. B Presence of immunoglobulin 
isotypes varies in different parts of the body. In the external mucosal milieu, IgA is the dominantly present 
isotype, while IgE and IgG4 levels are low. Systemically, IgE and IgG4 levels are higher. Also potential interac-
tions with the allergen tropomyosin are shown, indicating that different isotypes could bind to different epitopes 
simultaneously, which affect to possibility for IgE crosslinking. Note that picture is not drawn at scale; tropo-
myosin is 27 kDa and antibodies are ~150 kDA.
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Diagnostic in vitro assays and immunoglobulin 
isotypes 
In vitro diagnostics ultimately aim at 1) discrimi-
nating allergic patients from healthy individuals, 
2) predicting the severity of clinical symptoms and 
3) identifying to what allergens a person is allergic 
to. As discussed in Chapter 1, current diagnostic 
procedures allow discrimination between sensi-
tized and non-sensitized individuals, but poorly 
correlate with clinical status [25]. Allergen-specific 
IgE levels seem to have more predictive value for 
clinical status for inhalant allergens, compared to 
food-allergens. 
To discriminate between the primary sensitizer 
and potential cross-reactive allergen inhibition as-
says are used. Serum is incubated with an allergen 
and subsequently the effect of pre-incubation is 
determined by measuring the reduction of binding 
to another allergen. The allergen resulting in most 
reduction in binding to another allergen is likely 
the allergen of primary sensitization.
Inhibition methods also can be applied to study if 
non-IgE immunoglobulin isotypes could reduce 
binding of IgE to allergens [26]. Specific IgE loaded 
on cells expressing the IgE receptor will bind to the 
epitopes of allergens. In case other immunoglobu-
lin isotypes in solution recognize the same epitope, 
IgE-allergen binding could be inhibited. Inhibition 
also could occur when other isotypes recognize 
other parts of the protein, but by steric hindrance 
reduce the binding of IgE to the allergen [27].
The ImmunoCAP is widely used to determine al-
lergen-specific IgE levels. The ImmunoCAP is also 
able to determine levels of allergen-specific IgG4 
and IgA, but this is not often applied routinely. The 
CAPS containing the allergens was used to pre-in-
cubate serum, followed by detection of remaining 
allergen-specific IgE using the default ImmnoCAP 
procedure (Chapter 3). This method is currently 
not available at ImmunoCAP, but may be suited to 
be performed automated after validation.
The basophil activation test (BAT) is increasingly 
used in experimental settings. The advantage of us-
ing basophils over the serological assays is the re-
quirement of FcεR cross-linking to activate the ba-
sophils [28]. The test is relatively easy to perform. 
However, the test should be done relatively shortly 
after collection of the blood sample (eg preferably 
the same day) and the sample cannot be frozen for 
later analysis. IgE immobilized on the membrane 
of the cell is used, whereas IgE in solution is re-
moved by washing. Like serological tests, the BAT 
is performed on a systemic sample, thereby omit-
ting the influence of the site where the allergen is 
encountered.
As different isotypes and isotype subclasses have 
different effector functions, allergen-specific anti-
bodies other than IgE are relevant in vivo. Allergen 
specific IgG4 levels are often used as readout in 
immunotherapy studies [29-31]. Allergen-specific 
IgG4 is able to prevent cross-linking of IgE immo-
bilized on mast cells and basophils, and the low 
affinity IgE receptor (CD23) on B cells [15]. Even 
though allergen-specific IgA is increased locally 
after specific immunotherapy, there is no evidence 
that serum-IgA can block IgE-allergen cross-link-
ing. Allergen specific IgA is found in several body 
fluids, including serum and saliva, but IgA-allergen 
epitope studies are rather limited. In a study where 
IgE, IgG4 and IgA epitopes to cow’s milk allergy 
were determined, IgA bound allergens at different 
regions compared to IgE and IgG4 [32]. It needs 
to be established whether these results would have 
been different when mucosal IgA was used instead 
of serum IgA. 
Regardless of the precise Ig epitopes, immuno-
globulin isotype (and/or subclass) ratio may en-
hance the predictive value compared to evaluat-
ing allergen specific IgE levels alone. Preliminary 
data showed that salivary specific IgA2 in relation 
to serum specific IgE correlated with severity of 
symptoms upon challenge with intra-nasal house 
dust mite in HDM allergic patients (Chapter 4). 
In literature several studies describe that IgG4 can 
block interaction between allergen and IgE. In im-
munotherapy, the ratio IgG4 / IgE correlates with 
effective immunotherapy [33]. No differences in 
affinity of allergen specific IgE and IgG4 were ob-
served between patients that did receive or did not 
receive birch pollen immunotherapy [34].
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Results from diagnostic assays correlate better 
with clinical status of patients when the presence 
of blocking antibodies are taken into account (re-
sulting in enhanced specificity) compared to assays 
that detect the concentration of allergen-specific 
IgE present in serum (high sensitivity but less spe-
cific). The facilitated antigen presentation (FAP)-
assay, detecting binding of allergen-IgE to CD23 
on B cells is sensitive for blocking antibodies that 
interfere with formation of IgE-allergen complex-
es. FAP by B cells to Th2 cells allows efficient Th2 
responses with low doses of allergen, whereas after 
immunotherapy presence of allergen-specific IgG 
resulted in inhibition of FAP [15, 35]. In conclu-
sion, several diagnostic assays that correlate better 
with clinical status of patients are available, but 
generally are more complicated compared to ana-
lyzing allergen-specific IgE levels only.
II MODULATION OF THE IMMUNE SYSTEM
Early life
The immune system of neonates is not fully mature 
at birth. This delayed immune maturation is influ-
enced by breast feeding. IgG-allergen complexes 
as well as TGF-ß present in breast milk have been 
identified as crucial for inducing tolerance to aller-
gy development in neonates [36, 37]. Modulation 
of the neonatal immune system may have conse-
quences later in life.
After birth or hatch (in avians), IgA-producing B 
cells are lacking in the intestines. Upon coloniza-
tion with bacteria, IgA production is initiated in 
mice [38]. Similar patterns were observed in chick-
ens after hatch. After birth or hatch the availabil-
ity of maternally derived immunoglobulins disap-
pears; whereas the neonatal immune system isn’t 
mature yet (Chapter 7). In this period we observed 
a transitionally changed composition of microbi-
ota, which was related to transitionally increased 
cytokine production, and to the level of IgA. Dur-
ing this period, cytokine production and IgG pro-
duction was increased. This period could be a time 
window crucial for maturation of the neonatal im-
mune system with life long lasting consequences.
In humans, the ratio between the IgA subclasses 
was reported to change with age [39]. Numbers 
of IgA1 producing B cells remained similar in je-
junum, whereas with age, numbers of IgA2 pro-
ducing B cells increased. As we hypothesize that 
IgA2 may be mainly induced by innate factors, 
this increase in IgA2 could either reflect exposure 
to bacterial antigens in the mucosa, or be derived 
from initially IgA1 B cells that switch sequentially 
to IgA2. It remains to be established whether those 
IgA1 and IgA2 B cells vary in antigen specificity 
and whether class switch recombination to either 
subclass are equally likely. The association ob-
served between both the presence of specific bacte-
rial strains in the intestine of infants and increased 
concentrations of endotoxin in the environment of 
children, and increased protection against allergic 
symptoms like eczema, could be partly mediated 
by the intestinal IgA response [40, 41].
Potential routes for immunomodulation
Modulation of the immune system by dietary 
components can in theory result in increased or 
decreased activation of the immune system. The 
vast majority of antigenic properties of food are 
eliminated by digestive enzymes that reduce most 
of the proteins into peptides too small for MHC 
II presentation. Still, intact or partly intact (thus 
still functional) ingredients may come into con-
tact with the immune system and modulate its’ 
response, especially in young infants. 
Dietary ingredients can have a direct effect on 
proliferation or induction of apoptosis of immune 
cells. Another possibility by which dietary ingre-
dients can modulate the innate immune system is 
by activation of intracellular signaling pathways 
resulting in for instance up-regulation or down-
regulation of T cell co-stimulatory membrane pro-
teins and induction or inhibition of production of 
T cell activating cytokines. 
Food components (e.g. pre-biotics) can affect com-
position of the intestinal microbiota and therefore 
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indirectly affect the host’s immune system [42]. 
Next to proteins, oligosaccharides may contrib-
ute to induction of allergen specific T regulatory 
cells that are able to prevent allergic symptoms in 
whey sensitized mice [43]. ß-glucans from varying 
sources (oat, barley, mushrooms) have been shown 
to be bound by dectin-recepors and can induce 
pro-inflammatory cytokine production by mac-
rophages or macrophage-like cells [44, 45]. An-
other, indirect effect of food components could be 
by affecting other physiological conditions like the 
epithelial barrier. Vitamins D and A for instance, 
have significant impact on the host immune sys-
tem as those factors are involved in regulatory im-
mune responses (Chapter 5) [46-49].
The majority of food proteins is (partly) digested 
by enzymes in the gastro-intestinal tract and there-
fore presented as peptides to the innate immune 
system. Short peptides (eg hexa-peptides) are too 
small to be processed and presented on MHC, 
but still could exert bioactivity on the human im-
mune system. For instance various short peptide 
sequences from casein have been shown to have 
various immunomodulatory effects on the human 
immune system [50].
Immunomodulation by dietary ingredients
Many pattern recognition receptors involved in 
recognition of pathogens have been identified 
[51]. Also some food proteins can be bound by 
those innate immune receptors, but data available 
is limited. Glycosylated proteins can be taken up 
by dendritic cells via the mannose receptor [52]. 
Involvement of receptors that recognize structures 
from microbes or food result in efficient phagocy-
tosis. Immunoglobulin (IgG) can serve as soluble 
receptor that forms immune-complexes which 
are efficiently phagocytosed via IgG receptors on 
APC. However, many other interactions with yet 
unidentified extracellular and intracellular recep-
tors may be involved as well. Also a-specific non-
receptor mediated uptake (pinocytosis) could ac-
count for the uptake of food-derived fragments by 
APC [53]. Upon intracellular processing by profes-
sional APCs, peptides are presented on the MHC 
II class and co-stimulatory molecules can be up 
regulated next to cytokine secretion. These factors 
together determine if and how the Th cell becomes 
activated. Th cell activation requires matching 
specificity of the antigen peptide-MHC complex 
and the TCR. 
Dairy is an interesting part of our diet as it is both 
widely consumed, can modulate the human im-
mune system, and allergies against proteins pre-
sent in cow’s milk can occur. Recently, promising 
studies have become available showing that con-
sumption of untreated cows (farm) milk is asso-
ciated with protection against allergy later in life 
[54]. This effect could be abrogated when heat pro-
cessed milk was consumed [55].
Several mechanisms could be involved in the 
protective effect of farm milk consumption. Im-
munomodulation may occur via major fraction 
present in cow’s milk; like lactose, phospholipids 
or major proteins like caseins, α-lactalbumin, ß-
lactoglobulin or lactoferrin. Diet directly or indi-
rectly affects the immune system via the microbi-
ota. Dairy products contain a number of immune 
proteins and molecules like vitamins that can exert 
bioactivity on the human immune system, which 
recently has been reviewed by Van Neerven et. al. 
[56]. 
Otherwise, bovine milk contains high levels of im-
munoglobulins that might be involved in inducing 
tolerance after consumption. In an elegant mouse 
study, IgG-allergen complexes were involved in in-
ducing tolerance in the offspring [36]. Next to this, 
cow’s milk contains cross-reactive proteins like IL-
10 and TGF-ß (Chapter 8) [57]. Bovine IL-10 binds 
to the human receptor [57], and bovine TGF-ß (1 
and 2) in its bio-active form is identical to human 
TGF-ß [56]. Especially TGF-ß is present in suffi-
cient amounts (several ng/ml) and could pass the 
acidic conditions in the stomach, especially in in-
fants. Therefore, dietary immunomodulation that 
depends on bio-active immune proteins may pro-
vide opportunities especially in infants.
Bovine IgG does bind to FcγRI and II on human 
monocytes and dendritic cells (Chapter 9). This 
is an interesting observation as IgG allergen com-
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III TOLERANCE
Both central and peripheral tolerance is crucial to 
prevent auto-immune disease, allergy and massive 
inflammation of the gastro-intestinal tract. Toler-
ance in this paragraph refers to peripheral toler-
ance, not induced in the thymus but mainly by the 
mucosal tissues. Induction of tolerance prevents 
inflammation upon encounter of dietary antigens 
or intestinal bacteria and is a key feature of mu-
cosal tissue. Tolerance induction can occur by ad-
ministration of low or high doses of antigen. High 
doses of antigen result in unresponsiveness, anergy 
or clonal deletion [60], whereas low doses of anti-
gen cause induction of active regulation by T regs 
[61]. Interestingly, tolerance to food that is induced 
in the ileum results in systemic tolerance, whereas 
tolerance to bacteria induced in the colon does not 
result in systemic tolerance [62]. The term oral 
tolerance therefore refers to tolerance to soluble 
dietary proteins rather than tolerance to the intes-
tinal microbiota. Oral tolerance is induced in the 
intestinal mucosal tissue. Below the mechanism of 
induction of this peripheral tolerance is discussed. 
Supernatants of epithelial cells are able to induce 
tolerogenic DC’s in vitro. One of the phenotypic 
differences of tolerogenic DC’s is expression of 
the integrin αIEL (CD103) and the absence of 
CX3CR1. CD103+CX3CR1- and CD103-Cx3CR1+ 
DCs seem to originate from a separate lineage [63, 
64]. Amongst the feature of this subset are, expres-
sion of TLR2 but lack of TLR4 expression, active 
pinocytosis of dextran-FITC while they did not 
express the mannose receptor and production of 
IL-12 [65]. CD103+ DCs like other DC subsets are 
relatively unresponsive to LPS (Chapter 5) [66]. 
Those tolerogenic DCs occur in both the intestinal 
as the respiratory mucosa [63, 65, 67, 68].
Compared to CX3CR1+ DCs, mouse bone mar-
row-derived resting CD103+ DCs have higher ba-
sal expression levels of costimulatory molecules 
CD80, CD86 and CD83, but similar levels were ob-
served when CX3CR1 DCs were stimulation with 
LPS [69]. Compared to CD103 DCs, CX3CR1 DCs 
were more active in phagocytosis and expression 
of scavenger receptors. Also expression of almost 
all TLRs and production of IL-6 and TNF-α, but 
not IL-10 and IL-12 was elevated in CD103- DC 
upon stimulation.
A crucial feature of tolerogenic DCs is the ability 
to induce Tregs. Mucosal induction of Tregs is es-
sential for induction of tolerance to food and other 
harmless antigens. CD103+ DCs and epithelial cells 
have the capability to convert retinal to retinoic 
acid (RA) by the NALDH enzyme. This induction 
of Tregs by CD103+ DCs depend on RA and TGF-
ß production by mucosal tolerogenic DCs [18]. 
Several Treg subsets have been described: Th3, Tr1 
and CD4+CD25+. Tregs can be naturally occur-
ring and induced in response to specific antigens 
(CD4+CD25+). Tolerogenic DCs have the ability to 
induce antigen-specific FoxP3 expressing regula-
tory T cells against non-self-antigens. 
Allergen specific Tregs are induced upon suc-
cessful allergen-specific immunotherapy [17, 29]. 
Those Tregs can produce IL-10 that inhibits IgE 
production and enhances IgG4 production. IgG4 
is able to compete with IgE for allergen binding 
places, thereby preventing crosslinking of IgE im-
mobilized on mast cells and basophils. Those Tregs 
also inhibit DC-mediated Th(2) cell activation.
Next to T regulatory cell mediated tolerance, IgA 
production is involved in maintaining homeostasis 
by preventing translocation of microbiota over the 
gut epithelium [70, 71]. Likewise, allergen-specific 
IgA may prevent allergens to bind to IgE [72, 73]. 
Recently several regulatory B cell subset (Breg) 
has been identified, differentiated by expression of 
combination of markers like CD1d, CD24, CD38 
and CD27 [74]. Different subsets of Bregs have the 
plexes have been shown to be involved in neonatal 
tolerance induction in a mouse model [36]. Patho-
gen- and allergen-specific IgG has been identified 
in bovine milk, and has immunomodulatory ca-
pacity (Chapter 9) [58, 59].
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ability to suppress T cells and APCs and seem to 
contribute to protection against different immune-
mediated diseases like allergy, multiple sclerosis 
and Systemic lupus erythematosus [75]. It needs to 
be established if Bregs can produce antibodies, and 
whether Bregs are a stable subset or derived from a 
particular differentiation stage of B cells.
Can tolerogenic DCs protect against allergy?
Tolerogenic DCs-mediated tolerance may occur 
via the induction of Tregs, via non-inflammatory 
cytokine production or unresponsiveness to anti-
gens. Those DCs may also induce protective IgA 
production. 
TSLP produced by epithelial cells is bound by DCs 
that in turn enhance Th2 responses. This Th2 im-
munity can both support tolerogenic Th2 immune 
responses, and Th2 mediated allergy [76, 77]. 
TSLP also was found to enhance CSR by increas-
ing BAFF production by DCs [78]. 
Goblet cells transfer antigen from the lumen to 
CD11c+ DC’s, which are often CD103+ as well [79]. 
CD103+ DCs have been identified as potent anti-
gen presenters and inducers of Tregs by producing 
TGF-ß and RA [18, 67]. Under non-inflammatory 
conditions, the antigens transferred by goblet cells 
to CD103+ DCs may induce specific regulatory T 
cells [79]. This mechanism may potently induce 
Treg mediated tolerance to proteins from food and 
thereby also prevent allergy. This is consistent with 
the expression of the high affinity IgG receptor 
(CD64) that binds to IgG bound to soluble anti-
gen (Chapter 5). CCR7+ CD103+ DCs have been 
identified in the colon-associated MLN [68]. Those 
DCs are believed to originate from the intestinal 
mucosa where those cells could have bound an-
tigens followed by migration to draining lymph 
nodes. The recent finding that goblet cells transfer 
antigen to CD103 DCs, combined with the finding 
that CD103 DCs efficiently induce Tregs could be 
a key mechanism in mucosal immune regulation.
DCs have been shown to induce mucosal IgA pro-
duction [80-82]. However the precise subset ac-
countable for DC induced IgA production needs to 
be identified. Tolergenic CD103+ DCs are a likely 
candidate, for their ability to produce TGF-ß, RA 
and IL-10. Also Tregs induced by CD103 DCs may 
be involved in IgA induction (discussed below). 
In vitro we established a monocyte-derived CD103 
expressing DC culture. Those DCs were co-cul-
tured with B cells to study the effect of those DCs on 
IgA production. The plasma cell marker CD38 was 
highly expressed in the presence of RA-induced 
CD103 DCs (Chapter 6). In addition, CD103+ DCs 
seem to enhance IgA2 production, probably due to 
production of TGF-ß and RA (Chapter 6).
IV MUCOSAL IGA IN RELATION TO ALLERGY
The mucosal immune system harbours a number 
of unique features to both tolerate harmless anti-
gens and protect against infections. Typically, high 
levels of IgA are being produced, many tolerogenic 
APCs are present and Tregs are being induced mu-
cosally. IgA(1) may also leak to systemic fluids, but 
also can be produced systemic, employing differ-
ent mechanism compared to mucosally induced 
IgA in both human and mice (Chapter 6) [80]. In 
this paragraph the potential role of the mucosal 
immune system is discussed in relation to IgA-
mediated protection against allergy.
Structure and distribution of IgA1 and IgA2 
Structurally IgA1 and IgA2 mainly differ in the 
hinge region connecting the Fab and Fc fragments 
[83]. Both subclasses bind to the FcαR (CD89) 
with similar affinity with a region conserved in 
both IgA1 and IgA2, and IgA bound by FcαR on 
interstitial DC induces production of the non-
inflammatory cytokine IL-10 [84, 85]. The hinge 
region of IgA2 is shorter compared IgA1, which 
protects against proteolysis by bacterial enzymes.
IgA2-B cells are particularly abundant in the colon 
and rectum, which has the highest bacterial load 
of the gastro-intestinal tract. In serum and ileum, 
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IgA1 levels are higher than IgA2 levels, whereas 
levels in jejunum are relatively similar [24]. In the 
respiratory tract (tonsil and lungs) IgA1 B cells 
are more abundant than IgA2 B cells [86]. Also 
exposure to allergens is different along the gastro-
intestinal tract as well as other mucosal surfaces. 
The combination of differential distribution of 
IgA subclasses and different exposure to allergens 
on different mucosal regions may have important 
consequences in relation to a possible role of IgA 
in protection against allergy.
Differential regulation of IgA1 and IgA2 pro-
duction
The observation that IgA1 and IgA2 may play dif-
ferent roles in protection against allergy (Chapter 
4 and 6) [73] raised the question whether IgA sub-
classes are induced under the influence of different 
stimuli. Literature reporting factors that induce 
IgA CSR is abundant [80, 87-89], whereas litera-
ture discriminating IgA1 and IgA2 is limited to a 
few reports only [19, 90]. 
CSR occurs both in systemic immune organs and 
in the mucosa, and in the presence or absence of 
Th cells (Figure 3). IgA CSR and production can 
be induced by both T cell dependent and T cell in-
dependent stimuli. Activation of CD40 on B cells 
through ligation with CD40 ligand on T cells leads 
to TGF-ß1 production which in turn is involved in 
IgA class switch recombination (CSR) [91]. When 
B cells were stimulated with irradiated CD40L+ 
cells only, IgA1 germline and productive IgA1 ex-
pression was higher compared to IgA2 [91]. This 
difference was not visible when exogenous TGF-ß1 
was added. Addition of IL-10 enhanced IgA pro-
duction, but was not crucial under those CD40 de-
pendent conditions. Addition of anti TGF-ß1 an-
tibodies completely inhibited IgA (IgA1 and IgA2 
not specified) production and CSR [91].
The role of IL-10 in inducing IgA production and 
CSR also has been studied under T-cell independ-
ent conditions. When instead of CD40L, the cy-
tokines APRIL and IL-10 were added to IgD+ B 
cells, IgA2 expression on the membrane and secre-
tion of IgA2 was higher compared to IgA1 [19]. 
IgA2 secretion and CSR was further enhanced 
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Figure 3. Ig isotype switching can occur via different routes, both systemically and mucosal and result in different isotypes
and degrees of somatic hypermutation (SHM). The most widely studied route is depicted at the left. In the mucosa DCs can 
induce production of mainly IgA. The role of Tregs in isotype switching is incompletely understood. Tregs may preferentially 
induce IgA and be is potent as Th cells in inducing SHM.
Figure 3. Ig isotype switching can occur via different routes, both systemically and mucosal and result 
in different isotypes nd degre s of somat c hypermutation (SHM). The mo t widely studied route 
is depicted at the left. In the mucosa DCs can induce production of mainly IgA. The role of Tregs in 
isotype switching is incompletely understood. Tregs may preferentially induce IgA and be is potent as 
Th cells in inducing SHM.
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when flagellin was added. Consistent with our 
findings (Chapter 6) APRIL and IL-10 resulted in 
more IgA2 production compared to BAFF and IL-
10.
IgA1 production is more easily induced under the 
influence of CD40 activation compared to IgA2 
[19]. IgA2 production and CSR however, seems to 
be more readily induced under the influence of the 
T cell independent cytokine APRIL, but not BAFF. 
BAFF might be more important in regulating plas-
ma cell survival compared to APRIL [92].
Work in mouse models has revealed that both the 
T cell-dependent and T cell-independent route 
are involved in IgA induction [93]. The T cell in-
dependent route might be especially relevant for 
inducing natural antibodies (limited SHM, figure 
3) that bind to intestinal bacteria, either commen-
sals or pathogens. In our work in chickens, we 
observed limited changes occurring in the CDR3 
region of IgA, together with 70% coated intestinal 
bacteria (Chapter 7).
Mucosal network favouring IgA induction
The precise location and local environment crucial 
for induction of IgA production are currently be-
ing identified. IgA production depends on a num-
ber of factors that are typically present abundantly 
in the mucosa. Those factors include different cell 
types and accompanying cytokines and other mol-
ecules (summarized in Figure 4).
The list of factors produced by intestinal epithelial 
cells is growing, of which several can bind to re-
ceptors on B cells, like RA, APRIL and BAFF, in 
addition to cytokines TGF-ß and IL-10. These fac-
tors promote IgA1 and IgA2 production either di-
rectly or via DCs. IEC produce APRIL, which has 
been identified as IgA2 switch factor, in combina-
tion with IL-10 and TLR5 ligation (e.g. by flagel-
lin) [19]. Also the plasma cell inducing factor RA 
(Chapter 6) is being synthesized by IEC and DC, 
which also promotes accessibility of the IgA region 
on the genome, potentially enhancing IgA CSR 
[94]. RA also affects homing to the intestine of dif-
ferent cells, including B cells by inducing α4ß7 and 
CCR9 [95, 96]. Production of BAFF by IEC could 
promote plasma cell survival that may lead to pro-
longed production of IgA. IgA CSR is potently in-
duced by the presence of TGF-ß [97, 98] and en-
hanced by IL-10 (Chapter 6). Both cytokines are 
produced by IECs [99]. Those factors produced 
by IEC are also being produced by mucosal DCs 
but could also be diet-derived (e.g. breast milk or 
cow’s milk) [18]. However, it has not been identi-
fied if those factors are differentially produced by 
DC subsets.
Currently, it is debated in the literature to what 
extent organized lymphoid structures are required 
for intestinal T cell-independent IgA CSR [93]. 
Probably, this debate is partly caused by differences 
between human and mice. In general, B cells dif-
fer between human and mice, especially with re-
gard to immunoglobulin subclasses. Mice produce 
a single IgA subclass, whereas humans produced 
IgA1 and IgA2. We have evidence (Chapter 6) that 
those IgA subclasses are differentially regulated in 
humans (discussed above). Consequently, the con-
clusion that T cell-independent IgA2 CSR occurs 
in the lamina propria may be possible in humans 
because it occurs independently of T cell help [19]. 
This is in line with mouse studies showing a cru-
cial role for CD28 in systemic IgA responses, but 
not in mucosal IgA responses [100]. In mice, IgA 
production is largely maintained in the absence of 
germinal centres, but in mice lacking any organ-
ized lymphoid structures IgA production was ab-
rogated [93, 101].
Recently, neutrophils have been related to induc-
tion of IgA production in the marginal zone of 
spleen [102]. Marginal zone neutrophils were ac-
tivated (non-inflammatory) upon intestinal colo-
nization. In vitro co-culturing of marginal zone 
neutrophils and B cells resulted in production of 
BAFF, APRIL and IL-21 by neutrophils, which was 
involved in IgA production. In needs to be estab-
lished to what extent this mechanism contributes 
to IgA-production in vivo [103]. 
Mucosal factors associated with eczema
A number of factors produced in the mucosa have 
been associated with presence or absence of aller-
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Figure 4. Local and systemic parts of mucosal B cell responses in allergy and tolerance to allergens. Different 
DC subsets induce different Th cell responses and downstream B cell Ig production. Activated cells do (solid 
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gic symptoms like eczema. Children having toxic 
Staphylococcus aureus in the intestine produce 
increased levels of APRIL and IgA and developed 
less often eczema later in life [104]. Also an as-
sociation was found between the composition of 
intestinal microbiota and IgA production during 
ontogeny (Chapter 7). In addition, levels of APRIL 
are reduced in skin biopsies of individuals with al-
lergic eczema, whereas levels of BAFF and TSLP 
are increased. Currently the exact mechanism be-
hind development of atopic eczema has not been 
elucidated, but the factors depicted in figure 5, pro-
vide a possible model that may explain the associa-
tion of eczema with decreased levels of APRIL and 
IgA and increased levels of TSLP. Reduced levels 
of APRIL and increased levels of TSLP and BAFF 
may be the result of aberrant immune responses 
in the tissue, or may be causative for the develop-
ment of eczema in allergic patients [104-106]. The 
notion that the presence of specific bacteria early 
in life (4 months of age) was associated with a re-
duced frequency of eczema later in life (18 months 
of age) suggests that those factors may be causally 
related to eczema development. In our adult house 
dust mite allergic patients, presence of eczema 
was associated with reduced levels of allergen spe-
cific IgA2 (Chapter 4). This association was even 
stronger for patients suffering from both eczema 
and asthma, though this needs to be confirmed in 
a larger study. IgA2 production is induced by fac-
tors like APRIL and inhibited by TSLP (Chapter 
6). The reduced levels of serum IgA2 in patients 
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with eczema might be caused by the reduced levels 
of APRIL and increased levels of TSLP (Figure 5). 
Alternatively, allergic patients have reduced levels 
of mucosal (salivary) IgA. Reduced IgA-mediated 
mucosal protection upon allergen encounter may 
enhance Th2 mediated eosinophilia and IgE class 
switching [107] and thereby contribute to develop-
ment of eczema.
The role of Tregs in IgA induction
Tregs are essential to control inflammatory re-
sponses, including production of cytophilic im-
munoglobulins. Interestingly, regulatory cytokines 
IL-10 and TGF-ß do not inhibit but rather enhance 
IgA production. IgA is a non-inflammatory isotype 
as it does not activate complement and binding of 
IgA to myeloid cells induces IL-10 production. As 
Tregs are imported sources of those regulatory cy-
tokines [17], IgA production might be enhanced 
by Tregs. In addition to producing cytokines, Tregs 
express co-stimulatory molecules as found on Th 
cells [108, 109]. Taken together, Tregs are likely 
potent inducers of IgA production. Surprisingly 
little reports are available studying the role of Tregs 
in IgA induction [26, 110]. In vitro culturing of B 
cells and Tregs showed that Treg blocked IgE pro-
duction, enhanced IgG4 production, but no evi-
dence was found for changes in IgA production in 
the presence of Tregs (identified as CD4+CD25+, 
while FoxP3 expression was not determined) [26]. 
However, a profound role for Tregs was found in 
a mouse study, where IgA production was limited 
when mice were treated with an anti CD25 anti-
body [110]. IgA production was restored upon 
adoptive transfer of Tregs.
Mechanism of IgA2 mediated protection against 
allergy: a hypothesis
In a mouse model T cells were able to induce sig-
nificantly more mutations in the complementarity 
determining region (CDR) of IgA, which deter-
mines antigen specificity, compared to T cell-inde-
pendent induced B cells [93]. It also was observed 
that T cell-independent signals mainly induce 
IgA2 CSR. As a result, IgA2 could be of lower af-
finity when its induction would solely depend on 
TI activation. However, sequential switching from 
IgG1 and IgA1 to IgA2 has been reported [19]. 
IgA1 and IgG1 B cells are most likely to switch to 
those respective isotypes under the influence of T 
cells. B cells sequentially switching from affinity 
matured IgG1 and IgA1 to IgA2 under the influ-
ence of APRIL could therefore still contain high 
numbers of substitutions in the CDR [19]. There 
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Figure 6. Hypothetical model linking IgA levels with allergic eczema and its associated decreased levels of APRIL and increased levels of TSLP. Bacterial exposure in early life may prevent allergic sensitization and 
development of eczema and/or asthma later in life. Immunotherapy increases production of IgA, and inhibits development of allergic symptoms. Those interactions may me mediated by the factors APRIL and TSLP.
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Figure 5. Hypothetical model linking IgA levels with allergic eczema and its associated decreased levels of 
APRIL and increased levels of TSLP. Bacterial exposure in early life may prevent allergic sensitization and 
development of eczema and/or asthma later in life. Immunotherapy increases production of IgA, and inhibits 
development of allergic symptoms. Those interactions may me mediated by the factors APRIL and TSLP.
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is no evidence that IgE B cells could undergo CSR 
to IgA2, and this would be hard to prove in vivo 
due to the very low frequency of IgE-producing B 
cells. However, the observation that IgG1 B cells 
T cell-independently switch to IgA2 and that IgA2 
correlated with protection in our house dust mite 
patient data suggests that allergen-specific IgE-
producing B cells that reside locally in the mucosa 
may switch further to IgA2 under T cell-independ-
ent conditions. The potential protective role of mu-
cosal IgA has been suggested in the seventies of the 
20th century, and was found to be associated with 
eczema in infants [111, 112]. However, the protec-
tive role of IgA against the development of allergy 
and clinical symptoms upon allergen exposure has 
been controversial. This might be largely due to the 
fact that IgA has often been determined in serum, 
and that IgA combined levels were determined 
rather than IgA1 and IgA2 allergen-specific lev-
els. Indeed, increased numbers of allergen-specific 
IgA2, but not IgA1, B cells were present in the nasal 
mucosa after birch pollen immunotherapy [72]. In 
addition, there is evidence that pointing to CSR lo-
cally in the nasal mucosa and bronchia [113-115].
It needs to be noted that the T cell-independent IgE 
CSR cytokine APRIL inhibits Th2 responses and 
production of Th2-dependent immunoglobulins 
[116]. Therefore increased levels of IgA2 induced 
by APRIL and IL-10 may correlate with protec-
tion against allergy because it is confounded by a 
simultaneous inhibition of the Th2 compartment. 
The finding that allergen-specific IgA2-producing 
B cells have been identified after immunotherapy 
indicates that IgA2 may indeed exert a functional 
role in the mucosa by protecting against allergy. In 
addition, IgA2 levels that seem to be involved in 
protection against allergy also were associated with 
progression of allergic disease in HDM-allergic pa-
tients (Chapter 4). 
IV CONCLUSIONS AND FUTURE DIRECTIONS: MUCOSAL IGA IN RELATION 
  TO ALLERGY 
The mucosa harbours a complex immune system 
that is able to both induce tolerance to dietary in-
gredients and commensal bacteria, and to mount 
protective immune responses to pathogens. Di-
etary ingredients are not only tolerated by the im-
mune system, but also may modulate the immune 
system. In case of lack of tolerance, diseases like al-
lergy could develop. Mechanisms of immunomod-
ulation by dietary ingredients are only started to 
be understood. Further understanding of the re-
lation between dietary ingredients and mucosal 
immune responses may provide opportunities to 
prevent development of allergy and help maintain-
ing intestinal homeostasis. Intestinal homeostasis 
requires both tolerance and the ability to recognise 
potential harmful bacteria, viruses and parasites. 
Our current understanding of homing of lympho-
cytes through the body, indicate possibilities to 
also modulate the respiratory immune system via 
the intestinal mucosa. This is facilitated by induc-
tion of homing receptors on B cells and T cells. 
Likely, dietary immunomodulation largely de-
pends on DC responses. DCs determine the fate of 
Th cells by modulation of expression of cell surface 
molecules and secretion of cytokines. How these 
cell surface molecules and cytokines are modu-
lated depends among others on the interacting DC 
subset. The development and responsiveness of 
DC subsets is in turn affected by the local environ-
ment. This local environment consists of several 
cell types, of which the importance of epithelial 
cells is increasingly recognised. In addition, the 
diet influences the local environment and might 
directly affect cell-responsiveness when dietary 
ingredients bind directly to receptors on the cell 
membrane. Dairy products are anticipated to be 
potent modulators of the human immune system 
as bovine milk contains cytokines and immuno-
globulins that can bind to the human receptors. In 
addition the vitamins A and D support induction 
of regulatory tolerance. Bioactivity of immune-
reactive ingredients from bovine milk, depend on 
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proper processing to prevent degradation result-
ing in loss of immune reactivity. This could also be 
the reason that consumption of raw but not heated 
farm milk early in life is associated with reduced 
allergic symptoms later in life.
Reviewing the literature about B cells and B cell 
responses in relation to allergy, a number of issues 
arise that need further research. The importance 
of the location of allergen encounter in relation to 
the locally present immunoglobulin isotypes and 
subclasses is still underestimated.  Serological lev-
els of allergen-specific IgA are most likely inaccu-
rate to estimate the protective role IgA could have 
against allergy. In addition, IgA subclass levels dif-
fer in relation to the clinical status of the patients. 
Therefore, allergen-specific detection of mucosally 
present IgA subclasses could provide opportunities 
for finding a better association between Ig levels 
and clinical status of patients. 
Mechanisms of T cell-independent induction of 
IgA are currently being identified [19, 80, 102]. 
These mechanisms seem to be relatively similar be-
tween intestinal and the nasal respiratory mucosa. 
In both cases, epithelial cells produced APRIL and/
or BAFF, and TGF-ß1 and RA, and have DCs in 
place producing cytokines favouring IgA induc-
tion. Also DC responses in relation to allergy are 
increasingly becoming elucidated [76, 117-119]. 
However, data linking DC-dependent induction 
of IgA in relation to allergy is lacking. Studying 
DC- dependent mucosal IgA induction in relation 
to allergy is important, as the specificity of B cells 
undergoing DC-mediated but Th cell independent 
IgA CSR might well be different compared to Th 
or Treg-dependent IgA CSR. The specificity of de 
novo induced IgA is relevant as mucosal protec-
tion against allergy is likely more effective when 
the IgA produced is allergen-specific. In addition, 
understanding of mucosal IgA CSR in relation to 
allergy is important to be able to more efficiently 
develop strategies that enhance induction of IgA 
protective against allergy. Until now it is not clear 
to what extent TI IgA-CSR contributes to mucosal 
IgA production in humans, but innate cells like ep-
Key messages
•	 Levels of mucosal IgA2, but not IgA1, may be a relevant parameter in the  
diagnosis of allergy.
•	 Specific serum-IgA2 levels, but not IgA1 levels, are decreased in patients 
with eczema, and IgA2 production is affected by the eczema-related fac-
tors APRIL and TSLP.
•	 Detailed IgE-epitope comparison explains limited sensitization of shellfish 
allergic patients to molluscan allergens.
•	 Dietary factors may influence mucosal IgA production.
Key questions
•	 Does allergen-specific mucosal IgA2 protect against sensitization to al-
lergens and is induction of allergen-specific IgA2 a useful target for immu-
notherapy?
•	 Does induction of protective IgA in allergy depend on T cells or not, and 
what is the role of intestinal microbiota on IgA specificity?
•	 Can IgE-producing allergen-specific B cells in the mucosa switch to IgA2 
and could this occur upon local encounter of allergens?
•	 Are reduced levels of APRIL and increased levels of TSLP causally related 
to the development of eczema and asthma?
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ithelial cells and DCs are likely major contributors 
to in vivo IgA production in both the intestinal and 
respiratory mucosa [120]. An interesting question 
is to what extent T cell-independent IgA produc-
tion is able to prevent development of allergy and 
clinical symptoms upon allergen exposure, and to 
what extent allergen-specific T cell help is required.
The relation between allergen-specific IgA and the 
clinical status of allergic patients may well be dif-
ferent between the different allergies (e.g. food and 
inhalation). Though the immune system and the 
luminal content greatly vary between the respira-
tory and intestinal tract, the general principle of 
protective recognition of IgA by allergens may be 
consistent.
Mechanistic parameters to assess the success of 
immunotherapy include IgE and IgG4 formation, 
and the presence of allergen specific Tregs. Pe-
ripheral induction of Tregs upon mucosal immu-
notherapy depends on DC responses. Those DCs 
also affect Th cell reactivity and DCs can induce 
IgA production. Also Tregs likely enhance produc-
tion of IgA. In addition Tregs might be able to also 
induce somatic hypermutation (in contrast to DC-
mediated IgA induction) and thereby allow induc-
tion of high affinity allergen specific IgA in the 
mucosa. Until now, these mechanisms are rarely 
considered as part of the success of immunothera-
py. Clinical improvement as the result of immuno-
therapy is associated with IgE-IgG4 ratios. In ad-
dition, induction of mucosal IgA production upon 
mucosal (e.g. sublingual immunotherapy) needs 
further investigation (Figure 5). Allergen-specific 
IgA at mucosal surfaces can bind the allergen and 
thereby prevent formation of IgE-allergen com-
plexes (Chapter 4, figure 5). Allergen-specific IgG4 
induced after immunotherapy can block forma-
tion of IgE-allergen complexes systemically. To our 
current understanding, mucosal protection against 
allergy depends on IgA2 rather than IgA1. In ad-
dition, allergen-specific mucosal IgA may prevent 
progression of allergic status into eczema and 
asthma. Though allergen-specific IgA2-producing 
B cells could be induced by immunotherapy, it is 
unclear from what type of B cells those cells origi-
nate and through what mechanism these IgA2 B 
cells are induced.
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Type I allergy is mediated by allergen-specific IgE 
antibodies that are produced by B cells upon stim-
ulation by T- helper type 2 cells. Immunoglobu-
lins have varying antigen- and allergen specificities 
(introduced in chapter 1). IgE needs to be specific 
for an allergen and bind simultaneously to distinct 
epitopes on the allergen to induce degranulation 
by cross-linking of IgE immobilized on high affin-
ity IgE receptors expressed on mast cells and ba-
sophils (Chapter 2). IgE molecules can be specific 
for a protein of a single species or bind to similar 
regions on allergens from different species, there-
by causing cross-reactivity. This is discussed for 
shrimp and mussel tropomyosin in chapter 2, and 
fig and ficus in chapter 3. In most cases of cross-
reactivity the primary sensitizing allergen can be 
identified by inhibition assays (Chapter 3).
The presence of allergen-specific IgE in serum 
of sensitized patients does not necessarily cause 
clinically relevant symptoms of allergy. For exam-
ple, when blocking immunoglobulins of non-IgE 
isotypes are present, like IgG4 which is induced 
by specific immunotherapy, IgE-mediated effec-
tor functions can be inhibited. Until now, serum- 
derived IgA has not been shown to be able to block 
IgE-allergen interactions, and a protective role of 
allergen-specific IgA is still debated. The aim of 
this thesis was to study how the mucosal immune 
system and especially the induction of allergen-
specific IgA could protect against allergy.
Compared to non-house dust mite allergic con-
trols, patients with house dust mite allergy had 
decreased levels of allergen-specific IgA2, but not 
IgA1 (Chapter 4). The mechanisms underlying the 
differential regulation of the two IgA subclasses 
IgA1 and IgA2 in humans are largely unknown. 
Factors in the local mucosal tissue are involved in 
differentiating between IgA1 and IgA2 production. 
Evidence for a role of dendritic cells (DC) in IgA 
production is increasing. We generated and char-
acterized two DC types not previously described 
in literature by using the mucosal factors retinoic 
acid (RA) and transforming growth factor (TGF)-
ß (Chapter 5). Those RA- and TGF-ß-derived 
dendritic cells have tolerogenic characteristics, as 
shown by reduced inflammatory cytokine produc-
tion (IL-12 and TNF-α), but non-significant re-
duction in IL-10 production, and reduced expres-
sion of activation- and maturation markers after 
stimulation with bacterial ligands.
To study the role of epithelial cell- and DC-derived 
molecules in the regulation of production of IgA 
by B cells and plasma cells, the mucosa-related cy-
tokines APRIL, BAFF, IL-10, TGF-ß, and vitamin 
A-derived RA were added to B cells. Addition of 
RA resulted in differentiation of B cells into plasma 
cells (CD38+) and enhanced secretion of IgA1, and 
enhanced secretion of IgA2 when also IL-10 and 
APRIL or BAFF was present (Chapter 6). Our data 
indicate that production of IgA1 is increased in 
the presence of BAFF (probably by plasma cells), 
whereas IgA2 production is increased in the pres-
ence of APRIL which is produced by either DCs 
or epithelial cells in vivo (probably by de-novo in-
duction). When RA and IL-10 were added, B cells 
upregulated homing integrin ß7 on the membrane, 
which is believed to preferably direct homing to 
the small intestine. In literature, increased levels of 
APRIL have been associated with decreased preva-
lence of eczema, whereas increased levels of TSLP 
have been associated with the presence of eczema. 
In chapter 6, it is shown that APRIL is involved 
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in induction of IgA2, and that TSLP potently in-
hibits IgA1, and to a lesser extent also IgA2 pro-
duction, which is consistent with reports showing 
that increased levels of IgA inversely correlate with 
eczema. In chapter 4, we described that indeed 
an association between reduced levels of allergen-
specific IgA2 in serum and presence of eczema and 
asthma can be demonstrated. Also the tissue (sys-
temic, e.g. serum versus mucosal, e.g. saliva) where 
IgA is measured is differentially linked to the clini-
cal status in house dust mite-allergic patients. In-
terestingly, whereas allergen-specific levels of IgA2 
appeared to be associated with absence of allergy, 
IgA1 levels were not. In house dust mite-allergic 
patients the ratio between serum-IgE and saliva-
IgA2 was associated with the severity of local re-
sponses to a nasal allergen challenge. 
IgA production is decreased in the absence of in-
testinal bacteria, and colonization of the gut induc-
es production of IgA. The ontogeny of the bacteria-
specific repertoire of intestinal IgA in relation to 
the composition of the intestinal microbiota has 
not been studied before. In chickens we analysed 
the CDR3-repertoire development in the first ten 
weeks post hatch. No association between bacte-
rial composition and IgA CDR3 repertoire was 
found, indicating that bacteria may induce IgA 
production but not cause extensive modification 
in the specificity of IgA (Chapter 7). Transitional 
changes in the composition of the microbiota were 
restored once IgA production was initiated, sug-
gesting that IgA is directly involved in regulation 
of the intestinal microbiota composition.
Diet-derived RA is a key regulator of tolerance and 
IgA production in the mucosa. In addition, dietary 
ingredients can directly interact with cells of the 
intestinal immune system. In chapter 8 we show 
that bovine IL-10 binds to the human IL-10 recep-
tor and thereby inhibits bacterial ligand-induced 
activation of monocytes and DCs. Bovine milk 
also contains immunoglobulins that are specific 
for bacterial ligands and inhalation allergens that 
are also encountered by the human mucosal im-
mune system. Bovine IgG efficiently binds to hu-
man IgG receptors, and can modulate myeloid cell 
activation by LPS (Chapter 9). Immunoglobulins 
from bovine milk may therefore provide potent 
opportunities to either induce tolerance or anti-
gen-specific immune responses in the intestinal 
mucosa resulting in the production of protective 
IgA, thereby contributing to protection against 
infections. This protection may be mediated by 
bovine IgG alone, or in cooperation with IL-10, 
TGF-ß and vitamin A-derived RA; factors that are 
involved in induction of IgA.
The findings from chapters 2-9 are discussed 
(Chapter 10)and applied to the field of allergy, 
both for the clinic and experimental research. The 
finding that human IgA1 and IgA2 are differen-
tially regulated by innate factors and differentially 
correlated with the presence or absence of allergy 
and with the severity of clinical symptoms is a 
promising finding. This finding may provide new 
opportunities for diagnosis of allergy as well as 
allergen-specific immunotherapy. Finally, the ef-
ficacy of mucosal vaccination strategies could be 
affected by the innate mucosal mechanisms of reg-
ulation of IgA production and the effects of dietary 
components as described in this thesis.
 162    Samenvatting
De meest bekende en meest voorkomende allergie is Type I allergie. Type I allergie 
wordt veroorzaakt door antistof type E (IgE). IgE wordt, net als andere antistoffen, 
geproduceerd door zogeheten B cellen, meestal na stimulatie  van T helper type 2 
(Th2)  cellen. Deze Th2 en B cellen reageren heel specifiek op een stukje (epitoop) van 
een bepaald eiwit (een eiwat dat allergie veroorzaakt wordt allergeen genoemd), wat 
verklaart waarom iemand voor een bepaald eiwit allergisch kan zijn, zonder last te 
hebben van andere eiwitten. Om allergie te veroorzaken, moet IgE niet alleen een al-
lergeen herkennen, maar het allergeen moet tegelijkertijd door meerdere IgE molecu-
len gebonden worden. Als een allergeen tegelijkertijd door meerdere IgE moleculen 
herkend wordt, kan het allergie veroorzaken (Hoofdstuk 2). Het allergeen tropomy-
osine (speelt een rol bij functionering van spieren) is een belangrijk allergeen voor 
schaal- en schelpdier allergie, dat grote gelijkenis vertoont tussen dieren. Daardoor 
kan een specifiek IgE molecuul zowel tropomyosin van bijvoorbeeld een garnaal als 
van een mossel herkennen. In de praktijk lijkt dat echter weinig voor te komen in 
Nederland, doordat de IgE-epitopen voldoende verschillend zijn (Hoofdstuk 2). Het 
principe van kruisreactiviteit komt voor tussen schaal- en schelpdieren maar ook tus-
sen vijg (vrucht) en ficus (plant). Kruisreactiviteit kan met specifieke inhibitie assays 
onderzocht worden (Hoofdstuk 3). De inhibitie assay beschreven voor twee patiënten 
in hoofdstuk 3, toont aan dat waarschijnlijk de ficus plant de primaire oorzaak is voor 
de allergie, waarna het IgE van de patiënt ook kruisreageert met vijg.
Voor de diagnose van allergie wordt vaak gekeken of een patiënt allergeen-specifiek 
IgE in het bloed heeft. De aanwezigheid van dit specifieke IgE wordt sensibilisering ge-
noemd, maar bewijst nog niet dat iemand daadwerkelijk allergisch is. Dit komt onder 
meer doordat er ook andere (met name IgG4 ), antistoffen aanwezig kunnen zijn die 
het allergeen binden, en voorkomen dat IgE eraan kan binden. Er is nog geen over-
tuigend bewijs dat IgA antistoffen in bloed ook allergie kan voorkomen bij gesensibi-
liseerde mensen. 
In dit proefschrift is onder andere gekeken of er een relatie is tussen de aanwezigheid 
van allergeen specifiek IgA en allergie voor huisstofmijt. Daarbij werd een verband 
gevonden tussen IgA in speeksel en bescherming tegen allergie, en dat allergische 
mensen die ook eczeem hebben, in hun bloed lagere levels hebben van allergeen speci-
fiek IgA (Hoofdstuk 4). Mensen maken twee soorten IgA: IgA1 en IgA2. De genoemde 
relaties tussen allergie en IgA, waren gevonden voor IgA2 en niet voor IgA1.
Een interessante vraag is dan, of er factoren zijn die specifiek de productie van IgA1 of 
IgA2 beïnvloeden. Het meeste IgA wordt geproduceerd in de zogenaamde mucosale 
weefsels van de longen en vooral de darmen. Productie van antistoffen wordt deels 
gestimuleerd door Th cellen, maar kan ook gestimuleerd worden door dendritische 
cellen (DC), vooral in de mucosa. In Hoofdstuk 5 laten we zien dat de mucosale fac-
toren TGF-ß1  en retinoic acid (RA), wat gevormd wordt uit vitamine A, beïnvloeden 
hoe een DC reageert op stimulatie met bacteriële producten. Als DCs gedifferentieerd 
worden in de aanwezigheid van TGF-ß1 en RA, produceren ze minder ontsteking 
stimulerende cytokinen. Ook de expressie van co-stimmulatoire moleculen op het 
membraan van de DCs was verminderd onder invloed van TGF-ß1 en RA.
IgE is een antistof van 
het type E, verder zijn 
er nog IgG, IgM, IgA 
en IgD.
Th2 zijn T helper cel-
len die specifiek zijn 
voor een stukje van 
een eiwit, in dit geval 
een eiwit wat allergie 
kan veroorzaken. De 
aanduiding 2 in Th2 
geeft aan wat voor 
soort afweerresponse 
de Th cel kan maken.
Een inhibitie assay 
test of hetzelfde IgE 
molecuul aan eiwitten 
van verschillende 
plant of diersoorten 
kan binden.
In tegenstelling tot IgE, 
kan IgG4 niet binden 
aan (IgE)receptoren 
op mestcellen.
TGF-ß1 is een eiwit 
dat een belangrijke rol 
speelt in het immuun 
systeem. TGF-ß1 valt 
onder de zogenaamde 
cytokinen, die regu-
leren of er onsteking 
(inflammatie) of juist 
tolerantie geinduceerd 
wordt door het im-
muun systeem.
Samenvatting (Dutch Summary)
In het immuunsysteem 
regaeren cellen op 
stimulatie. Stimulatie 
gebeurt door eiwitten 
op de celwand en door 
eiwitten (cytokinen) 
die uitgescheiden 
worden door de cel.
DCs zijn immuuncel-
len die belangrijk zijn 
aan het begin van 
de immuunresponse. 
DCs zijn niet specifiek 
(zoals Th en B cellen), 
maar wel essentieel 
om Th cellen te 
stimuleren, en blijken 
nu ook B cellen te 
kunnen stimuleren.
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Zoals beschreven is in hoofdstuk 6, spelen TGF-ß1 en RA ook een rol in de productie 
van IgA1 en IgA2. Ook andere mucosale cytokinen als APRIL, BAFF, TSLP en IL-10 
zijn in deze experimenten gebruikt. Deze mucosale factoren worden geproduceerd 
door epitheliale cellen, die het lichaam scheiden van de buitenomgeving, en DCs. De 
aanwezigheid van RA zorgde ervoor dat de B cellen verder differentieerden naar plas-
ma cel en daarmee samenhangend, meer IgA uitscheidden. De productie van IgA1 
was het hoogste in de aanwezigheid van BAFF, terwijl IgA2 levels het hoogst waren 
in de aanwezigheid van APRIL. Voor de maximale productie van IgA1 en IgA2 waren 
niet alleen BAFF of APRIL nodig, maar ook RA en IL-10. De combinatie van RA en 
IL-10 zorgde ook voor verhoogde expressie van integrine ß7, wat de B cellen helpt om 
naar de (dunne) darm te migreren. IgA producerende B cellen zijn van belang voor 
de bescherming van de grote oppervlakte van de darm tegen pathogenen, en naar we 
vermoeden ook allergenen.
TSLP remde de productie van IgA, wat een interessant bevinding is omdat TSLP vaak 
verhoogd is in mensen met eczeem. Huisstofmijt allergische patiënten met eczeem, 
hadden lagere levels van allergeen-specifiek IgA2 in hun bloed. Aanwezigheid van 
eczeem correleert ook met afwijkende levels van APRIL en BAFF, die ook invloed 
hebben op IgA productie. Omdat dezelfde factoren die IgA productie beïnvloeden 
afwijken in patienten met eczeem, en omdat patienten met eczeem verlaagde niveaus 
van IgA hebben, toont dit mogelijk een verband aan tussen factoren die invloed heb-
ben op IgA productie en eczeem.
De productie van IgA wordt gestimuleerd door de aanwezigheid van bacteriën in de 
darm, en andersom helpt IgA de darm te beschermen tegen pathogene bacteriën. In 
hoofdstuk 7 worden de resultaten beschreven van het volgen van IgA productie, IgA 
specificiteits-repertoire en bacteriesamenstelling in de darm van kuikens vanaf dat 
ze uit het ei komen, tot de leeftijd van 10 weken. Het repertoire van het IgA in de 
darm van deze kuikens konden we niet koppelen aan de samenstelling van de bacte-
riepopulatie in de darm. Wel was er een verband tussen de productie niveaus van IgA 
en de bacteriesamenstelling. De samenstelling van de bacteriën veranderende met de 
leeftijd, en werd stabiel wanneer productie van IgA op een hoog niveau was gekomen.
Het dieet heeft ook invloed op het immuun systeem. Een speciale situatie doet zich 
voor als eiwitten uit koemelk ook binden aan receptoren op bijvoorbeeld DCs bij 
de mens, oftewel, als cytokinen of antistoffen kruis-reageren. Het ontstekingsrem-
mende cytokine IL-10 van koeien bindt ook aan de receptor voor IL-10 van mensen 
(Hoofdstuk 8). Bovine IL-10 is ongeveer evengoed in staat als humaan IL-10 om de 
ontstekingsreactie te remmen van humane immuuncellen. Ook IgG van koeien bindt 
aan receptoren voor IgG van de mens (Hoofdstuk 9). Daarnaast is RA en TGF-ß1 
beschikbaar via koemelk. Deze bevindingen bieden mogelijkheden om het menselijke 
immuun-systeem te reguleren met behulp van koemelk.
De bevindingen uit de hoofdstukken 2 – 9 worden geïntroduceerd (Hoofdstuk 1) 
en bediscussieerd (Hoofdstuk 10) in de context van onderzoek dat gaande is binnen 
het vakgebied van de allergie. De algemene conclusie is dat dieet en regulatie van het 
mucosale immuunsysteem mogelijkheden bieden om de ontwikkeling van allergie te 
beïnvloeden.
Co-stimmulatoire 
moleculen zijn nodig 
om Th cellen te kun-
nen activeren. De 
Th cellen kunnen na 
activatie vervolgens 
antistof productie 
stimuleren. 
Repertoire: Een 
antistof-producerende 
B cel, maakt één type 
antistof tegelijkertijd, 
met 1 specificiteit. Om 
het brede scala aan 
antigenen te kunnen 
herkennen zijn er 
veel verschillende B 
cellen nodig die elk 
een andere specifiteit 
voor een bacterie of 
eiwit hebben, wat het 
repertoire genoemd 
wordt.
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